Network-based microbial compositions and methods
A diverse network ecology of bacterial strains addresses the limitations of traditional probiotics by effectively restoring and enhancing microbiota function, treating conditions like CDAD and type 2 diabetes, and improving gastrointestinal health.
Patent Information
- Application Number
- JP2024141842
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2013-03-15
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing probiotics are limited in their ability to restore or enhance the microbiota function effectively, failing to adequately address dysbiosis and associated conditions such as CDAD, type 2 diabetes, obesity, and irritable bowel diseases, due to their narrow scope and limited species range.
A network ecology of diverse bacterial strains, including specific Clostridium and Bifidobacterium species, is administered to form a functional network in the gastrointestinal tract, restoring and enhancing microbiota function to treat or prevent conditions like CDAD, type 2 diabetes, and irritable bowel diseases.
The network ecology effectively restores a healthy microbiome, reducing pathogen colonization, enhancing metabolic functions, and inducing host responses to improve overall gastrointestinal health and prevent or reduce severity of associated diseases.
Smart Images

Figure 2024167277000001_ABST
Abstract
Description
[Technical Field]
[0001] RELATED APPLICATIONS This application claims the benefit of US Provisional Patent Application No. 61 / 798,666, filed March 15, 2013, which is incorporated herein by reference in its entirety.
[0002] REFERENCE TO SEQUENCE LISTING This application contains a Sequence Listing that has been submitted in electronic format as a text file entitled 26184PCT_sequencelisting.txt, created on March 10, 2014, and is 4,196,066 bytes in size. This Sequence Listing is incorporated by reference. [Background technology]
[0003] Microorganisms colonize the gastrointestinal (GI) tract of mammals, on the skin, and within other epithelial and tissue niches, such as the oral cavity, ocular surface, and vagina. The GI tract harbors a rich and diverse microbial community. The GI tract is a complex system that provides an environment, or niche, for many different species or organismal communities, including diverse bacterial strains. In a healthy human GI tract, hundreds of different species can form commensal communities, and this complement of organisms evolves from birth, ultimately forming a functionally mature microbial community by approximately three years of age. Interactions between these microbial strains and between microorganisms and the host (e.g., the host's immune system) shape the structure of the community, with resource availability influencing the distribution of microorganisms and competition for resources influencing the distribution of organisms. Such resources can be food, space, and availability of growing space or physical structures for microorganisms to attach to. For example, the host's diet contributes to the formation of the GI tract flora.
[0004] A healthy microbiota provides multiple benefits to the host, including colonization resistance against a wide range of pathogens, essential nutrient biosynthesis and absorption, and immune stimulation that maintains a healthy intestinal epithelium and properly regulated systemic immunity. In a "dysbiosis" environment, i.e., a disrupted symbiotic relationship, the function of the microbiota is lost or disrupted, leading to increased susceptibility to pathogens, altered metabolic profiles, or the induction of pro-inflammatory signals that can lead to local or systemic inflammation or autoimmunity. Thus, the gut microbiota plays a prominent role in the pathogenesis of many diseases and disorders. Many of these diseases and disorders are chronic conditions that significantly reduce the subject's quality of life and can ultimately be life-threatening.
[0005] Probiotic manufacturers assert that their bacterial preparations promote mammalian health by preserving the natural microflora of the GI tract and enhancing normal regulation of abnormal immune responses. See, e.g., U.S. Patent No. 8,034,601. However, probiotics are limited to a fairly narrow group of genera and a correspondingly limited number of species. By themselves, probiotics do not adequately replace deficient natural microflora or correct GI tract dysbiosis in many situations.
[0006] Therefore, in response to the need for robust, efficient and effective compositions and methods for preventing, diagnosing and / or treating pre-diabetes and diabetes by restoring or enhancing microbiota function, we provide compositions and methods for treating a subject that address these and other shortcomings of the prior art. Summary of the Invention
[0007] Disclosed herein are methods for treating, preventing, or lessening the severity of a disorder selected from the group consisting of Clostridium difficile-associated diarrhea (CDAD), type 2 diabetes, obesity, irritable bowel disease (IBD), colonization by a pathogen or pathobiont, and infection by a drug-resistant pathogen or pathobiont, the method comprising administering to a mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, the therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, the plurality of isolated bacteria or purified bacterial preparations being selected from the group consisting of N262.S, ... 290.S, N284.S, N271.S, N282.S, N288.S, N302.S, N279.S, N310.S, N323.S , N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, N341.S, N346 .S, N338.S, N336.S, N345.S, N355.S, N356.S, N343.S, N329.S, N361.S, N3 53.S, N381.S, N344.S, N352.S, N357.S, N358.S, N369.S, N372.S, N375.S, N380.S, N374.S, N377.S, N368.S, N370.S, N373.S, N376.S, N389.S, N394. S, N431.S, N434.S, N390.S, N397.S, N387.S, N440.S, N396.S, N399.S, N40 3.S, N414.S, N430.S, N432.S, N436.S, N437.S, N457.S, N545, N386.S, N40 2.S, N405.S, N415.S, N421.S, N422.S, N423.S, N458.S, N459.S, N493.S, N 416.S, N439.S, N447.S, N490.S, N526, N429.S, N433.S, N448.S, N488.S, N 508.S, N509.S, N510.S, N511.S, N408.S, N446.S, N451.S, N474.S, N520.S , N521.S, N535.S, N516.S, N463.S, N518.S, N586, N450.S, N465.S, N519.S , N537.S, N419.S, N468.S, N477.S, N514.S, N382.S, N460.S, N462.S, N512.S、N517.S、N523.S、N547.S、N548.S、N577.S、N581.S、N585.S、N616.S、N466.S、N469.S、N480.S、N482.S、N484.S、N515.S、N533.S、N709、N730、N478.S、N572.S、N400.S、N543.S、N582.S、N621.S、N689、N769、N481.S、N525.S、N528.S、N534.S、N574.S、N580.S、N590.S、N591.S、N597.S、N664、N693、N530.S、N687、N470.S、N529.S、N539.S、N546.S、N570.S、N579.S、N602.S、N614.S、N648.S、N652.S、N655.S、N672.S、N681.S、N690.S、N692.S、N698.S、N737.S、N738.S、N785、N841、N878、N880、N881、N987、N988、N996、N1061、N479.S、N538.S、N542.S、N578.S、N609.S、N611.S、N617.S、N666.S、N675.S、N682.S、N844、N845、N846、N852、N876、N982、N1008、N649.S、N657.S、N678.S、N686.S、N710.S、N522.S、N651.S、N653.S、N654.S、N680.S、N712.S、N792、N802、N804、N807、N849、N858、N859、N875、N885、N942、N961、N972、N1051、N587.S、N589.S、N612.S、N625.S、N656.S、N714.S、N779、N781、N828、N829、N860、N894、N925、N927、N935、N947、N983、N1023、N441.S、N584.S、N794、N788、N524.S、N604.S、N610.S、N623.S、N663.S、N669.S、N676.S、N703.S、N775.S、N777.S、N780.S、N817.S、N827.S、N836.S、N871.S、N874.S、N898.S、N907.S、N998.S、N1088、N1089、N660.S、N665.S、N667.S、N733.S、N734.S、N739.S、N741.S、N782.S, N789.S, N796.S, N798.S, N800.S, N809.S, N816.S, N842.S, N843.S, N869.S, N986.S, N995.S, N1002.S, N100 4.S, N1019.S, N1093, N668.S, N685.S, N835.S, N851.S, N464.S, N695.S, N776.S, N793.S, N815.S, N833.S, N89 It is possible to form a network ecology selected from the group consisting of N1.S, N1070.S, N1092, N795.S, N797.S, N808.S, N811.S, N826.S, N830.S, N832.S, N840.S, N945.S, N960.S, N968.S, N1091, N805.S, N822.S, N928.S, N936.S, N1078.S and N913.S.
[0008] In some embodiments, the therapeutic bacterial composition comprises at least one bacterial entity, wherein said bacterial entity is capable of forming a network ecology with one more bacterial entity present in the gastrointestinal tract of the mammalian subject at or after administration. In certain embodiments, the network ecology includes N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N387.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462. .S, N463.S, N464.S, N470.S, N474.S, N488.S, N490.S, N493.S, N508.S, N509.S, N510.S, N511.S, N512.S, N514.S, N515.S, N517.S, N 518.S, N519.S, N520.S, N523.S, N524.S, N529.S, N539.S, N543.S, N546.S, N547.S, N548.S, N570.S, N574.S, N577.S, N579.S, N580. S, N582.S, N584.S, N585.S, N589.S, N591.S, N597.S, N602.S, N604.S, N609.S, N610.S, N611.S, N612.S, N614.S, N616.S, N621.S, N 623.S, N625.S, N648.S, N651.S, N652.S, N653.S, N654.S, N655.S, N660.S, N663.S, N664, N665.S, N666.S, N669.S, N672.S, N676.S, N681.S, N687, N689, N690.S, N692.S, N693, N695.S, N698.S, N703.S, N709, N712.S, N714.S, N730, N734.S, N737.S, N738.S, N769, N7 75.S, N777.S, N779, N780.S, N781, N785, N788, N792, N793.S, N794, N797.S, N798.S, N802, N804, N807, N817.S, N827.S, N828, N830.and N998.S, N832.S, N833.S, N836.S, N840.S, N841, N844, N845, N849, N852, N858, N859, N860, N869.S, N871.S, N874.S, N875, N878, N880, N881, N885, N894, N898.S, N907.S, N913.S, N925, N927, N942, N947, N961, N968.S, N972, N982, N983, N986.S, N987, N988, N996, and N998.S.
[0009] In one embodiment, the network ecology includes N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N387.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N474.S, N 488.S, N490.S, N493.S, N508.S, N509.S, N510.S, N511.S, N512.S, N514.S, N515.S, N517.S, N518.S, N519.S, N520.S, N523.S, N524.S, N529.S, N539.S , N543.S, N546.S, N547.S, N548.S, N570.S, N574.S, N577.S, N579.S, N580. S, N582.S, N584.S, N585.S, N589.S, N591.S, N597.S, N602.S, N604.S, N609. S, N610.S, N611.S, N612.S, N614.S, N616.S, N621.S, N623.S, N625.S, N648 .S, N651.S, N652.S, N653.S, N654.S, N655.S, N660.S, N663.S, N664, N665. S, N666.S, N669.S, N672.S, N676.S, N681.S, N687, N689, N690.S, N692.S, N 693, N695.S, N698.S, N703.S, N709, N712.S, N714.S, N730, N734.S, N737.S, N738.S, N769, N775.S, N777.S, N779, N780.S, N781, N785, N788, N792, N793 .S, N794, N797.S, N798.S, N802, N804, N807, N817.S, N827.S, N828, N830.S , N832.S, N833.S, N836.S, N840.S, N841, N844, N845, N849, N852, N858, N85 9, N860, N869.S, N871.S, N874.S, N875, N878, N880, N881, N885, N894, N898.consisting essentially of N907.S, N913.S, N925, N927, N942, N947, N961, N968.S, N972, N982, N983, N986.S, N987, N988, N996 or N998.S.
[0010] In another embodiment, the network ecology is selected from the group consisting of N387.S, N399.S, N512.S, N462.S, N651.S, N982, and N845. In one embodiment, the network ecology comprises N387.S, and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_396, Clade_444, Clade_478, Clade_500, and Clade_553. In another embodiment, the network ecology comprises N387.S, and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_396, Clade_444, Clade_478, Clade_500, and Clade_553. In certain embodiments, clade_262 comprises one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; wherein clade_396 comprises one or more bacteria selected from the group consisting of Acetivibrio ethanolgignens, Anaerosporobacter mobilis, Bacteroides pectinophilus, Clostridium aminovalericum, Clostridium phytofermentans, Eubacterium hallii, and Eubacterium xylanophilum; and wherein clade_444 comprises one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacterium rectale, Eubacterium sp.oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburia faecalis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69, wherein clade_478 includes one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii, Gemmiger formicilis, and Subdoligranulum variabile, and wherein clade_500 includes one or more bacteria selected from the group consisting of Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes shahii, Alistipes sp. HGB5, Alistipes sp. JC50, and Alistipes sp. RMA 9912, wherein clade 553 includes one or more bacteria selected from the group consisting of Collinsella aerofaciens, Collinsella intestinalis, Collinsella stercoris, and Collinsella tanakaei.
[0011] In one embodiment, clade_262 includes one or more bacteria of the genus Ruminococcustorques, wherein clade_396 includes one or more bacteria of the genus Eubacterium hallii, wherein clade_444 includes one or more bacteria selected from the group consisting of Eubacterium rectale and Roseburia inulinivorans, wherein clade_478 includes one or more bacteria of the genus Faecalibacterium prausnitzii, wherein clade_500 includes one or more bacteria of the genus Alistipes putredinis, and wherein clade_553 includes one or more bacteria of the genus Collinsella aerofaciens.
[0012] In other embodiments, clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_396 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; and wherein clade_444 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:173. wherein clade_478 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1896, SEQ ID NO:880 and SEQ ID NO:932; wherein clade_500 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135 and SEQ ID NO:136; and wherein clade_553 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:659, SEQ ID NO:660, SEQ ID NO:661 and SEQ ID NO:662.
[0013] In other embodiments, clade_262 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_396 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; and wherein clade_444 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:17 wherein clade_478 includes one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896, SEQ ID NO:880 and SEQ ID NO:932; wherein clade_500 includes one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135 and SEQ ID NO:136; and wherein clade_553 includes one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:659, SEQ ID NO:660, SEQ ID NO:661 and SEQ ID NO:662.
[0014] In one embodiment, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1670; wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 848; wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1639 and SEQ ID NO: 856; wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 880; wherein clade_500 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 132; and wherein clade_553 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 659.
[0015] In other embodiments, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1670, wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 848, wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1639 and SEQ ID NO: 856, wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 880, wherein clade_500 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 132, and wherein clade_553 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 659.
[0016] In other embodiments, the network ecology comprises N399.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_360, Clade_396, Clade_444, Clade_478, and Clade_494. In yet other embodiments, the network ecology comprises N399.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_360, Clade_396, Clade_444, Clade_478, and Clade_494.
[0017] In some embodiments, clade_262 comprises one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; wherein clade_360 comprises one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium 2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceae bacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8, wherein clade_396 includes one or more bacteria selected from the group consisting of Acetivibrio ethanolgignens, Anaerosporobactermobilis, Bacteroides pectinophilus, Clostridium aminovalericum, Clostridiumphytofermentans, Eubacterium hallii, and Eubacterium xylanophilum, wherein clade_444 includes one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacteriumrectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburia faecalis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Roseburia sp.11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69, wherein clade_478 includes one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii, Gemmiger formicilis, and Subdoligranulum variabile, and wherein clade_494 includes one or more bacteria selected from the group consisting of Clostridium orbiscindens, Clostridium sp. NML04A032, Flavonifractor plautii, Pseudoflavonifractor capillosus, and Ruminococcaceae bacterium D16.
[0018] In another embodiment, clade_262 includes one or more bacteria of Ruminococcus torques, wherein clade_360 includes one or more bacteria of Dorea longicatena, wherein clade_396 includes one or more bacteria of Eubacterium hallii, wherein clade_444 includes one or more bacteria of Eubacterium rectale, wherein clade_478 includes one or more bacteria of Faecalibacterium prausnitzii, and wherein clade_494 includes one or more bacteria of Pseudoflavonifractor capillosus.
[0019] In one embodiment, clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_360 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; wherein clade_396 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; wherein clade_444 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; wherein clade_478 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932; and wherein clade_494 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1591, SEQ ID NO:1655, SEQ ID NO:609, SEQ ID NO:637, and SEQ ID NO:886.
[0020] In some embodiments, clade_262 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_360 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and wherein clade_396 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; wherein clade_444 comprises one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; wherein clade_478 comprises one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932; and wherein clade_494 comprises one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1591, SEQ ID NO:1655, SEQ ID NO:609, SEQ ID NO:637, and SEQ ID NO:886.
[0021] In other embodiments, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1670, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 774, wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 848, wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 856, wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 880, and wherein clade_494 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1591.
[0022] In one embodiment, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1670, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 774, wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 848, wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 856, wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 880, and wherein clade_494 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1591.
[0023] In another embodiment, the network ecology comprises N462.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_360, and Clade_478. In yet another embodiment, the network ecology comprises N462.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_360, and Clade_478.
[0024] In other aspects, clade_262 comprises one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; wherein clade_360 comprises one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium 2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceae bacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8, wherein clade_478 comprises one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii, Gemmiger formicilis, and Subdoligranulum variabile.
[0025] In other aspects, clade_262 includes one or more bacteria of the genus Coprococcus, wherein clade_360 includes one or more bacteria of the genus Dorea longicatena, and wherein clade_478 includes one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii and Subdoligranulum variabile.
[0026] In yet another aspect, clade_262 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_360 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and wherein clade_478 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932.
[0027] In certain aspects, clade_262 comprises one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_360 comprises one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and wherein clade_478 comprises one more bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932.
[0028] In another aspect, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:674, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:774, and wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1896 and SEQ ID NO:880.
[0029] In other aspects, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:674, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:774, and wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequences SEQ ID NO:1896 and SEQ ID NO:880.
[0030] In another embodiment, the network ecology comprises N512.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_360, and Clade_444. In one embodiment, the network ecology comprises N512.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_360, and Clade_444.
[0031] In other embodiments, clade_262 comprises one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; wherein clade_360 comprises one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium 2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceae bacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8, and wherein clade_444 comprises one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacterium rectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburia faecalis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69.
[0032] In certain embodiments, clade_262 includes one or more bacteria selected from the group consisting of Coprococcus comes and Ruminococcus torques, wherein clade_360 includes one or more bacteria of Dorea longicatena, and wherein clade_444 includes one or more bacteria of Eubacterium rectale.
[0033] In one embodiment, clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674, wherein clade_360 comprises a bacterium having a 16S sequence with 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774. and wherein clade_444 includes another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865.
[0034] In another embodiment, clade_262 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674, wherein clade_360 comprises 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:77. 4, and wherein clade_444 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865.
[0035] In certain embodiments, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1670 and SEQ ID NO:674, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:774, and wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:856.
[0036] In one embodiment, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequences SEQ ID NO: 1670 and SEQ ID NO: 674, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequence SEQ ID NO: 774, and wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequence SEQ ID NO: 856.
[0037] In another embodiment, the network ecology comprises N845 and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_360, and Clade_378. In a particular embodiment, the network ecology comprises N845 and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_360, and Clade_378.
[0038] In other aspects, clade_262 comprises one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; wherein clade_360 comprises one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium 2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceae bacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8, wherein clade_378 comprises one or more bacteria selected from the group consisting of Bacteroides barnesiae, Bacteroides coprocola, Bacteroides coprophilus, Bacteroides dorei, Bacteroides massiliensis, Bacteroides plebeius, Bacteroides sp. 3_1_33FAA, Bacteroides sp. 3_1_40A, Bacteroides sp. 4_3_47FAA, Bacteroides sp. 9_1_42FAA, Bacteroides sp. NB_8, and Bacteroides vulgatus.
[0039] In certain embodiments, clade_262 includes one or more bacteria of the genus Coprococcus, wherein clade_360 includes one or more bacteria of the genus Dorea longicatena, and wherein clade_378 includes one or more bacteria of the genus Bacteroides dorei.
[0040] In another aspect, clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_360 comprises bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:674. and wherein clade_378 includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:267, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:284, SEQ ID NO:289, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:323, and SEQ ID NO:331.
[0041] In certain aspects, clade_262 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; wherein clade_360 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and wherein clade_378 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:267, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:284, SEQ ID NO:289, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:323, and SEQ ID NO:331.
[0042] In one embodiment, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:674, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:774, and wherein clade_378 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:274.
[0043] In another embodiment, clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence SEQ ID NO:674, wherein clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence SEQ ID NO:774, and wherein clade_378 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence SEQ ID NO:274.
[0044] In some embodiments, the network ecology comprises N982 and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_172, Clade_262, and Clade_396. In other embodiments, the network ecology comprises N982 and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_172, Clade_262, and Clade_396.
[0045] In certain embodiments, clade_172 includes Bifidobacteriaceaegenomosp. C1, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium gallicum, Bifidobacterium infantis, Bifidobacterium kashiwanohense, Bifidobacterium longum, Bifidobacterium pseudocatenulatum, Bifidobacterium pseudolongum, Bifidobacterium scardovii, Bifidobacterium sp. HM2, Bifidobacterium sp. HMLN12, Bifidobacterium sp. M45, Bifidobacterium sp. MSX5B, Bifidobacterium sp.TM_7 and Bifidobacterium thermophilum, wherein clade_262 includes one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques, and wherein clade_396 includes one or more bacteria selected from the group consisting of Acetivibrio ethanolgignens, Anaerosporobacter mobilis, Bacteroides pectinophilus, Clostridium aminovalericum, Clostridium phytofermentans, Eubacterium hallii, and Eubacterium xylanophilum.
[0046] In another embodiment, clade_172 includes one or more bacteria of Bifidobacterium longum, wherein clade_262 includes one or more bacteria of Coprococcus comes, and wherein clade_396 includes one or more bacteria of Eubacterium hallii.
[0047] In one embodiment, clade_172 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, and SEQ ID NO:365, wherein clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, and SEQ ID NO:365, includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674, and wherein clade_396 includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875.
[0048] In another aspect, Clade_172 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, and SEQ ID NO:365, wherein Clade_172 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, and SEQ ID NO:365, Clade_262 contains another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674, and wherein clade_396 contains another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875.
[0049] In another aspect, clade_172 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 356, wherein clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 674, and wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 848.
[0050] In certain embodiments, clade_172 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:356, wherein clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:674, and wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:848.
[0051] In another embodiment, the network ecology comprises N651.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_444, Clade_516, and Clade_522. In yet another embodiment, the network ecology comprises N651.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_444, Clade_516, and Clade_522.
[0052] In one embodiment, clade_444 comprises one or more bacteria selected from the group consisting of Butyrivibriofibrisolvens, Eubacterium rectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburiafaecalis, Roseburia faecis, Roseburiahominis, Roseburia intestinalis, Roseburiainulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69; wherein clade_516 comprises one or more bacteria selected from the group consisting of Anaerotruncus colihominis, Clostridium methylpentosum, Clostridium sp. YIT 12070, Hydrogenoanaerobacterium saccharovorans, Ruminococcus albus, and Ruminococcus flavefaciens, and wherein clade_522 comprises one or more bacteria selected from the group consisting of Bacteroides galacturonicus, Eubacterium eligens, Lachnospira multipara, Lachnospirapectinoschiza, and Lactobacillus rogosae. In another embodiment, clade_444 comprises one or more bacteria selected from the group consisting of Roseburia inulinivorans, wherein clade_516 comprises one or more bacteria selected from the group consisting of Anaerotruncus colihominis, and wherein clade_522 comprises one or more bacteria selected from the group consisting of Eubacterium eligens.In some embodiments, Clade_444 includes another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865, wherein Clade_444 includes another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865, Clade_516 includes one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1005, SEQ ID NO:164, SEQ ID NO:1656, SEQ ID NO:1660, SEQ ID NO:606, and SEQ ID NO:642, and wherein clade_522 includes one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1046, SEQ ID NO:1047, SEQ ID NO:1114, SEQ ID NO:280, and SEQ ID NO:845.
[0053] In other embodiments, clade_444 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; clade_516 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1005, SEQ ID NO:164, SEQ ID NO:1656, SEQ ID NO:1660, SEQ ID NO:606, and SEQ ID NO:642; and clade_522 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1046, SEQ ID NO:1047, SEQ ID NO:1114, SEQ ID NO:280, and SEQ ID NO:845.
[0054] In one embodiment, clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO: 1639, wherein clade_516 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO: 164, and wherein clade_522 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO: 845.
[0055] In one embodiment, clade_444 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1639, wherein clade_516 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 164, and wherein clade_522 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 845.
[0056] In another aspect, the composition further comprises a pharmaceutically acceptable excipient. In one aspect, the therapeutic bacterial composition is substantially depleted of residual habitat products from fecal material. In certain aspects, the composition is formulated for oral administration. In other embodiments, the composition is capable of inducing the formation of IgA, RegIII-gamma, IL-10, regulatory T cells, TGF-beta, alpha-defensin, beta-defensin, or antimicrobial peptides in a mammalian subject. In another embodiment, the composition is edible.
[0057] The present invention provides compositions, including any of the compositions administered according to the above methods. The present invention also includes dosage units containing a predetermined ratio of isolated bacteria present in the above network ecology.
[0058] The present invention provides a method for producing short chain fatty acids (SCFAs) in a mammalian subject, the method comprising: administering to said mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, said therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, said plurality of isolated bacteria or purified bacterial preparations capable of forming one or more bacterial functional pathways, said one or more bacterial functional pathways being selected from the group consisting of N262.S, N290.S, N284.S, N271.S, N282.S, N288.S, N302.S, N279.S, N310.S, N323.S , N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, N341.S, N346. S, N338.S, N336.S, N345.S, N355.S, N356.S, N343.S, N329.S, N361.S, N353. S, N381.S, N344.S, N352.S, N357.S, N358.S, N369.S, N372.S, N375.S, N380 .S, N374.S, N377.S, N368.S, N370.S, N373.S, N376.S, N389.S, N394.S, N431 .S, N434.S, N390.S, N397.S, N387.S, N440.S, N396.S, N399.S, N403.S, N41 4.S, N430.S, N432.S, N436.S, N437.S, N457.S, N545, N386.S, N402.S, N405 .S, N415.S, N421.S, N422.S, N423.S, N458.S, N459.S, N493.S, N416.S, N43 9.S, N447.S, N490.S, N526, N429.S, N433.S, N448.S, N488.S, N508.S, N509. S, N510.S, N511.S, N408.S, N446.S, N451.S, N474.S, N520.S, N521.S, N535 .S, N516.S, N463.S, N518.S, N586, N450.S, N465.S, N519.S, N537.S, N419.S , N468.S, N477.S, N514.S, N382.S, N460.S, N462.S, N512.S, N517.S, N523. S, N547.S, N548.S, N577.S, N581.S, N585.S, N616.S, N466.S, N469.S, N480.S、N482.S、N484.S、N515.S、N533.S、N709、N730、N478.S、N572.S、N400.S、N543.S、N582.S、N621.S、N689、N769、N481.S、N525.S、N528.S、N534.S、N574.S、N580.S、N590.S、N591.S、N597.S、N664、N693、N530.S、N687、N470.S、N529.S、N539.S、N546.S、N570.S、N579.S、N602.S、N614.S、N648.S、N652.S、N655.S、N672.S、N681.S、N690.S、N692.S、N698.S、N737.S、N738.S、N785、N841、N878、N880、N881、N987、N988、N996、N1061、N479.S、N538.S、N542.S、N578.S、N609.S、N611.S、N617.S、N666.S、N675.S、N682.S、N844、N845、N846、N852、N876、N982、N1008、N649.S、N657.S、N678.S、N686.S、N710.S、N522.S、N651.S、N653.S、N654.S、N680.S、N712.S、N792、N802、N804、N807、N849、N858、N859、N875、N885、N942、N961、N972、N1051、N587.S、N589.S、N612.S、N625.S、N656.S、N714.S、N779、N781、N828、N829、N860、N894、N925、N927、N935、N947、N983、N1023、N441.S、N584.S、N794、N788、N524.S、N604.S、N610.S、N623.S、N663.S、N669.S、N676.S、N703.S、N775.S、N777.S、N780.S、N817.S、N827.S、N836.S、N871.S、N874.S、N898.S、N907.S、N998.S、N1088、N1089、N660.S、N665.S、N667.S、N733.S、N734.S、N739.S、N741.S、N782.S、N789.S、N796.S、N798.S、N800.S、N809.S、N816.S、N842.S、N843.S、N869.S、N986.S、N995.S, N1002.S, N1004.S, N1019.S, N1093, N668.S, N685.S, N835.S, N851.S, N464.S, N695. S, N776.S, N793.S, N815.S, N833.S, N891.S, N1070.S, N1092, N795.S, N797.S, N808.S, A functional network ecology can be formed by a network selected from the group consisting of N811.S, N826.S, N830.S, N832.S, N840.S, N945.S, N960.S, N968.S, N1091, N805.S, N822.S, N928.S, N936.S, N1078.S, and N913.S.
[0059] In one embodiment, the functional network ecology is N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N474.S, N488. S, N490.S, N493.S, N508.S, N509.S, N510.S, N511.S, N512.S, N514.S, N515 .S, N517.S, N518.S, N519.S, N520.S, N523.S, N524.S, N528.S, N529.S, N539 .S, N543.S, N546.S, N547.S, N548.S, N570.S, N574.S, N577.S, N579.S, N58 0.S, N582.S, N584.S, N585.S, N589.S, N591.S, N597.S, N602.S, N604.S, N60 9.S, N610.S, N611.S, N612.S, N614.S, N616.S, N621.S, N623.S, N625.S, N6 48.S, N651.S, N652.S, N653.S, N654.S, N655.S, N660.S, N663.S, N664, N665 .S, N666.S, N669.S, N672.S, N676.S, N681.S, N687, N689, N690.S, N692.S, N693, N695.S, N698.S, N703.S, N709, N712.S, N714.S, N730, N734.S, N737.S , N738.S, N769, N775.S, N777.S, N779, N780.S, N781, N785, N788, N792, N79 3.S, N794, N797.S, N798.S, N802, N804, N807, N817.S, N827.S, N828, N830.S , N832.S, N833.S, N836.S, N840.S, N841, N844, N845, N849, N852, N858, N85 9, N860, N869.S, N871.S, N874.S, N875, N878, N880, N881, N885, N894, N898.In another embodiment, the functional network ecology is N528.S, and the plurality of bacterial functional pathways includes the functional pathways KO:K00656, KO:K01069, KO:K01734, KO:K03417, KO:K03778, and KO:K07246.
[0060] The present invention encompasses a method of catalyzing the secondary metabolism of bile acids in a mammalian subject, the method comprising: administering to the mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, the therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, the plurality of isolated bacteria or purified bacterial preparations capable of forming one or more bacterial functional pathways, the one or more bacterial functional pathways being selected from the group consisting of N262.S, N290.S, N284.S, N271.S, N282.S, N288.S, N302.S, N279.S, N310.S, N323.S, and the like. , N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, N341.S, N346. S, N338.S, N336.S, N345.S, N355.S, N356.S, N343.S, N329.S, N361.S, N353. S, N381.S, N344.S, N352.S, N357.S, N358.S, N369.S, N372.S, N375.S, N380 .S, N374.S, N377.S, N368.S, N370.S, N373.S, N376.S, N389.S, N394.S, N431 .S, N434.S, N390.S, N397.S, N387.S, N440.S, N396.S, N399.S, N403.S, N41 4.S, N430.S, N432.S, N436.S, N437.S, N457.S, N545, N386.S, N402.S, N405 .S, N415.S, N421.S, N422.S, N423.S, N458.S, N459.S, N493.S, N416.S, N43 9.S, N447.S, N490.S, N526, N429.S, N433.S, N448.S, N488.S, N508.S, N509. S, N510.S, N511.S, N408.S, N446.S, N451.S, N474.S, N520.S, N521.S, N535 .S, N516.S, N463.S, N518.S, N586, N450.S, N465.S, N519.S, N537.S, N419.S , N468.S, N477.S, N514.S, N382.S, N460.S, N462.S, N512.S, N517.S, N523. S, N547.S, N548.S, N577.S, N581.S, N585.S, N616.S, N466.S, N469.S, N480.S、N482.S、N484.S、N515.S、N533.S、N709、N730、N478.S、N572.S、N400.S、N543.S、N582.S、N621.S、N689、N769、N481.S、N525.S、N528.S、N534.S、N574.S、N580.S、N590.S、N591.S、N597.S、N664、N693、N530.S、N687、N470.S、N529.S、N539.S、N546.S、N570.S、N579.S、N602.S、N614.S、N648.S、N652.S、N655.S、N672.S、N681.S、N690.S、N692.S、N698.S、N737.S、N738.S、N785、N841、N878、N880、N881、N987、N988、N996、N1061、N479.S、N538.S、N542.S、N578.S、N609.S、N611.S、N617.S、N666.S、N675.S、N682.S、N844、N845、N846、N852、N876、N982、N1008、N649.S、N657.S、N678.S、N686.S、N710.S、N522.S、N651.S、N653.S、N654.S、N680.S、N712.S、N792、N802、N804、N807、N849、N858、N859、N875、N885、N942、N961、N972、N1051、N587.S、N589.S、N612.S、N625.S、N656.S、N714.S、N779、N781、N828、N829、N860、N894、N925、N927、N935、N947、N983、N1023、N441.S、N584.S、N794、N788、N524.S、N604.S、N610.S、N623.S、N663.S、N669.S、N676.S、N703.S、N775.S、N777.S、N780.S、N817.S、N827.S、N836.S、N871.S、N874.S、N898.S、N907.S、N998.S、N1088、N1089、N660.S、N665.S、N667.S、N733.S、N734.S、N739.S、N741.S、N782.S、N789.S、N796.S、N798.S、N800.S、N809.S、N816.S、N842.S、N843.S、N869.S、N986.S、N995.S, N1002.S, N1004.S, N1019.S, N1093, N668.S, N685.S, N835.S, N851.S, N464.S, N695 .S, N776.S, N793.S, N815.S, N833.S, N891.S, N1070.S, N1092, N795.S, N797.S, N808.S A functional network ecology can be formed by using a network of N811.S, N826.S, N830.S, N832.S, N840.S, N945.S, N960.S, N968.S, N1091, N805.S, N822.S, N928.S, N936.S, N1078.S, and N913.S.
[0061] In one embodiment, the functional network ecology comprises N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N474.S, N488. S, N490.S, N493.S, N508.S, N509.S, N510.S, N511.S, N512.S, N514.S, N515 .S, N517.S, N518.S, N519.S, N520.S, N523.S, N524.S, N529.S, N539.S, N543 .S, N546.S, N547.S, N548.S, N570.S, N574.S, N577.S, N579.S, N580.S, N58 2.S, N584.S, N585.S, N589.S, N591.S, N597.S, N602.S, N604.S, N609.S, N61 0.S, N611.S, N612.S, N614.S, N616.S, N621.S, N623.S, N625.S, N648.S, N6 51.S, N652.S, N653.S, N654.S, N655.S, N660.S, N663.S, N664, N665.S, N666 .S, N669.S, N672.S, N676.S, N681.S, N687, N689, N690.S, N692.S, N693, N6 95.S, N698.S, N703.S, N709, N712.S, N714.S, N730, N734.S, N737.S, N738.S , N769, N775.S, N777.S, N779, N780.S, N781, N785, N788, N792, N793.S, N79 4, N797.S, N798.S, N802, N804, N807, N817.S, N827.S, N828, N830.S, N832.S , N833.S, N836.S, N840.S, N841, N844, N845, N849, N852, N858, N859, N860, N869.S, N871.S, N874.S, N875, N878, N880, N881, N885, N894, N898.S, N907.In another embodiment, the functional network ecology is N660.S, and the plurality of bacterial functional pathways includes the functional pathways of KO:K00656 and KO:K01442.
[0062] In some embodiments, the present invention encompasses compositions further comprising a pharmaceutically acceptable excipient. In one embodiment, the composition is formulated for oral administration. In another embodiment, the composition can induce the formation of butyrate, propionate, acetate, 7-deoxybile acid, deoxycholic acid (DCA), and lithocholic acid (LCA) in a mammalian subject. In another embodiment, the composition can induce the depletion of glucose, pyruvate, lactate, cellulose, fructan, starch, xylan, pectin, taurocholate, glycolate, ursocholate, cholate, glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate, or chenodeoxycholate in a mammalian subject; or the formation and depletion of the intermediate metabolites acetyl-CoA, butyryl-CoA, propanoyl-CoA, chenodeoxycholoyl-CoA, or ursodeoxycholoyl-CoA. In another embodiment, the composition is formulated with one or more prebiotic compounds. In some embodiments, the composition is edible.
[0063] The present invention encompasses compositions, including any of the compositions administered in the above-described manner.
[0064] The present invention also encompasses dosage units containing predetermined ratios of isolated bacteria present in the network ecology described above.
[0065] The present invention includes a pharmaceutical formulation comprising a purified bacterial population consisting essentially of a bacterial network capable of forming germinating bacterial spores, wherein the bacterial network is present in an amount effective to populate the gastrointestinal tract of a mammalian subject to which the formulation is administered, under conditions that result in an increase in at least one type of bacteria that was not detectably present in the bacterial network or gastrointestinal tract prior to administration.
[0066] The present invention also includes pharmaceutical formulations comprising a purified bacterial population comprising a plurality of bacterial entities, wherein the bacterial entities are present in an amount effective to induce the formation of a functional bacterial network in the gastrointestinal tract of a mammalian subject requiring the formulation and to which the formulation is administered. In some embodiments, the functional bacterial network comprises bacterial entities present in the formulation. In other embodiments, the functional bacterial network comprises bacterial entities present in the gastrointestinal tract upon administration. In other embodiments, the functional bacterial network comprises bacterial entities not present in the formulation or the gastrointestinal tract upon administration. In one embodiment, the formulation may be provided as an oral finished pharmaceutical dosage form comprising at least one pharmaceutically acceptable carrier. In some embodiments is the formulation of claim 83 or claim 84, wherein the mammalian subject is suffering from dysbiosis, including a gastrointestinal disease, disorder, or condition selected from the group consisting of Clostridium difficile associated diarrhea (CDAD), type 2 diabetes, type 1 diabetes, obesity, irritable bowel syndrome (IBS), irritable bowel disease (IBD), ulcerative colitis, Crohn's disease, colitis, colonization by a pathogen or pesticide, and infection by a drug-resistant pathogen or pesticide.
[0067] In another embodiment, the bacterial network is purified from fecal material that has been subjected to a treatment process that includes depletion or inactivation of pathogenic substances. In one embodiment, the bacterial network is substantially depleted of detectable levels of a first pathogenic substance. In some embodiments, the bacterial network is substantially depleted of residual habitat products of the fecal material.
[0068] In one embodiment, the invention provides a method of treating or preventing microbial incompatibility in a human subject, comprising administering to the human subject the formulation of claim 83 or claim 84 in an amount effective to treat or prevent microbial incompatibility or reduce the severity of at least one symptom of microbial incompatibility in the human subject to which the formulation is administered.
[0069] In another embodiment, the formulation is provided as an oral finished pharmaceutical dosage form comprising at least one pharmaceutically acceptable carrier, the dosage form comprising at least about 1 x 10 colony forming units of bacterial spores per dose of the composition, wherein the bacterial spores comprise at least two bacterial entities comprising a 16S rRNA sequence having at least 97% identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:674, SEQ ID NO:1670, SEQ ID NO:774, SEQ ID NO:848, SEQ ID NO:856, SEQ ID NO:1639, SEQ ID NO:880, SEQ ID NO:1896, SEQ ID NO:1591, SEQ ID NO:164, SEQ ID NO:845, and SEQ ID NO:659.
[0070] In yet another embodiment, administration of the formulation results in the reduction or elimination of at least one pathogen and / or pestbiont present in the gastrointestinal tract at the time the therapeutic composition is administered. In one embodiment, administration of the formulation results in the engraftment of at least one spore-forming bacterium present in the therapeutic composition.
[0071] In one embodiment, administration of the formulation results in an expansion of at least one type of bacteria not present in the formulation in the gastrointestinal tract of the subject to which the formulation is administered. In another embodiment, the at least one type of spore-forming bacteria is not detectably present in the gastrointestinal tract of the subject to which the formulation is administered at the time the formulation is administered. In yet another embodiment, administration of the formulation results in at least two of: i) a reduction or elimination of at least one pathogen and / or pestbiont present in the gastrointestinal tract at the time the formulation is administered; ii) engraftment of at least one type of spore-forming bacteria present in the therapeutic composition; and iii) an expansion of at least one type of spore-forming or non-spore-forming bacteria not present in the therapeutic composition.
[0072] In some embodiments, administration of the therapeutic composition results in a reduction or elimination of at least one pathogen and / or pestbiont present in the gastrointestinal tract at the time the therapeutic composition is administered, and results in at least one of: i) engraftment of at least one spore-forming bacterium present in the therapeutic composition; and ii) expansion of at least one bacterium not present in the therapeutic composition.
[0073] In another aspect, a method for inducing bacterial colonization of the gastrointestinal tract of a human subject comprises administering to the human subject an orally acceptable pharmaceutical formulation comprising a purified bacterial network under conditions such that at least i) a subset of spore-forming bacteria persists in the gastrointestinal tract, or ii) at least one species of bacteria not present in the therapeutic composition expands in the gastrointestinal tract.
[0074] The present invention provides a pharmaceutical formulation comprising a purified first bacterial entity and a purified second bacterial entity, wherein the first bacterial entity comprises a first nucleic acid sequence encoding a first polypeptide capable of catalyzing a first chemical reaction, and the second bacterial entity comprises a second nucleic acid sequence encoding a second polypeptide capable of catalyzing a second chemical reaction; the pharmaceutical formulation is formulated for oral administration to a mammalian subject in need thereof, wherein the first chemical reaction and the second chemical reaction are capable of occurring in the gastrointestinal tract of the mammalian subject, under conditions where a first product of the first chemical reaction, a substance present in the mammalian subject, or a combination of the first product and a substance is used as a substrate in a second chemical reaction to form a second product, and the second product induces a host cell response. In one embodiment, the substance is a protein or a food-derived protein of the mammalian subject. In another embodiment, the host cell response comprises the production of a biological substance by a host cell. In certain embodiments, the biological substance comprises a cytokine, a growth factor, or a signaling polypeptide.
[0075] In one embodiment, the host cell response comprises an immune response. In another embodiment, the host cell response comprises decreased gastric motility. In yet another embodiment, the host cell response comprises altered host gene expression, increased host metabolism, decreased intestinal permeability, increased epithelial cell junctional integrity, decreased lipolysis by the action of lipoprotein lipase in adipose tissue, decreased hepatic gluconeogenesis, increased insulin sensitivity, increased production of FGF-19, or altered energy recovery and / or storage.
[0076] The present invention encompasses a pharmaceutical formulation comprising a purified first bacterial entity and a purified second bacterial entity, wherein the first bacterial entity and the second bacterial entity form a functional bacterial network in the gastrointestinal tract of a mammalian subject to which the pharmaceutical formulation is administered, the functional network controlling the amount and / or activity of a biological substance capable of inducing a host cell response.
[0077] The invention also encompasses a pharmaceutical formulation comprising a purified first bacterial entity and a purified second bacterial entity, wherein the first bacterial entity and the second bacterial entity form a functional bacterial network in the gastrointestinal tract of a mammalian subject to which the pharmaceutical formulation is administered, and the functional network induces the production of a biological substance capable of inducing a host cellular response.
[0078] The present invention includes a therapeutic composition comprising a network of at least two bacterial entities, wherein the network comprises at least one keystone bacterial entity and at least one non-keystone bacterial entity, wherein each of the at least two bacterial entities is provided in an amount effective to treat or prevent a gastrointestinal disease, disorder, or condition in a mammalian subject. In one embodiment, the network comprises at least three bacterial entities. In another embodiment, the network comprises at least three bacterial entities, including at least two keystone bacterial entities.
[0079] The present invention includes a therapeutic composition comprising a network of at least two keystone bacterial entities capable of forming germination-competent spores, wherein each of the at least two keystone bacterial entities is provided in an amount effective to treat or prevent a gastrointestinal disease, disorder, or condition in a mammalian subject. In one embodiment, the composition comprises a network of at least two keystone bacterial entities capable of forming germination-competent spores.
[0080] In one embodiment, the invention comprises a therapeutic composition comprising: a first network of at least two bacterial entities, the first network comprising a keystone bacterial entity and a non-keystone bacterial entity; and a second network of at least two bacterial entities, the second network comprising at least one keystone bacterial entity and at least one non-keystone bacterial entity, wherein each network is provided in an amount effective to treat or prevent a gastrointestinal disease, disorder, or condition in a mammalian subject.
[0081] The present invention includes a therapeutic composition comprising a network of at least two bacterial entities, wherein the network comprises a first keystone bacterial entity and a second keystone bacterial entity, each of the two bacterial entities provided in an amount effective to treat or prevent a gastrointestinal disease, disorder, or condition in a mammalian subject. In one embodiment, the first and second keystone bacterial entities are present in the same network. In another embodiment, the first and second keystone bacterial entities are present in different networks.
[0082] In some aspects, the present invention includes a diagnostic composition for detecting microbial incompatibility, the diagnostic composition comprising a first detection moiety capable of detecting a first keystone bacterial entity and a second detection moiety capable of detecting a first non-keystone bacterial entity, wherein the keystone bacterial entity and the non-keystone bacterial entity constitute a network, and wherein the absence of at least one of the keystone bacterial entity and the non-keystone bacterial entity in a mammalian subject indicates microbial incompatibility.
[0083] The present invention includes a method for altering the microbiome population present in a mammalian subject, the method comprising the steps of determining the presence of an incomplete network of bacterial entities in the gastrointestinal tract of the mammalian subject, and introducing into the gastrointestinal tract of the mammalian subject an effective amount of one or more auxiliary bacterial entities that were not detectable in the gastrointestinal tract of the mammalian subject prior to administration, such that the incomplete network is completed, thereby altering the microbiome population.
[0084] In one embodiment, one or more auxiliary bacterial entities become part of an incomplete network, thereby forming a complete network. In another embodiment, one or more auxiliary bacterial entities alter the microbiota of the mammalian subject such that the one or more additional bacterial entities complete the incomplete network. In yet another embodiment, one or more auxiliary bacterial entities comprise a network.
[0085] The present invention includes a method for detecting and correcting microbial incompatibility in a mammalian subject in need thereof, the method comprising: providing a fecal sample from the mammalian subject comprising a plurality of bacterial entities; contacting the fecal sample with a first detection moiety capable of detecting a first bacterial entity present in a network; detecting the absence of the first bacterial entity in the fecal sample, thereby detecting microbial incompatibility in the mammalian subject; and administering to the mammalian subject a composition comprising an effective amount of the first bacterial entity. In one embodiment, the method includes confirming that the microbial incompatibility in the mammalian subject has been corrected.
[0086] The present invention includes a system for predicting microbial incompatibility in a subject, the system including: a storage memory for storing a dataset associated with a sample obtained from the subject, the dataset including content data of at least one network of bacterial entities; and a processor communicatively coupled to the storage memory for determining, with an interpretation function, a score predictive of microbial incompatibility in the subject.
[0087] The present invention also includes a kit for diagnosing a microbial incompatibility condition in a mammalian subject in need thereof, comprising a plurality of detection means suitable for use in detecting (1) a first bacterial entity, including a keystone bacterial entity, and (2) a second bacterial entity, wherein the first and second bacterial entities comprise a functional network ecology. [Brief explanation of the drawings]
[0088] [Figure 1] 1 is a schematic diagram of the 16S rRNA gene showing the coordinates of hypervariable regions 1 through 9 (V1 through V9) according to an embodiment of the present invention. Based on numbering using the E. coli system of nomenclature defined by Brosius et al., *Complete nucleotide sequence of a 16S ribosomal RNA gene (16S rRNA) from Escherichia coli*, PNAS 75(10):4801-4805 (1978), the coordinates of V1 through V9 are 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294, and 1435-1465, respectively. [Figure 2] FIG. 2 highlights in bold the nucleotide sequence of each hypervariable region in the exemplary reference E. coli 16S sequence described by Brosius et al. [Figure 3] FIG. 3 shows the OTU and clade composition of the network tested in experiment SP-376 according to an embodiment of the present invention. [Figure 4] Figure 4 shows the results of a nutrient utilization assay with Clostridium difficile and potential pathogen competitors. A plus sign (+) indicates a nutrient for the isolate tested. A minus sign (-) indicates a non-nutrient for the isolate tested. [Figure 5]Figure 5 shows microbial diversity measured in ethanol-treated spore treatment samples and pre- and post-treatment patient samples according to an embodiment of the present invention. Total microbial diversity was determined using the Chao1 alpha-diversity index, measured at the same genomic sampling depth to ensure sufficient and comparable sequence coverage of the target samples. Pre-treatment patients (purple) possessed microbiomes with significantly reduced total diversity compared to ethanol-treated spore treatment (red) and post-treatment patients at days 5 (blue), 14 (orange), and 25 (green). [Figure 6] Figure 6 shows how a patient's microbial ecology changes from a dysbiotic state to a healthy state upon treatment with the ethanol-treated spore treatment. Principal coordinate analysis based on the overall diversity and structure (Bray Curtis beta diversity) of the patient's microbiome before and after treatment indicates that the combination of engraftment of OTUs from the spore treatment and an enrichment of the patient's microbial ecology results in a microbial ecology that differs from both the pre-treatment microbiome and the ecology of the ethanol-treated spore treatment. [Figure 7] FIG. 7 shows the growth of Bacteroides species in patients treated with spore loads in accordance with an embodiment of the present invention. [Figure 8] Figure 8 shows species survival versus species enrichment in a patient's microbiome after treatment with a bacterial composition, such as, but not limited to, an ethanol-treated spore group, according to an embodiment of the present invention. The relative abundance of the species that survived or enriched as described was determined based on the number of 16S sequence reads. Each plot is from a different patient treated with a bacterial composition, such as, but not limited to, an ethanol-treated spore group for recurrent C. difficile. [Figure 9] FIG. 9 is a set of survival curves showing the efficacy of an ethanol-enriched spore panel in a mouse C. difficile prophylaxis model, according to an embodiment of the present invention. [Figure 10]FIG. 10 illustrates an in vivo hamster Clostridium difficile relapse prevention model to confirm the efficacy of ethanol-treated spores and ethanol-treated, gradient-purified spores according to an embodiment of the present invention. [Figure 11] FIG. 11 shows an in vivo hamster Clostridium difficile relapse prevention model to confirm the efficacy of a network ecology bacterial composition according to an embodiment of the present invention. [Figure 12] FIG. 12 shows the secondary bile acid metabolism KEGG orthology pathways and associated enzyme gene products defined by EC numbers. [Figure 13] FIG. 13 shows the butyrate (i.e., butanoate) production KEGG orthology pathways and associated enzyme gene products defined by EC numbers. [Figure 14] FIG. 14 shows the propionate (i.e., propanoate) production KEGG orthology pathways and associated enzyme gene products defined by EC numbers. [Figure 15] FIG. 15 shows acetate production KEGG orthology pathways and associated enzyme gene products defined by EC numbers. [Figure 16] FIG. 16 is a schematic diagram of a method for computationally deriving network ecology according to an embodiment of the present invention. [Figure 17] Figure 17 is a schematic diagram showing how keystone OTUs (nodes 2 and 4, shaded circles) are central members of many network ecologies that include non-keystone OTUs (nodes 1, 3, and 5-9). Different network ecologies include [node 2 - node 7], [node 3 - node 2 - node 4], [node 2 - node 4 - node 5 - node 6 - node 7], [node 1 - node 2 - node 8 - node 9], and [node - node 3]. [Figure 18]Figure 18 illustrates the derivation of network ecology classes according to an embodiment of the present invention. A subset of networks is selected for use in defining network classes based on key biological criteria. Hierarchical network clusters are defined by the presence (white) and absence (blue) of OTUs, and / or functional metabolic pathways and classes are defined as branches of a hierarchical clustering tree based on morphological redundancy measures. [Figure 19] Figure 19 shows the phenotypes assigned to samples for computational derivation of network ecologies representative of health (Hpost, Hdon & Hgen) and disease (DdonF & DpreF) states of the microbiome. The microbiome compositions of samples with different phenotypes may overlap with the intersection defined by the H, HD, and D designations, and have different biological implications. [Figure 20] Figure 20 shows an exemplary phylogenetic tree and the relationships between OTUs and clades. A, B, C, D, and E represent OTUs, also known as leaves in the tree. Clade 1 contains OTUs A and B, clade 2 contains OTUs C, D, and E, and clade 3 is a subset of clade 2 containing OTUs D and E. Nodes in the tree that define clades can be either statistically supported or statistically unsupported. OTUs in certain clades are more similar to each other than they are to OTUs in other clades, and the strength of a clade assignment is indicated by the degree of statistical support for the upstream node of an OTU within a clade. [Figure 21] FIG. 21 is a high-level block diagram illustrating an example of a computer for use as a server or user device, according to one embodiment.
[0089] The figures depict various embodiments of the present invention for illustrative purposes only. Those skilled in the art will readily appreciate from the following discussion that alternative embodiments of the structures and methods illustrated herein may be utilized without departing from the inventive principles described herein. DETAILED DESCRIPTION OF THE INVENTION
[0090] Overview The present invention discloses therapeutic compositions comprising bacterial combinations for the prevention, regulation, and treatment of gastrointestinal diseases and other disorders and conditions that lead to or are caused by a dysbiotic microbiome in the host's niche. Such conditions include, but are not limited to, Clostridium difficile-associated diarrhea (CDAD), type 2 diabetes, ulcerative colitis, and infections caused by antibiotic-resistant bacteria such as carbapenem-resistant Klebsiella pneumoniae (CRKp) and vancomycin-resistant Enterococcus (VRE). These compositions are advantageously suitable for safe administration to humans and other mammalian subjects and are effective in numerous gastrointestinal diseases, disorders, and conditions, as well as nutritional health in general. While bacterial compositions are known, they are generally combinations of bacteria combined without understanding the ecology formed by a single bacterial strain or a consortium of bacterial organisms, leading to insufficient efficacy, instability, substantial variability, and a lack of sufficient safety.
[0091] The human body is an ecosystem in which the microbiota and microbiome play a crucial role in the basic normal functioning of human systems (e.g., metabolic, immunological, and neurological). The microbiota and resulting microbiome constitute an ecology of microorganisms that coexist within a single subject and interact with each other and their host (i.e., the mammalian subject), forming a dynamic unit with unique biodiversity and functional characteristics. Within these networks (i.e., ecologies) of interacting microorganisms, certain members contribute more significantly than others; as such, these members are also found in many different ecologies, and their loss from an ecology can have significant effects on the functional capacity of a particular ecology. Robert Paine coined the concept of "keystone species" in 1969 to describe the existence of such anchor species that are essential to an ecosystem, regardless of their abundance in the ecological community (see Paine RT. 1969. A note on trophic complexity and community stability. The American Naturalist 103: 91-93). Paine originally described the role of the starfish, Pisaster ochraceus, in marine systems, and this concept has since been experimentally confirmed in numerous ecosystems.
[0092] The present invention provides methods for defining significant network ecologies and functional network ecologies occurring in healthy and diseased subjects, providing the compositional components of these network ecologies. The methods allow for the derivation of ecological modules (i.e., groups or networks of organisms and metabolic functions) within larger ecologies that can catalyze a shift from a dysbiotic microbiome to one indicative of a healthy state. In other embodiments, the methods allow for the de novo construction of network ecologies, e.g., functional network ecologies, based on desired biological characteristics, including functional traits. The methods further provide keystone species (i.e., operational taxonomic units or OTUs) and keystone metabolic functions that are members of these bacterial communities based on their widespread distribution across many different networks. Importantly, this method distinguishes itself from previous computational approaches by being the first to define the actual network ecologies found within many healthy subjects. The network ecologies comprise collections of bacterial OTUs (i.e., genera, species, or strains) that form coherent, intact biological communities with defined phylogenetic and / or functional characteristics. That is, the structure-function relationships contained within any network ecology have a unique biodiversity profile and, consequently, biological functional capacity. Specific bacterial combinations and the resulting functional capacity of the microbiome may be effective in treating or preventing gastrointestinal diseases, disorders, and conditions, or in treating or preventing systemic diseases, disorders, and symptoms influenced by the gastrointestinal microbiota. Furthermore, network ecologies, along with specific nodes (e.g., OTUs, phylogenetic clades, functional pathways), possess modularity in their structure and function, including the network backbone into which different r-groups (e.g., OTUs, phylogenetic clades, functional pathways) can be integrated to achieve specific biological properties of the network ecology. A network ecology defined in terms of its functional mode is referred to as a functional network ecology.
[0093] The network ecologies provided herein are useful in environments experiencing bacterial dysbiosis, given their ability to accomplish one or more of the following: (i) disrupting existing microbiota and / or microbiomes; (ii) establishing new microbiota and / or microbiomes; and (iii) stabilizing functional microbiota and / or microbiomes that support health. Such network ecologies can exist sustainably upon introduction into a mammalian subject, or they can exist temporarily until such time as a functional microbiota and / or microbiome is re-established. In a therapeutic setting, treatment with a collection of microbial OTUs transforms the microbiome of a treated host from a diseased state to a healthy state. This change in overall diversity and composition is mediated by both: (i) the engraftment of OTUs comprising the therapeutic composition into the host ecology (engrafted ecology) and (ii) the establishment of OTUs not derived from the therapeutic composition, but where treatment with the therapeutic composition alters the environmental conditions such that these OTUs can establish. This Augmented Ecology consists of OTUs that were present in lower abundance in the host prior to treatment or that were exogenously introduced from a source other than the therapeutic composition itself.
[0094] Provided herein is a computational method based at least in part on network theory (Proulx SR, Promislow DEL, Phillips PC. 2005. Network thinking in ecology and evolution. Trends in Ecology & Evolution 20: 345-353) that describes the ecological and functional structure of a group of microorganisms based on the presence or absence of specific OTUs (i.e., bacterial orders, families, genera, species, or strains) or the specific functions of these OTUs in a sample of mammalian subjects. In particular, these network ecologies and functional network ecologies are not simply inferred based on clustering of OTUs according to binary co-occurrence calculated from average relative abundance across a set of samples of interest (e.g., Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J, and Huttenhower C. 2012. Microbial co-occurrence relationships in the human microbiome. PLoS Computational Biology 8: e1002606. Lozupone C, Faust K,Raes J, Faith JJ, Frank DN, Zaneveld J, Gordon JI, and Knight R. 2012. Identifying genomic and metabolic features that can underlie early successional and opportunistic lifestyles of human gut symptoms. Genome Research 22:1974-1984), instead, ecologies represent actual communities of bacterial OTUs that are computationally derived and explicitly present within one or more subjects as ecological networks. Furthermore, we provide a method for characterizing the biological significance of an ecological network in terms of its phylogenetic diversity, functional properties, and implications for health or disease.The present invention describes an ecology suitable for the treatment or prevention of diseases, disorders and conditions of the gastrointestinal tract or that are distal to the gastrointestinal tract but that are caused or perpetuated by dysbiosis of the gut microbiota.
[0095] DEFINITIONS As used herein, the phrase "purified bacterial preparation" refers to a preparation containing bacteria that has been separated from at least one associated substance found in the source material or any material that involves the bacteria in any process used to make the preparation.
[0096] A "bacterial entity" includes one or more bacteria. Generally, a first bacterial entity is distinguishable from a second bacterial entity.
[0097] As used herein, the term "formation" refers to synthesis or production.
[0098] The term "induce," as used herein, as the context indicates, means to increase the amount or activity of a given material.
[0099] As used herein, the term "depletion" refers to a decrease in amount.
[0100] As used herein, "prebiotics" refer to edible foods or beverages, or components thereof, that enable specific changes in both the composition and / or activity of the gastrointestinal microflora, which confer benefits on the well-being and health of the host. Prebiotics may include complex polysaccharides, amino acids, peptides, or other nutritional components essential for the survival of bacterial compositions. Prebiotics include, but are not limited to, amino acids, biotin, fructooligosaccharides, galactooligosaccharides, inulin, lactulose, mannanoligosaccharides, oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, transgalacto-oligosaccharides, and xylooligosaccharides.
[0101] As used herein, a "given percentage" refers to a percentage that is predetermined or selected in advance.
[0102] As used herein, a "germinable bacterial spore" is a spore that is capable of forming a vegetative cell under certain environmental conditions.
[0103] As used herein, "detectably present" refers to being present in an amount that can be detected using the assays provided herein or assays otherwise known in the art that exist as of the date of submission.
[0104] As used herein, "enhanced" refers to an increase in amount and / or localization until detectably present.
[0105] As used herein, "fecal matter" refers to the solid waste products of digested food and includes feces or bowel washings.
[0106] As used herein, a "host response" is a response initiated by the cells that make up the host organism.
[0107] As used herein, a "mammalian subject protein" refers to a protein produced by and encoded by the genome of a mammalian subject.
[0108] As used herein, the phrase "food-derived" refers to proteins found in ingested foods.
[0109] As used herein, the phrase "biological material" refers to a material produced by a biological organism.
[0110] As used herein, the phrase "sensing moiety" refers to the element of an assay that functions to detect an analyte.
[0111] As used herein, the phrase "incomplete network" refers to a partial network that lacks a complete set of components necessary to perform one or more network functions.
[0112] As used herein, the term "auxiliary" refers to additional and non-identical.
[0113] As used herein, the phrase "antioxidant" refers to any one or more of a variety of substances, including, but not limited to, beta-carotene (a vitamin A precursor), vitamin C, vitamin E, and selenium, that inhibit oxidation or reactions promoted by reactive oxygen species (ROS) and other radical and non-radical species. Additionally, antioxidants are molecules that can slow or prevent the oxidation of other molecules. Non-exemplary examples of antioxidants include astaxanthin, carotenoids, coenzyme Q10 ("CoQ10"), flavonoids, glutathione, Goji (wolfberry), hesperidin, lactowberry, lignans, lutein, lycopene, polyphenols, selenium, vitamin A, vitamin C, vitamin E, zeaxanthin, or combinations thereof.
[0114] A "backbone network ecology," or simply a "backbone network" or "backbone," is a composition of microorganisms that forms a foundation upon which a network ecology or functional network ecology can be established or subtracted to optimize the network ecology or functional network ecology, respectively, to have specific biological characteristics or to contain desired functional properties. Microbiome therapeutics can include these "backbone network ecologies" in their entirety, or the "backbone network" can be modified by adding or removing "R-groups" to impart desired characteristics and properties to the network ecology. An "R-group" can be defined in several terms, including, but not limited to, each OTU, each or multiple OTUs from a particular phylogenetic clade or a desired phenotype, such as the ability to form spores, or a functional bacterial composition that includes them. A "backbone network" can include a computationally derived network ecology in its entirety, or it can be a subset of a calculated network that represents important nodes in the network that contribute to efficacy, such as, but not limited to, the composition of keystone OTUs. The number of organisms in the human gastrointestinal tract and the diversity among healthy individuals indicate functional redundancy in the healthy gut microbiome ecology. See The Human Microbiome Consortia. 2012. Structure, function, and diversity of the healthy human microbiome. Nature 486: 207-214. This redundancy makes it highly likely that a non-distinct subset of OTUs or functional pathways (i.e., the "backbone network") are essential for maintaining a healthy state and / or catalyzing the transition from a dysbiotic state to a healthy state. One way to exploit this redundancy is through the substitution of OTUs (see below) that share a given clade or additional members of the clade not found in the backbone network.
[0115] "Bacterial composition" refers to a collection of microorganisms containing two or more OTUs. Backbone network ecology, functional network ecology, network class, and core ecology are all types of bacterial composition. "Bacterial composition" can also refer to a composition of enzymes derived from a microorganism or multiple microorganisms. As used herein, bacterial composition includes a therapeutic microbial composition, a prophylactic microbial composition, a spore population, a purified spore population, or an ethanol-treated spore population.
[0116] "Clade" refers to an OTU or member of a phylogenetic tree that is downstream of a statistically significant node in the phylogenetic tree (Figure 20). A clade comprises a set of terminal leaves (i.e., tree tips) of a phylogenetic tree that are distinct monophyletic evolutionary units and share some degree of sequence similarity. Clades are hierarchical. In one embodiment, the tree nodes selected to define a clade depend on the resolution appropriate to the underlying data used to calculate the tree morphology.
[0117] "Colonization" of a host organism includes non-transient inhabitation by bacteria or other microorganisms. As used herein, "reduced colonization" of the gastrointestinal tract (or any other microbiota niche) of a host subject by pathogenic or non-pathogenic bacteria includes a reduction in the time that bacteria inhabit the gastrointestinal tract as well as a reduction in the number (or concentration) of bacteria within the gastrointestinal tract or attached to the luminal side of the gastrointestinal tract. A reduction in adherent pathogens can be demonstrated directly, for example, by determining the pathogen load of a biological sample, or the reduction can be measured indirectly, for example, by measuring the pathogen load in the stool of a mammalian host.
[0118] A "combination" of two or more bacteria includes the physical coexistence of the two bacteria, either in the same substance or product or in a physically associated product, as well as the temporal co-administration or co-localization of the two bacteria.
[0119] Bacterial "cytotoxic" activity includes the ability to kill bacterial cells, such as pathogenic bacterial cells. "Cytostatic" activity or bacteria includes the ability to partially or completely inhibit the growth, metabolism, and / or proliferation of bacterial cells, such as pathogenic bacterial cells. Cytotoxic activity may also be applied to other cell types, such as, but not limited to, eukaryotic cells.
[0120] "Dysbiosis" refers to a state of the microbial flora or microbiome of the intestine or other body parts, including mucous membranes or skin surfaces, in which the normal diversity and / or function of the ecological network is disrupted. Any disruption of the preferred (e.g., ideal) state of the microbiota can be considered dysbiosis, even if the dysbiosis does not lead to a detectable decrease in health. This state of dysbiosis can be unhealthy, unhealthy only under certain circumstances, or can prevent a subject from becoming healthier. Dysbiosis can be due to a decrease in diversity, an overgrowth of one or more pathogens or pests, commensal organisms that can cause disease only when certain genetic and / or environmental conditions are present in the patient, or a shift to an ecological network that no longer provides an effective function for the host and therefore no longer promotes health.
[0121] "Ecological niche" or simply "niche" refers to the ecological space occupied by an organism or group of organisms. A niche describes how an organism or group or organisms responds to the distribution of resources, physical parameters (e.g., host tissue space) and competitors (e.g., thrive when resources are abundant and predators, parasites, and pathogens are scarce), and then how it modifies these same factors (e.g., act as a food source for predators and prey consumers, and limit access to resources by other organisms).
[0122] A "germinant" is a substance or composition or physico-chemical process capable of inducing, either directly or indirectly, the vegetative growth of a bacterium in resting spore form or a group of bacteria in spore form in a host organism and / or in vitro.
[0123] "Inhibition" of a pathogen or non-pathogen includes the inhibition of any desired function or activity by the bacterial compositions of the present invention. Demonstration of inhibition, such as a reduction in the growth of pathogenic bacteria or a reduction in the amount of pathogenic bacterial colonization, is provided herein or otherwise understood by those skilled in the art. Inhibition of the "growth" of pathogenic or non-pathogenic bacteria includes inhibiting the increase in size of pathogenic or non-pathogenic bacteria and / or inhibiting the proliferation (or multiplication) of pathogenic or non-pathogenic bacteria. Inhibition of pathogenic or non-pathogenic bacterial colonization may be demonstrated by measuring the amount or burden of the pathogen before and after treatment. "Inhibition" or "inhibitory" activity includes complete cessation and partial reduction of one or more activities of a pathogen, such as growth, proliferation, colonization, and function. Inhibition of function includes, for example, inhibition of the expression of a virulence gene product, such as a toxin or wetting pili, induced by the bacterial composition.
[0124] "Isolated" includes bacteria or other entities or substances that are (1) separated from at least some of the components with which they were associated when originally produced (whether in nature or in an experimental setting) and / or (2) produced, prepared, purified, and / or manufactured by the hand of man. Isolated bacteria include cultured bacteria, even if the culture is a monoculture. Isolated bacteria can be separated from at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more of the other components with which they were originally associated. In some embodiments, isolated bacteria are greater than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater than about 99% pure. As used herein, a substance is "pure" when it is substantially free of other components. The terms "purify," "purifying," and "purified" refer to bacteria or other substances that have been isolated from at least some of the components with which they were associated when originally produced or created (e.g., in nature or in an experimental setting) or at any time after their initial production. A bacterium or group of bacteria may be considered purified if it is isolated from a material or environment containing the bacterium or group of bacteria during or after production, or if it is isolated by subculturing; a purified bacterium or group of bacteria may contain up to about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than about 90% other substances and still be considered "isolated." In some embodiments, purified bacteria and bacterial populations are greater than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or greater than about 99% pure. In the exemplary bacterial compositions provided herein, one or more bacterial species present in the composition may be produced independently from one or more other bacteria produced and / or present in the material or environment containing that bacterial species. Bacterial compositions and their bacterial components are typically purified from residual habitat products.
[0125] A "keystone OTU" or "keystone function" refers to one or more OTUs or functional pathways (e.g., KEGG or COG pathways) that are common to many network ecologies or functional network ecologies and are members of networks that occur in many subjects (i.e., are pervasive). Due to the widespread nature of keystone OTUs and their associated functional pathways, they are central to the function of the network ecology in healthy subjects and are often absent or reduced in abundance in subjects with disease. Keystone OTUs and their associated functions can be present at low, moderate, or high abundance in a subject. A "non-keystone OTU" or "non-keystone function" refers to an OTU or function observed in a network ecology or functional network ecology that is not a keystone OTU or function.
[0126] "Microbiota" refers to a community of microorganisms (persistently or transiently) occurring in and on an animal subject, usually a mammal such as a human, and includes eukaryotes, archaea, bacteria, and viruses (including bacterial viruses, i.e., phages).
[0127] The "microbiome" is the genetic content of the community of microorganisms that live both permanently and transiently in and on the human body, including eukaryotes, archaea, bacteria, and viruses (including bacterial viruses (i.e., phages)), where "genetic content" includes all genomic DNA, RNA such as ribosomal RNA, epigenome, plasmids, and other types of genetic information.
[0128] "Bacterial carriage" or simply "carriage" refers to a group of microorganisms that inhabit a niche in or on humans. Carriage is often defined in terms of relative abundance. For example, OTU1 contains 60% of all bacterial carriage, meaning that OTU1 has a relative abundance of 60% compared to other OTUs in the measured sample. Carriage is most often based on genome sequencing data, where the relative abundance or carriage of a single OTU or group of OTUs is defined by the number of sequencing reads assigned to that OTU(s) compared to the total number of sequencing reads in the sample. Alternatively, carriage can be measured using microbiological assays.
[0129] "Microbial expansion" or simply "expansion" refers to: (i) microbial proliferation that is absent or undetectable (as determined using standard genomic and microbiological techniques) in the administered therapeutic microbial composition; (ii) microbial proliferation that is absent, undetectable, or present at low frequency in the host niche (e.g., gastrointestinal tract, skin, anterior nares, or vagina) prior to delivery of the microbial composition; and (iii) microbial proliferation that is observed after administration of the microbial composition, or present at low frequency, e.g., 2-fold, 5-fold, 1×10, or more. 2 , 1×10 3 , 1×10 4 , 1×10 5 , 1×10 6 , 1×10 7 or 1 x 10 8 The term "augmentation ecology" refers to the establishment or significant expansion of a microbial community that significantly increases in abundance above the normal range of the host. The microorganisms that comprise the augmentation ecology may originate from exogenous sources, such as food and the environment, or may grow from microniches within the host where they reside at low frequency. Administration of the bacterial-microorganism composition induces an environmental shift in the target niche that promotes conditions favorable for the growth of these symbiotic microorganisms. In the absence of treatment with the bacterial composition, the host may be continually exposed to these microorganisms; however, the sustained growth and positive health benefits associated with the increased abundance of a stable population of microorganisms that comprise the augmentation ecology are not observed.
[0130] "Microbial engraftment" or simply "engraftment" refers to the establishment within a target niche of OTUs present in a bacterial composition that are not present in the treated host prior to treatment. The microorganisms that comprise the engraftment ecology are found in the therapeutic microbial composition and establish as components of the host microbial ecology upon treatment. The engrafted OTUs may establish for a transient period of time within the microbial ecology inhabiting the host after treatment with the bacterial composition, or may exhibit long-term stability. The engraftment ecology may induce an environmental shift within the target niche that promotes conditions favorable for the growth of commensal microorganisms that can catalyze a transition from a dysbiosis ecology to one representative of a healthy state.
[0131] As used herein, the term "mineral" is understood to include boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, nickel, phosphorus, potassium, selenium, silicon, tin, vanadium, zinc, or combinations thereof.
[0132] "Network ecology" refers to a collection of clades or OTUs that co-occur within a certain number of subjects. As used herein, a "network" is mathematically defined by a graph that shows how specific nodes (i.e., clades or OTUs) and ends (connections between specific clades or OTUs) are related to each other and defines the structural ecology of a collection of clades or OTUs. Any given network ecology will possess unique phylogenetic diversity and functional characteristics. Network ecology can also be defined in terms of its functional capabilities, where, for example, nodes can consist of components such as, but not limited to, enzymes, Clusters of Orthologous Groups (COGS; http: / / www.ncbi.nlm.nih.gov / books / NBK21090 / ), or KEGG orthology pathways (www.genome.jp / kegg / ); these networks are referred to as "functional network ecologies." Functional network ecology can be put into practice by defining groups of OTUs that together contain the functions defined by the functional network ecology.
[0133] "Network class" and "network class ecology" refer to a group of network ecologies that are computationally determined to generally contain ecologies with similar phylogenetic and / or functional characteristics. Thus, a network class encompasses key biological features, defined either phylogenetically or functionally, of a group (i.e., cluster) of related network ecologies. One exemplary network class ecology is an engineered collection of microorganisms, typically nonpathogenic bacteria, that exhibit core features of a set of phylogenetically or functionally related network ecologies found in many different subjects. In many instances, while engineered as described herein, the network class exists as a network ecology observed in one or more subjects. Network class ecologies are useful for reversing or alleviating dysbiosis in subjects whose underlying related network ecology is perturbed. Exemplary network classes are provided in Table 12, and examples of phylogenetic signatures by family of network classes are provided in Table 13.
[0134] By free of "non-edible products" is meant that the bacterial compositions or other materials provided herein do not have substantial amounts of non-edible products, e.g., products or materials that are inedible, harmful, or otherwise undesirable in a product suitable for administration to a human subject, e.g., oral administration. Non-edible products are often found in prior art bacterial preparations.
[0135] "Operational Taxonomic Unit" and "OTU" (or plural "OTUs") refer to the terminal leaves of a phylogenetic tree and are defined by a nucleic acid sequence, e.g., an entire genome or a specific gene sequence, and all sequences that share sequence identity with this nucleic acid sequence at the species level. In some embodiments, the specific gene sequence can be a 16S sequence or a portion of a 16S sequence. In other embodiments, the entire genomes of two entities are sequenced and compared. In another embodiment, selected regions, such as multilocus sequence tags (MLST), specific genes or sets of genes, can be genetically compared. In 16S embodiments, OTUs that share 97% or greater average nucleotide identity across the entire 16S or a variable region of the 16S are considered to be the same OTU. See, e.g., Claesson MJ, Wang Q, O'Sullivan O, Greene-Diniz R, Cole JR, Ross RP, and O'Toole PW. 2010. Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res 38: e200., Konstantinidis KT, Ramette A, and Tiedje JM. 2006. The bacterial species definition in the genomic era. Philos Trans R Soc Lond B Biol Sci 361: 1929-1940. In embodiments involving complete genomes, MLST, or a specific gene or set of genes other than 16S, OTUs sharing 95% or more average nucleotide identity are considered the same OTU.See, for example, Achtman M, and Wagner M. 2008. Microbial diversity and the genetic nature of microbial species. Nat. Rev. Microbiol. 6: 431-440. Konstantinidis KT, Ramette A, and Tiedje JM. 2006. The bacterial species definition in the genomic era. Philos Trans R Soc Lond B Biol Sci 361:1929-1940. OTUs are often defined by comparing sequences between organisms. Generally, sequences with less than 95% sequence identity are not considered to form part of the same OTU. OTUs can also be characterized by any combination of nucleotide markers or genes, particularly highly conserved genes (e.g., "housekeeping" genes), or a combination thereof. Such characterization can utilize, for example, WGS data or entire genome sequences.
[0136] Table 1 below lists operational taxonomic units (OTUs) with taxonomic assignments to genus, species, and phylogenetic clades. Whether a bacterial OTU is a member of a clade is based on 16S sequence data. Clades are defined based on the morphology of a phylogenetic tree constructed from full-length 16S sequences using maximum likelihood methods well known to those skilled in the art of phylogenetics. Clades are constructed to ensure that all OTUs of a given clade: (i) are within a specific number of nodes that are mutually supported by bootstrap, and (ii) are within 5% genetic homology. OTUs within the same clade can be genetically and phylogenetically distinct from OTUs of different clades based on 16S-V4 sequence data, while OTUs within the same clade are closely related. OTUs within the same clade are evolutionarily related and may or may not be distinguishable from each other using 16S-V4 sequence data. Due to their evolutionary relatedness, members of the same clade have similar functional roles in bacterial ecology, such as that found in the human gut. Compositions in which one species is replaced by another species of the same clade are likely to have conserved ecological functions and are therefore useful in the present invention. All OTUs are designated with respect to their putative ability to form spores and whether they are pathogens or pests (see definitions for an explanation of "pests"). NIAID priority pathogens are designated "Category A," "Category B," or "Category C," and opportunistic pathogens are designated "OP." Non-pathogenic OTUs, or OTUs with unknown ability to exist as pathogens, are designated "N." "SEQ ID NO." refers to the OTU's identifier in the sequence listing file, and "Public DB Accession" refers to the OTU's identifier in the public sequence repository.
[0137] "Pathobionts" are specific bacterial species found in healthy hosts that can cause immune-mediated pathologies and / or diseases in response to specific genetic or environmental factors (Chow et al. 2011. Curr Op Immunol. Pathobionts of the intestinal microbiota and inflammatory disease. 23: 473-80). As such, pasobionts are opportunistic microorganisms that are mechanistically distinct from acquired infectious organisms. Therefore, the term "pathogen" encompasses both acquired infectious organisms and pasobionts.
[0138] "Pathogen," "pathobiont," and "pathogenic," as they relate to bacteria or any other organism or entity, include any such organism or entity that is capable of causing or affecting a disease, disorder, or condition in a host organism that contains the organism or entity, including, but not limited to, pre-diabetes, type 1 diabetes, or type 2 diabetes.
[0139] "Phenotype" refers to the set of observable characteristics of an individual entity. As an example, an individual subject may have a "healthy" or a "disease" phenotype. A phenotype describes the state of an entity, and all entities within a phenotype share the same set of characteristics that describe that phenotype. An individual's phenotype results, in part or in whole, from the interaction of that entity's genome and / or microbiome with its environment, including, in particular, its diet.
[0140] "Phylogenomic diversity" is a biological characteristic that refers to the biodiversity present in a given network ecology or network class ecology based on the OTUs that make up the network. Phylogenetic diversity is a relative term; a network ecology or network class that is relatively more phylogenetically diverse than other networks contains a greater number of unique species, genera, and taxonomic families. Species, genus, or taxonomic family endemism is typically defined using a phylogenetic tree that represents the genetic diversity for each of the total species, genera, or taxonomic families. In another embodiment, phylogenetic diversity can be measured using the total length or average branch length of the phylogenetic tree. Phylogenetic diversity can be optimized in bacterial compositions by encompassing a broad range of biodiversity.
[0141] "Phylogenetic tree" refers to a graphical representation of the evolutionary relationships of one genetic sequence to another, created using a defined set of phylogenetic reconstruction algorithms (e.g., parsimony, maximum likelihood, or Bayesian methods). The nodes of the tree represent different ancestral sequences, and the credibility of any node is provided by bootstrap or Bayesian posterior probabilities, which measure the uncertainty of the branches.
[0142] "Prediabetes" refers to a condition in which the amount of glucose in the blood is higher than normal, but not high enough to be classified as diabetes. Individuals with prediabetes are at increased risk of developing type 2 diabetes within 10 years. According to the CDC, prediabetes can be diagnosed by a fasting glucose level between 100 and 125 mg / dL, a plasma glucose level between 140 and 199 mg / dL two hours after glucose administration in an oral glucose tolerance test (OGTT), or a hemoglobin A1c test between 5.7% and 6.4%.
[0143] "rDNA," "rRNA," "16S-rDNA," "16S-rRNA," "16S," "16S sequencing," "16S-NGS," "18S," "18S-rRNA," "18S-rDNA," "18S sequencing," and "18S-NGS" refer to the nucleic acids encoding the RNA subunits of the ribosome. rDNA refers to the gene encoding the rRNA that contains the RNA subunit. Ribosomes contain two RNA subunits, called the small subunit (SSU) and the large subunit (LSU); the RNA genetic sequences of these subunits (rRNA) are linked by the genetic code to the gene (rDNA) that encodes them. rDNA genes and their complementary RNA sequences are variable but sufficiently conserved to allow molecular comparisons across organisms and are therefore widely used to determine the amount of evolutionary relatedness of organisms. Typically, the 16S rDNA sequence (approximately 1542 nucleotides long) of the 30S SSU is used for molecular-based taxonomic assignment of prokaryotes, and the 18S rDNA sequence (approximately 1869 nucleotides long) of the 40S SSU is used for eukaryotes. 16S sequences are generally highly conserved but contain certain hypervariable regions that harbor sufficient nucleotide diversity to distinguish most bacterial genera and species, and are therefore used for phylogenetic reconstruction.
[0144] "Residual habitat products" refers to materials originating from the habitat of microbial flora in or on humans or animals. For example, microbiota reside in the feces of the gastrointestinal tract, on the skin, in saliva, the mucous membranes of the respiratory tract, or secretions of the genitourinary tract (i.e., biological material associated with the bacterial community). Substantially free of residual habitat products means that the bacterial composition no longer contains biological material associated with the microbial environment in or on a human or animal subject, and is 100% free, 99% free, 98% free, 97% free, 96% free, or 95% free of any contaminating biological material associated with the microbial community. Residual habitat products may include abiotic material (including undigested food) or may include undesirable microorganisms. Substantially free of residual habitat products may also mean that the bacterial composition does not contain any detectable cells of human or animal origin, and only microbial cells are detectable. In one embodiment, being substantially free of residual habitat products can also mean that the bacterial composition is free of any detectable viral (including bacterial viruses (i.e., phage)), fungal, or mycoplasmal contaminants. In another embodiment, it means that fewer than 1×10%, 1×10%, 1×10%, 1×10%, 1×10%, 1×10%, or 1×10% of viable cells in the bacterial composition are human or animal cells, relative to the microbial cells. There are multiple ways to achieve this purity, none of which are limiting. Thus, contamination can be mitigated by isolating the desired component through multiple steps of streaking single colonies until successive replicate (e.g., two) streaks of a single colony show only single-colony morphology. Alternatively, contamination reduction can be achieved through multiple serial dilutions (e.g., 10 or 10 dilutions) of a single desired cell, such as through multiple 10-fold serial dilutions. This can be further confirmed by showing that multiple isolated colonies have similar cell shape and Gram staining behavior.Other methods for confirming adequate purity include genetic analysis (e.g., PCR, DNA sequencing), serological and antigenic analysis, enzyme and metabolic analysis, and the use of reagents and instrumentation such as flow cytometry to distinguish the desired component from contaminants.
[0145] The term "spore" or "spore" includes bacteria (or other single-celled organisms) that are generally viable and more resistant to environmental influences such as heat and disinfectants than the vegetative form of the same bacterium, and are usually capable of germination and growth. Spores are characterized by the absence of an active metabolism until germination is triggered in response to specific environmental signals. A "spore-forming bacterium" or "capable of forming spores" is a bacterium that contains the genes and other necessary capabilities to produce spores under the appropriate environmental conditions. A table of preferred spore-forming bacterial compositions is provided in Table 11.
[0146] A "spore population" refers to a plurality of spores present in a composition. Synonyms used herein include spore composition, spore preparation, ethanol-treated spore fraction, and spore ecology. Spore populations can be purified from fecal donations, for example, via ethanol or heat treatment or density gradient separation, or any combination of the methods described herein, to increase the purity, potency, and / or concentration of spores in the sample. Alternatively, spore populations can be obtained through culture methods starting from isolated spore species or spore OTUs, either in vegetative or spore form, or mixtures of such species.
[0147] In one embodiment, the spore preparation comprises spore-forming species, wherein the remaining non-spore-forming species have been inactivated by chemical or physical treatment, including ethanol, detergents, heat, sonication, etc.; or wherein the non-spore-forming species have been removed from the spore preparation by various separation processes, including density gradients, centrifugation, filtration, and / or chromatography; or wherein inactivation and separation methods are combined to produce the spore preparation. In yet another embodiment, the spore preparation comprises spore-forming species enriched over viable non-spore-forming or spore-forming vegetative forms. In this embodiment, the spores are enriched 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, 1000-fold, 10,000-fold, or greater than 10,000-fold compared to all vegetative forms of bacteria. In yet another embodiment, the spores in the spore preparation undergo partial germination during processing and formulation, such that the final composition contains spores from spore-forming species and vegetative bacteria.
[0148] A "sporulation inducer" is a substance or physical-chemical process capable of inducing sporulation in bacteria, either directly or indirectly, in a host organism and / or in vitro.
[0149] "Increasing bacterial spore production" includes active or sporulation-inducing agents. "Production" includes the conversion of vegetative bacterial cells to spores and increasing the rate of such conversion, as well as reducing germination of spore-form bacteria, reducing the rate of spore decay in vivo or ex vivo, or increasing the total yield of spores (e.g., by increasing the volumetric yield of fecal material).
[0150] "Subject" refers to any animal subject, including humans, laboratory animals (e.g., primates, rats, mice), farm animals (e.g., cattle, sheep, goats, pigs, turkeys, and chickens), and home pets (e.g., dogs, cats, and rodents). The subject may be suffering from a dysbiosis that contributes to or causes a condition classified as diabetes or pre-diabetes, including, but not limited to, mechanisms such as metabolic endotoxemia, altered metabolism of primary bile acids, immune system activation, or imbalanced or decreased production of short-chain and branched-chain fatty acids, including butyrate, propionate, and acetate.
[0151] The term "vitamin," as used herein, is understood to include any of a variety of fat-soluble or water-soluble organic substances (non-limiting examples include vitamin A, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin or niacinamide), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxine, pyridoxal, or pyridoxine hydrochloride), vitamin B7 (biotin), vitamin B9 (folic acid), and vitamin B12 (various cobalamins; commonly the vitamin supplement cyanocobalamin), vitamin C, vitamin D, vitamin E, vitamins K, K1, and K2 (i.e., MK-4, MK-7), folic acid, and biotin), provitamins, derivatives, and analogs that are essential in trace amounts for the normal growth and activity of the body and that are obtained naturally from plant and animal foods or produced synthetically.
[0152] "V1-V9 region" or "16S V1-V9 region" refers to the 16S rRNA and refers to the first through ninth hypervariable regions of the 16S rRNA gene, used for genetic typing of bacterial samples. These bacterial regions are defined as nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294, and 1435-1465, respectively, using numbering based on the Escherichia coli system of nomenclature. Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli, PNAS 75(10):4801-4805 (1978). In some embodiments, at least one of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions is used to characterize an OTU. In one embodiment, the V1, V2, and V3 regions are used to characterize an OTU. In another embodiment, the V3, V4, and V5 regions are used to characterize an OTU. In another embodiment, the V4 region is used to characterize an OTU. One skilled in the art can identify specific hypervariable regions of a candidate 16S rRNA by comparing a candidate sequence of interest to a reference sequence and identifying hypervariable regions based on homology to the reference hypervariable regions, or alternatively, can use whole genome shotgun (WGS) sequence characterization of a microorganism or microbial community.
[0153] Interactions between the microbiome and the host Interactions between the human microbiome and the host shape host health and disease through multiple mechanisms, including the provision of essential functions by the microbiota, including, but not limited to, the microbiota's functions in ensuring healthy levels of bile acid metabolism, energy harvesting and storage, and regulation of the immune response, as well as mitigating harmful and unhealthy levels of intestinal permeability or metabolic endotoxemia.
[0154] The Importance of Bile Acids to Human Health and the Role of the Microbiota Primary bile acids, cholic acid (CA) and chenodeoxycholic acid (CDCA), are synthesized from cholesterol in the human liver. The synthesized primary bile acids are conjugated with glycine, taurine, or sulfate before secretion into bile by specific transporters located in the basolateral membrane of hepatocytes. Dietary digestion triggers the release of bile from the gallbladder into the intestinal lumen, where bile acids form micelles with dietary lipids and fat-soluble vitamins, facilitating their absorption. Approximately 95% of bile acids are reabsorbed via specific transporters expressed in the distal ileum, while the remaining 5% escape the enterohepatic cycle and proceed to the large intestine, where they are excreted in feces. In the colon, bile acids can undergo deconjugation and dehydroxylation by the intestinal microflora. The resulting secondary bile acids are primarily deoxycholic acid (DCA) and lithocholic acid (LCA). In humans, the bile acid pool undergoes this enterohepatic cycle approximately 12 times per day. While the bile acid pool size is constant, bile acid flux varies throughout the day; bile acid flux and plasma bile acid concentrations are highest after a meal (see reviews Prawitt, J et al. 2011 Curr Diab Rep Bile acid metabolism and thepathogenesis of type 2 diabetes 11: 160-166; Nieuwdorp et al. 2014 Gastroenterology. Role of the Microbiome in Energy Regulation and Metabolism. pii: S0016-5085(14)00219-4. doi: 10.1053 / j.gastro.2014.02.008).
[0155] Commensal bacteria are involved in the processing of primary bile acids into secondary bile acids in the colon. Known biotransformations of bile acids by commensal GI bacteria include deconjugation of conjugated bile salts to liberate free bile acid and amino acid moieties, removal of hydroxyl groups, primarily the C-7 hydroxyl group of the cholic acid moiety, oxidation-reduction reactions of existing hydroxyl groups, and epimerization of bile acids.
[0156] The standard first step in bile acid metabolism is the deconjugation of the taurine or glycine group by enzymes called bile salt hydrolases to yield CA and CDCA. These bile acids then serve as substrates for a series of enzymatic steps that remove the 7-alpha hydroxyl group to form deoxycholic acid (DCA) and lithocholic acid (LCA). LCA is particularly water-soluble compared to other bile acids due to the loss of its hydrophilic side chain. Microorganisms also likely dehydroxylate conjugated primary bile acids, producing gluco-DCA, gluco-LCA, tauro-DCA, and tauro-LCA. Further modifications are possible, including microbial conversion of CDCA to its 7-beta hydroxy epimer, ursodeoxycholic acid (UDCA). Many other secondary bile acids are produced in smaller amounts by the gut microbiota, such as alpha-, beta-, gamma-, and omega-muricholic acid, and many others (see Swann JR et al., 2011 PNAS Systemic gut microbial modulation of bileacid metabolism in host tissue compartments 108: 4523-30).
[0157] The gut microbiota plays an important role in bile acid metabolism. Germ-free mice have altered bile acid metabolism, with no deconjugation, increased amounts of conjugated bile acids throughout the gut, and greatly reduced fecal excretion. Providing mice with ampicillin increases bile acid production threefold and reduces fecal production by 70%.
[0158] Dysbiosis of the gut microbiome, which affects bile acid metabolism, can affect obesity, glucose control, and inflammation, among other effects. Bile acids are essential solubilizers of lipids, fats, and fat-soluble vitamins, enhance nutrient absorption in the small intestine, and are also signaling molecules that regulate metabolism, including glucose homeostasis and basal metabolic rate. See Houten, SM et al. 2006 EMBO J. Endocrine function of bile acids. 25:1419-25; Prawitt, J et al. 2011 Curr Diab Rep. Bile acid metabolism and the pathogenesis of type 2 diabetes. 11: 160-166. For example, bile acid sequestrants (nonabsorbable polymers that complex bile acids in the intestinal lumen and divert them from the enterohepatic cycle) can improve glycemic control in patients with type 2 diabetes. Prawitt, J et al. 2011 Curr Diab Rep Bile acid metabolism and the pathogenesis of type 2 diabetes 11: 160-166.
[0159] The most prominent targets of action of bile acids and their metabolites include FXR (farnesoid X receptor), a nuclear orphan receptor in the liver and intestine, and TGR5, a G protein-coupled receptor found in the gallbladder, ileum, colon, brown and white adipose tissue. FXR is preferably activated by CDCA, which then upregulates the expression of gene products, including human FGF-19 (fibroblast growth factor 19). FGF-15 (the mouse analog of FGF-19) increases the basal metabolic rate and reverses weight gain in mice fed a high-fat diet. FXR activation also downregulates hepatic gluconeogenesis. Both conjugated and unconjugated bile acids can bind to FXR, but while unconjugated bile acids can diffuse across membranes due to their lower molecular weight, higher pKa, and tendency to exist in the protonated form, conjugated forms must be actively transported into cells to initiate signaling.
[0160] TGR5 is preferably activated by the secondary bile acids LCA and tauro-LCA, with a negative effect on the expression of incretin hormones, particularly GLP-1, which regulate insulin production and help maintain glucose homeostasis.
[0161] Therefore, bile acids are important metabolic regulators. Further insight into the importance of the interplay between the gut microbiome, bile acid metabolism, and glucose homeostasis is provided by the observation that treating obese male patients with a 7-day course of vancomycin reduces overall microbiota diversity, specifically depleting species from the diverse Clostridium IV and XIVa clusters. Among Clostridium species, there are various organisms that metabolize bile acids and others that produce short-chain fatty acids, including butyrate and propionate. In contrast, a 7-day course of amoxicillin treatment produces a trend toward increased microbiota diversity. Furthermore, fecal bile acid composition significantly changes after vancomycin treatment; secondary bile acids DCA, LCA, and iso-LCA decrease, while primary bile acids CA and CDCA increase. Amoxicillin treatment does not alter the proportion of bile acids in fecal samples. Serum FGF-19 levels also decrease after vancomycin treatment, but not after amoxicillin treatment. Peripheral insulin sensitivity decreases after vancomycin treatment but not after amoxicillin treatment. Vrieze, A et al., 2013 J Hepatol Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensistivitydx.doi.org / 10.1016 / j.jhep.2013.11.034
[0162] While the study by Vrieze et al. points to the potential for microorganisms to improve insulin homeostasis through enhanced secondary bile acid metabolism, the authors point out several limitations in their study. Most importantly, while the HIT-Chip analysis used to generate fecal microbial profiles provides valuable information regarding the class of organisms, it does not provide mechanistic information or identify the specific species or functional enzyme pathways responsible for the observed effects. Furthermore, the HIT-Chip is a hybridization-based assay, and sequence homology among organisms in the Clostridium cluster can lead to incorrect assignments. As a result, others have not been able to define specific compositions that can be used to regulate insulin sensitivity via bile acid metabolism.
[0163] In addition to their role as metabolic regulators, bile acids are also implicated in inflammatory diseases: Crohn's disease patients in the Metagenomics of the Human Intestinal Tract (MetaHIT) cohort showed decreased bile salt hydrolase (BSH) gene abundance compared with disease-free patients, and increased primary bile acids in patients with inflammatory bowel syndrome correlated with stool frequency and consistency (Duboc et al. 2012 Neurogastroenterol Motil. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. doi: 10.1111 / j.1365-2982.2012.01893.x). Furthermore, TGR5 is expressed in immune monocytes and macrophages as well as in GI and liver tissues, and FXR and TGR5 are known to be involved in regulating inflammation in enterohepatic tissues (Jones et al., 2014 Expert Opin Biol Ther The human microbiome and biolearning metabolism: dysbiosis, dysmetabolism, disease and interventiondoi:10.1517 / 14712598.2014.880420).
[0164] Several methods are available for the determination of bile acids in the serum, bile, and faces of individuals. According to Sharma (Sharma, KR, Review on bile acid analysis, Int J Pharm Biomed Sci 2012, 3(2), 28-34), various methods can be used, including chemical (Carey JB, et al, 1958, The bile acids in normal human serum with comparative observations in patients with jaundice. J Lab Clin Med 1958, 46, 860-865), thin-layer chromatography (Fausa O, and Shalhegg BA. 1976 Quantitative determination of bile acids and their conjugates using thin-layer chromatography and a purified 3-α hydroxysteroid dehydrogenase. Scand J Gastroenterol 9, 249-254), and high-performance liquid chromatography (Islam S, et al. Fasting serum bile acid level in cirrhosis “A semiquantitative index of hepatic function”. J Hepatol 1985, 1, 609-617; Paauw JD, at al. Assay fortaurine conjugates of bile acids in serum by reversed phase high performance liquid chromatography. J Chromatograph B Biomed Appl 1996, 685, 171-175), radioimmunoassay (Wildgrube J, Stockhausan H, Peter M, Mauritz G, Mahdawi R. Radioimmunoassay of bile acids in tissues, bile and urine.Clin Chem 1983, 29,494-498), enzyme-linked colorimetric and radioimmunoassay (Guo W, et al. A study on detection of serum fasting total bile acid and chologlycin in neonates for cholesterol. Chin Med Sci J 1996, 11, 244-247.), mass spectrometry (Sjovell J, et al. Mass spectrometry of bile acids. Method in enzymology. Vol. III, Academic Press, New York 1985.), tandem mass spectrometry (Griffiths WJ. Tandem mass spectrometry in study of fatty acids, bile acids and steroids. Mass Spectrum Rev 2003, 22, 81-152.), gas chromatography with high-resolution glass capillary column and mass spectrometry (Setchell KDR, Matsui A. Serum bile acid analysis. Clin Chim Acta 1983,127, 1-17.), gas chromatography (Fischer S, et al. Hepatic levels of bile acids in end stage chronic cholestatic liver disease. Clin Chim Acta 1996,251,173-186.), gas liquid chromatography (Van BergeHengouwen GP et al., Quantitative analysis of bile acids in serum and bile, using gas liquid chromatography. Clin Chim Acta 1974,54,249-261; Batta AK, et al.Characterization of serum and urinary bile acids in patients with primarybiliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect ofursodeoxycholic acid treatment. J Lipid Res 1989, 30, 1953- 1962) (Luminometric method) (Styrellius I, Thore A,Bjorkhem I. Luminometric method. In: Methods of enzymatic analysis. (Ed. III).Bergmeyer, Hans Ulirch [Hrsg]. 8: 274-281, 1985.) and UV absorption of solvents (Staver E, et al. Fluorimetric method for serum. In: Methods ofenzymatic analysis. (Ed.III). Bergmeyer, Hans Ulrich; 288-290, 1985;UV method for bile, gastric juice and duodenai aspirates, (edIII).8:285-287, 1985). et al.Measurement oftotal bile acids in gastric juice. 23, 594-598 Hanson NQ,Freier EF;Enzymatic measurement of total bile acid adapted to the Cobas Fara Centrifugal analyzer. Clin Chem. 1985, 35, 1538-1539) can be used.
[0165] The Importance of Short-Chain Fatty Acids (SCFAs) to Human Health and the Role of the Microbiota Short-chain fatty acids (SCFAs) are the primary products of bacterial fermentation in the colon. SCFAs, particularly acetate, propionate, and butyrate, are thought to have many potential benefits for mammalian hosts. SCFAs are organic acids with fewer than six carbons and include acetate, propionate, butyrate, valerate, isovalerate, and 2-methylbutyrate. While longer-chain fatty acids are primarily obtained from dietary sources, SCFAs are derived from the breakdown of indigestible plant fiber. Butyrate is the primary energy source for colonocytes, while propionate is thought to be metabolized primarily by the liver via portal circulation from the colon. Acetate is thought to be derived from the microbiota and more generally available to tissues.
[0166] In addition to serving as metabolic substrates, SCFAs have multiple benefits, including their essential role in immune homeostasis and immune regulation, particularly by regulatory T cells. Direct ingestion of acetate, propionate, or butyrate, or a mixture of all three, by mice stimulates the proliferation and maturation of colonic regulatory T cells (Tregs). Mice receiving SCFAs in their drinking water had significantly higher colonic CD4+FoxP3+ T cells (Tregs) than germ-free and SPFA-fed controls, and these Treg cells were functionally more potent, as measured by IL-10 mRNA and protein expression and their ability to inhibit CD8+ effector T cells in vitro (Smith PM et al. 2013 Science The microbial metabolites, short-chain fatty acid regulates colonic Treg cell homeostasis 341: 569-73). This effect of SCFAs is mediated by signaling via GPR43 (FFAR2), a G protein-coupled receptor expressed on various cell types, but most frequently on colonic Treg cells. GPR43 signaling is upstream of the modification of histone deacetylase activity (particularly HDAC9 and HDCA3), which is known to alter gene expression through chromatin remodeling. Furthermore, the effects of experimental colitis induced by adoptive T cell transfer are attenuated by SCFAs, including propionate alone and a mixture of acetate, propionate, or butyrate, in a GPR43-dependent manner.
[0167] Beyond the direct effects of orally administered SCFAs in animals, microorganisms can produce SCFAs in situ in the colon and improve outcomes in multiple disease models. The first butyrate-forming organism isolated from chickens was identified. 9Daily administration of cfu of Butyricicoccus pullicaecorum for one week ameliorates TNBS-induced E. coli in a rat model (Eeckhaut V et al., 2013 Gut Progress towards butyrate-producing pharmacological agents: Butyricicoccus pullicaecorum capsule and efficacy in TNBS modeling in comparison with therapeutics doi:10.1136 / gutjnl-2013-305293). In humans, topical administration of butyrate or sodium butyrate via rectal enemas can be beneficial for patients with ulcerative colitis (Scheppach W et al. 1992 Gastroenterol Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis 103:51-56; Vernia P et al. 2003 Eur. J. Clin. Investig. Topical butyrate improves efficacy of 5-ASA inrefractory distal ulcerative colitis: results of a multicentre trial. 33:244-48). Butyrate has effects at multiple levels, including signaling through GPR109A, which is expressed on the apical membrane of intestinal epithelial cells (IECs). GPR109A reduces NFKB-mediated gene expression, including reduced expression of the proinflammatory cytokines TNF-alpha, IL-6, and IL-1beta.
[0168] Oral administration of SCFAs to mice also has a direct effect on metabolism. SCFAs are a significant energy source, and therefore, fermentation by the microbiota can contribute up to 5–10% of basal energy requirements in humans. SCFAs upregulate the production of glucagon-like peptide 1 (GLP-1), peptide (P)YY, and insulin. GLP-1 and PYY are known to play roles in increasing satiety and reducing food intake. Furthermore, fecal transplantation from lean human donors to obese recipients with metabolic syndrome significantly increases insulin sensitivity after 6 weeks. This change is most correlated with the transplantation of Eubacterium hallii, a Gram-positive butyrate-fermenting microorganism (Vrieze, A., et al., 2012 Gastroenterol Transfer of intestinal microbiota from lean donors increases insulin sensitivity 143: 913-6).
[0169] A common underlying factor in both diabetes and obesity is the phenomenon of low-dose inflammation called metabolic endotoxemia (see below). Metabolic endotoxemia refers to increased intestinal permeability (leaky gut syndrome) in addition to increased lipopolysaccharide (LPS) translocation, mediating an inflammatory response that leads to insulin resistance, altered lipid metabolism, and liver inflammation, which contributes to nonalcoholic fatty liver disease (NAFLD). Low-dose bacteremia can also lead to the translocation of viable Gram-negative organisms to distal tissues, such as adipocytes, causing further inflammation. SCFAs again offer benefits, both by providing an energy source and strengthening colonic epithelial cell integrity, and by stimulating the expression of tight junction proteins, thereby reducing the translocation of Gram-negative LPS, bacterial cells, and their fractions (Wang HB et al., 2012 Dig Dis Sci Butyrate enhances intestinal lepithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription 57: 3126-35).
[0170] For all these reasons, it would be useful to have a microbial consortium with an enhanced ability to produce SCFAs for the treatment of diseases such as diabetes, obesity, inflammation, ulcerative colitis, and NAFLD.
[0171] Acetate, propionate, and butyrate are formed as end products in anaerobic fermentation. SCFA-producing bacteria in the gut obtain energy through substrate-level phosphorylation during the oxidative degradation of carbon precursors. However, the resulting reducing equivalents, captured in the form of NADH, must be removed to regenerate NAD+ and maintain redox balance, thus maintaining the energy drive to produce large amounts of reduced end products such as butyrate and propionate. Acetate, propionate, and butyrate are not the only end products of fermentation: gut microbes also produce lactate, formate, hydrogen, and carbon dioxide, depending on the circumstances. As discussed below, lactate and acetate can also lead to the formation of butyrate and propionate through the mutualism of nutrition by one microorganism on another.
[0172] The rate of SCFA production in the colon is highly dependent on many factors, including the availability of polysaccharide carbon sources (such as, but not limited to, fructans, starches, celluloses, galactomannans, xylans, arabinoxylans, pectins, inulins, fructooligosaccharides, etc.), the presence of alternative electron sinks such as sulfate and nitrates, redox potential, hydrogen (H) partial pressure, and pH. As noted above, organismal syntrophy can also play a role, for example, when lactate-forming organisms provide lactate as a substrate for butyrate- or propionate-producing strains, or when saccharolytic organisms degrade complex polysaccharides to provide mono- or disaccharides for fermentation. Acetate, which can reach concentrations up to 30 mM in the intestine, is also an important building block for butyrate production, via the action of the enzyme butyryl-CoA:acetate-CoA transferase, the final step in butyrate production. Importantly, this enzyme can also function as a propionyl-CoA:acetate CoA transferase, leading to the production of propionate.
[0173] Because diet is a major determinant of the variety of carbon sources and other nutrients available in the colon, it is clear that a functional ecology for SCFA production involves multiple organisms that can adapt to diet-induced changes in the intestinal environment. Thus, there is a need for bacterial compositions that can ferment sufficient amounts of SCFA products despite the various environmental conditions imposed by a changing diet. Such bacterial compositions would include organisms that can ferment a variety of carbon sources to SCFAs.
[0174] Role of the Microbiota in Metabolic Endotoxemia / Bacteremia Chronic, low-grade inflammation is a hallmark of obesity and is known to play a pathogenic role in the metabolic complications of the disease and poor health outcomes. In particular, obesity is associated with elevated plasma levels of bacterial lipopolysaccharide (LPS). Energy intake, particularly a high-fat diet (HFD), increases intestinal permeability and increases plasma LPS levels by 2-3 fold. Circulating LPS represents a pathway for bacterial fractions to enter the systemic circulation beyond the intestine (termed "metabolic endotoxemia"), either through increased diffusion via intestinal paracellular permeability or absorption by enterocytes during chylomicron secretion. Subcutaneous injection of LPS into wild-type mice maintained on a standard diet for 4 weeks led to increased whole-body, liver, and adipose tissue weights, adipose and liver inflammation, and fasting hyperglycemia and insulinemia, effects comparable to those induced by an HFD (Cani et al., 2007 Diabetes. Metabolic endotoxemia initiates obesity and insulin resistance doi:10.2337 / db06-1491). In addition to bacterial fractionation, translocation of live bacteria into host tissues (termed "metabolic bacteremia") can also be a hallmark of obesity (Shen et al., 2013 Mol Aspects Med. The gut microbiota, obesity and insulin resistance doi: 10.1016 / j.mam.2012.11.001).
[0175] Host-microbiota interactions at the intestinal mucosal interface are involved in intestinal barrier function and bacterial surveillance / sensing. Intestinal dysbiosis can promote bacterial translocation and obesity-associated inflammation. In one example, metabolic endotoxemia in HFD-induced obesity in mice is associated with a reduction in Bifidobacterium, and both can be improved by treatment with inulin (oligofructose) (Cani et al. Diabetologia Selective increases of bifidobacteria ingut microflora improve high-fat-diet-induced diabetes in mice through amechanism associated with endotoxemia doi: 10.1007 / s00125-007-0791-0). The beneficial effects of inulin and Bifidobacterium promote intestinal growth and involve enhanced production of intestinotrophic proglucagon-derived peptide 2 (GLP-2), a peptide produced by intestinal L-cells (Cani et al. Gut. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. doi:10.1136 / gut.2008.165886).Alternative pathways involved in host-microbiota interactions and intestinal barrier integrity and metabolic endotoxemia / bacteremia include enteroactive proglucagon-derived peptide (GLP)-2, endocannabinoid (eCB) signaling, and pattern recognition receptors, including nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) such as NOD1 / NLRC1 and NOD2 / NLRC2, and Toll-like receptors (TLRs) such as TLR-2, TLR-4, TLR-5, and the TLR adaptor protein myeloid differentiation transient response protein 88 (MyD88) (see review Shen et al., 2013 Mol Aspects Med. The gut microbiota, obesity and insulin resistance doi: 10.1016 / j.mam.2012.11.001).
[0176] The role of the microbiota in energy recovery and storage: The gut microbiota is involved in host energy recovery. Germ-free (GF) mice consume more energy than wild-type mice but are significantly leaner. Conventionalization of GF mice fed a low-fat, high-sugar diet with the microbiota of conventionally raised mice leads to 60% more obesity and insulin resistance despite reduced food intake (Backhed et al., 2004 PNAS The gut microbiota as an environmental factor that regulates fat storage doi: 10.1073 / pnas.0407076101). GF mice acclimated to the microbiota of obese mice experience significantly greater gains in total body fat than GF mice acclimated to the microbiota of lean mice. Obese (ob / ob) mice retain significantly less energy in their feces than their lean littermates, as measured by bomb calorimetry (Turnbaugh et al. 2006 Nature. An obesity-associated gut microbiome with increased capacity for energy harvest doi:10.1038 / nature05414). In humans, "surplus nutrition" (defined as energy expenditure as a percentage of the energy requirement to maintain body weight) is proportionally greater associated with Firmicutes and proportionally less associated with Bacteroidetes.Energy loss (fecal calorie content as a percentage of ingested calories) in lean subjects was negatively related to proportional changes in Firmicutes and positively related to proportional changes in Bacteroidetes, suggesting an influence of the gut microbiota on host energy recovery (Jumpertz et al., 2011 Am J Clin Nutr. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. doi: 10.3945 / ajcn.110.010132).
[0177] In addition to its influence on host energy recovery, the gut microbiota also contributes to energy storage. The increase in body fat observed during acclimation in GF mice is associated with a decrease in fasting-induced adipose factor (Fiaf) expression in the ileum and a 122% increase in lipoprotein lipase (LPL) activity in epididymal adipose tissue (Backhed et al., 2004 PNAS The gut microbiota as an environmental factor that regulates fat storage doi / 10.1073 / pnas.0407076101). Fiaf (also known as angiopoietin-like 4) is a protein secreted by adipose tissue, liver, and intestine that inhibits the activity of LPL, an enzyme critical in the hydrolysis of lipoprotein-associated triglycerides and the release of fatty acids for transport into cells. In adipocytes, the fatty acids released by LPL are re-esterified to triglycerides and stored as fat (Shen et al., 2013 Mol Aspects Med. The gut microbiota, obesity and insulin resistance doi: 10.1016 / j.mam.2012.11.001).
[0178] Other Functional Pathways The functional pathways and mechanisms by which the microbiota shapes host health and disease discussed thus far are not intended to be exhaustive. Alternative functional pathways and mechanisms exist, including, but not limited to, AMP-activated protein kinase (AMPK), TLR-5, and SREBP-1c and ChREBP.
[0179] Emergence of Bacterial Antibiotic Resistance Antibiotic resistance is an emerging public health problem (Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'Doye B, Pittet D, et al. 2011. Society's failure to protect a precious resource: antibiotics. Lancet 378: 369-371.). Numerous genera of bacteria harbor species that have developed resistance to antibiotics, including, but not limited to, vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant Klebsiella (CRKp). Klebsiella pneumoniae and Escherichia coli strains have become resistant to carbapenems, necessitating the use of older antibiotics, such as colistin, which are characterized by high toxicity (Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y, GniadkowskiM, Livermore DM, Miriagou V, Naas T, Rossolini GM, et al. 2012. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18: 413-431.). Numerous, multi-drug-resistant strains, including Pseudomonas aeruginosa, Enterobacter spp., and Acinetobacter spp., have been observed clinically, including isolates highly resistant to ceftazidime, carbapenems, and quinolones (European Centre for Disease Prevention and Control: EARSS netdatabase. http: / / ecdc.europa.eu.).In 2013, the US Centers for Disease Control and Prevention published a threat report (http: / / www.cdc.gov / drugresistance / threat-report-2013 / ), which listed Clostridium difficile, carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant Acinetobacter, drug-resistant Campylobacter, extended-spectrum beta-lactam-producing Enterobacteriaceae (ESBL), vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas aeruginosa, drug-resistant nontyphoidal Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus (MRSA), and drug-resistant Streptococcus The applicant cited numerous bacterial infection threats, including C. pneumoniae, vancomycin-resistant Staphylococcus aureus (VRSA), erythromycin-resistant Group A Streptococcus, and clindamycin-resistant Group B Streptococcus. The increasing failure of antibiotics due to the emergence of resistant microorganisms has led to a need for new therapeutic agents to treat bacterial infections. Administration of a bacterial composition for microbiome therapy offers the potential for such treatment. Applicants have discovered that patients suffering from recurrent C. difficile-associated diarrhea (CDAD) often harbor antibiotic-resistant Gram-negative bacteria, particularly Enterobacteriaceae, and that treatment with a bacterial composition effectively treats CDAD and reduces antibiotic-resistant Gram-negative bacteria.The gastrointestinal tract has been implicated as a reservoir for many of these organisms, including VRE, MRSA, Pseudomonas aeruginosa, Acinetobacter, and the yeast Candida (Donskey, Clinical Infectious Diseases 2004 39:214, "The Role of the Intestinal Tract as a Reservoir and Source for Transmission of Nosocomial Pathogens") and therefore as a source of nosocomial infections. Antibiotic therapy and other literature procedures are among the measures used to reduce colonization by these organisms in susceptible patients, including immunosuppressed patients. Bacterial-based therapeutics offer a new means for decolonization with the important advantage of not promoting antibiotic resistance, which antibiotic therapy promotes.
[0180] As described above, network ecology and functional network ecology refer to a collection of OTUs or functional modes, respectively, that co-occur within a group of interest. A network is mathematically defined by a graph that shows how specific nodes (i.e., OTUs or functional modes) and ends (connections between specific OTUs or functional modes) relate to each other to define the structural ecology of the collection of OTUs or functions. Any given network ecology or functional network ecology will possess unique phylogenetic diversity and functional characteristics.
[0181] A network class or core network refers to a group of network ecologies or functional network ecologies that are computationally determined to contain ecologies with similar phylogenetic and / or functional characteristics. Thus, a network class or core network contains key biological features of a group (i.e., cluster) of related network ecologies, defined either by phylogeny or function.
[0182] Keystone OTUs or functions are one or more OTUs or functions that are common to many network ecologies or functional network ecologies and are members of a network ecology or functional network ecology that occurs in many subjects (i.e., is pervasive). Due to their pervasive nature, keystone OTUs and functions are central to the function of the network ecology in healthy subjects and are often absent or reduced in abundance in subjects with disease. Keystone OTUs and functions can be present at low abundance, medium abundance, or high abundance in a subject.
[0183] Bacteria that are members of keystone OTUs, core networks, or network ecologies are provided herein.
[0184] Bacterial Compositions Bacteria and combinations of bacteria that constitute the network ecology and functional network ecology of the human gut microbiota are provided. The bacteria and combinations of bacteria that constitute the network ecology have the ability to meaningfully provide healthy microbiota function when administered to a mammalian host. Without being limited to a particular mechanism, members of the network ecology may inhibit the growth, proliferation, germination, and / or colonization of one or more pathogenic bacteria in the microbial niche of a dysbiotic microbiota, and members of the network ecology may also increase the growth, proliferation, germination, and / or colonization of desirable bacteria such that a normal, diverse, and protective microbiota colonizes and inhabits the intestinal lumen, establishing or re-establishing ecological defenses against pathogens or potential pathogens (e.g., some bacteria are pathogenic only when present in a microbially incompatible environment). The term pathogen refers to a bacterium or group of bacteria or any other organism or entity that can cause or affect a disease, disorder or condition in a host that contains the bacterium, organism or entity, including, but not limited to, metabolic diseases such as pre-diabetes, type 1 diabetes and type 2 diabetes.
[0185] As used herein, a "type" of bacteria, or two or more "types" of bacteria, may be distinguished at the genus level, species level, subspecies level, strain level, or any other taxonomic method, as described herein and as otherwise known in the art.
[0186] A bacterial composition can include two types of bacteria (referred to as a "binary combination" or "binary pair") and typically includes a large number of bacterial species. For example, a bacterial composition can include at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or at least 40, at least 50, or more than 50 species of bacteria, as defined by species or operational taxonomic units (OTUs) or otherwise provided herein. In some embodiments, the bacterial composition comprises at least 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600 or more bacterial species.
[0187] In another embodiment, the number of bacterial species present in the bacterial composition can be equal to or less than a known value. For example, in such an embodiment, the network ecology includes 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50 or fewer species of bacteria, such as 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10 or fewer species of bacteria, or 9 or fewer species of bacteria, 8 or fewer species of bacteria, 7 or fewer species of bacteria, 6 or fewer species of bacteria, 5 or fewer species of bacteria, 4 or fewer species of bacteria, or 3 or fewer species of bacteria.
[0188] Bacterial Compositions Represented by Species Bacterial compositions comprising a network ecology can be prepared, comprising at least two isolated bacteria selected from the species in Table 1.
[0189] In one embodiment, the bacterial composition comprises at least one, and preferably two or more, of the following: Enterococcus faecalis (formerly known as Streptococcus faecalis), Clostridium innocuum, Clostridium ramosum, Bacteroides ovatus, Bacteroides vulgatus, Bacteroides thetaoiotaomicron, Escherichia coli (1109 and 1108-1), Clostridium bifermentans, and Blautia producta (formerly known as Peptostreptococcus productus). In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0190] In one embodiment, the bacterial composition comprises at least one, and preferably two or more, of the following: Enterococcus faecalis (formerly known as Streptococcus faecalis), Clostridium innocuum, Clostridium ramosum, Bacteroides ovatus, Bacteroides vulgatus, Bacteroides thetaoiotaomicron, Escherichia coli (1109 and 1108-1), Clostridium bifermentans, and Blautia producta (formerly known as Peptostreptococcus productus). In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0191] In another embodiment, the bacterial composition comprises at least one, and preferably two or more, of the following: Acidaminococcus intestinalis, Bacteroidesovatus, two strains of Bifidobacterium adolescentis, two strains of Bifidobacterium longum, Blautia producta, Clostridium cocleatum, Collinsella aerofaciens, two strains of Dorea longicatena, Escherichia coli, Eubacterium desmolans, Eubacterium eligens, Eubacterium limosum, four strains of Eubacterium rectale, Eubacterium ventriosumi, Faecalibacterium prausnitzii, Lachnospirapectinoshiza, Lactobacillus casei, Lactobacillus casei / paracasei, Paracateroides distasonis, Raoultella sp., one strain of Roseburia (Roseburia faecalis or Roseburia faecis), Roseburia intestinalis, two strains of Ruminococcus torques, two strains of Ruminococcus obeum, and Streptococcus mitis. In alternative embodiments, at least one of the foregoing species is substantially absent from the bacterial composition.
[0192] In yet another embodiment, the bacterial composition comprises at least one, and preferably two or more, of the following: Barnesiella intestinihominis; Lactobacillus reuteri; a species characterized as one of Enterococcus hirae, Enterococcus faecium, or Enterococcus durans; a species characterized as one of Anaerostipes caccae or Clostridium indolis; a species characterized as one of Staphylococcus warneri or Staphylococcus pasteuri; and Adlercreutzia equolifaciens. In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0193] In other embodiments, the bacterial composition comprises at least one and preferably two or more of the following: Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium bartlettii, Clostridium bifermentans, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium camis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium difficile, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium innocuum, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium ramosum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridiumsubterminale, Clostridium symbiosum, Clostridium tertium, Clostridium tetani, Clostridium welchii, and Clostridium villosum. In alternative embodiments, at least one of the foregoing species is substantially absent from the bacterial composition.
[0194] In one embodiment, the bacterial composition comprising the network ecology comprises at least one, and preferably two or more, of the following: Clostridium innocuum, Clostridium bifermentans, Clostridium butyricum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, three strains of Escherichia coli, and Lactobacillus sp. In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0195] In one embodiment, the bacterial composition comprising the network ecology comprises at least one, and preferably two or more, of the following: Clostridium bifermentans, Clostridium innocuum, Clostridium butyricum, three strains of Escherichia coli, three strains of Bacteroides, and Blautia producta. In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0196] In one embodiment, the bacterial composition comprising the network ecology includes at least one, and preferably two or more, of the following: Bacteroides sp., Escherichia coli, and non-pathogenic Clostridium species, including Clostridium innocuum, Clostridium bifermentans, and Clostridium ramosum. In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0197] In one embodiment, the bacterial composition comprising the network ecology comprises at least one, and preferably two or more, of the following: Bacteroides species, Escherichia coli, and non-pathogenic Clostridium species such as Clostridium butyricum, Clostridium bifermentans, and Clostridium innocuum. In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0198] In one embodiment, the bacterial compositions comprising the network ecology include at least one, and preferably two or more, of the following: Bacteroides caccae, Bacteroides capillosus, Bacteroides coagulans, Bacteroides distasonis, Bacteroides eggerthii, Bacteroides forsythus, Bacteroides fragilis, Bacteroides fragilis-ryhm, Bacteroides gracilis, Bacteroides levii, Bacteroides macacae, Bacteroides merdae, Bacteroides ovatus, Bacteroides pneumosintes, Bacteroides putredinis, Bacteroides pyogenes, Bacteroides splanchnicus, Bacteroides stercoris, Bacteroides tectum, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides ureolyticus, and Bacteroides vulgatus. In an alternative embodiment, at least one of the aforementioned species is substantially absent from the bacterial composition.
[0199] In one embodiment, the bacterial composition comprising the network ecology comprises at least one, and preferably two or more, of the following: Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, Escherichia coli, Gemmiger, Desulfomonas, and Peptostreptococcus. In an alternative embodiment, at least one of the foregoing species is substantially absent from the bacterial composition.
[0200] In one embodiment, the bacterial composition comprising the network ecology comprises at least one, and preferably two or more of the following: Bacteroides fragilis ss. Vulgatus, Eubacteriumaerofaciens, Bacteroides fragilis ss. Thetaiotaomicron, Blautia producta (formerly known as Peptostreptococcus productus II), Bacteroides fragilis ss. Distasonis, Fusobacterium prausnitzii, Coprococccuseutactus, Eubacterium aerofaciens III, Blautia producta (formerly known as Peptostreptococcus productus I), Ruminococcus bronii, Bifidobacterium adolescentis, Gemmigerformicilis, Bifidobacterium longum, Eubacterium siraeum, Ruminococcus torques, Eubacterium rectale III-H, Eubacterium rectale IV, Eubacterium eligens, Bacteroideseggerthii, Clostridium leptum, Bacteroidesfragilis ss.A, Eubacterium biforme, Bifidobacterium infantis, Eubacterium rectale III-F, Coprococcus comes, Bacteroidescapillosus, Ruminococcus albus, Eubacterium formicigenerans, Eubacterium hallii, Eubacterium ventriosum I, Fusobacteriumrussii, Ruminococcus obeum, Eubacterium rectale II, Clostridium ramosum I, Lactobacillus leichmanii, Ruminococcus cailidus, Butyrivibrio crossotus, Acidaminococcus fermentans, Eubacterium ventriosum, Bacteroides fragilis ss. fragilis, Bacteroides AR, Coprococcus catus, Eubacterium hadrum, Eubacterium cylindroides, Eubacterium ruminantium, Eubacterium CH-1, Staphylococcus epidermidis, PeptostreptococcusBL, Eubacterium limosum, Bacteroides praeacutus, Bacteroides L, Fusobacterium mortiferum I, Fusobacterium naviforme, Clostridium innocuum, Clostridium ramosum, Propionibacterium acnes, Ruminococcus flavefaciens, Ruminococcus AT, Peptococcus AU-1, Eubacterium AG, -AK, -AL, -AL-1, -AN; Bacteroides fragilis ss. ovatus, -ss. d, -ss.f;Bacteroides L-1, L-5;Fusobacterium nucleatum, Fusobacterium mortiferum, Escherichia coli, Streptococcus morbiliorum, Peptococcus magnus, Peptococcus G, AU-2;Streptococcus intermedius, Ruminococcus lactaris, Ruminococcus CO Gemmiger X, Coprococcus BH, -CC;Eubacterium tenue, Eubacterium ramulus, Eubacterium AE, -AG-H, -AG-M, -AJ, -BN-1;Bacteroides clostridiiformis ss.clostridliformis, Bacteroides coagulans, Bacteroides orails, Bacteroides ruminicolass. brevis, -ss. ruminicola, Bacteroides splanchnicus, Desuifomonas pigra, Bacteroides L-4, -Ni; Fusobacterium H, Lactobacillus G, and Succinivibrio A. In alternative embodiments, at least one of the foregoing species is substantially absent from the bacterial composition.
[0201] Bacterial Compositions Represented by Operational Taxonomic Units (OTUs) Bacterial compositions can be prepared that include at least two isolated bacteria selected from the SEQ ID NOs (OTUs) in Table 1.
[0202] OTUs can be defined by either the entire 16S sequencing of the rRNA gene (Table 1), by sequencing specific hypervariable regions of this gene (i.e., V1, V2, V3, V4, V5, V6, V7, V8, or V9), or by sequencing any combination of hypervariable regions of this gene (e.g., V1-3 or V3-5). Bacterial 16S rDNA is approximately 1500 nucleotides long and is used to reconstruct the evolutionary relationships and sequence homology of one bacterial isolate to another using a phylogenetic approach. 16S sequences are used for phylogenetic reconstruction because, while generally highly conserved, they contain specific hypervariable regions that possess sufficient nucleotide diversity to distinguish most microbial genera and species.
[0203] To determine the sequence of either the entire 16S sequence or a hypervariable region of the 16S sequence using known techniques, genomic DNA is extracted from the bacterial sample, the 16S rDNA (either the entire region or a specific hypervariable region) is amplified using polymerase chain reaction (PCR), the PCR product is cleaned, and the nucleotide sequence is delineated to determine the genetic composition of the 16S gene or a subdomain of that gene. When performing entire 16S sequencing, the sequencing method used is, but is not limited to, Sanger sequencing. When more than one hypervariable region, such as the V4 region, is used, sequencing can be performed using the Sanger method or next-generation sequencing methods, such as, but not limited to, Illumina (sequencing by synthesis) methods, which use barcoded primers to allow for multiplex reactions.
[0204] OTUs can be defined by a combination of nucleotide markers or genes, particularly highly conserved genes (e.g., "housekeeping" genes), or a combination thereof, whole-genome or partial-genome sequences generated using amplified gene products, or whole-genome sequencing (WGS). Using well-defined methods well known to those skilled in the art, DNA extracted from bacterial samples contains specific genomic regions, is amplified using PCR, and sequenced to determine the nucleotide sequence of the amplified product. In the whole-genome shotgun (WGS) method, extracted DNA is sequenced directly without amplification. Sequence data can be generated using any sequencing technology, including, but not limited to, Sanger, Illumina, 454Life Sciences, Ion Torrent, ABI, Pacific Biosciences, and / or Oxford Nanopore.
[0205] In one embodiment, an OTU can be characterized by one or more variable regions (V1-V9) of the 16S sequence. These regions in bacteria are defined by nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294, and 1435-1465, respectively, using numbering based on the Escherichia coli system of nomenclature. (See, e.g., Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli, PNAS 75(10):4801-4805 (1978)). In some embodiments, at least one of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions is used to characterize an OTU. In one embodiment, the V1, V2, and V3 regions are used to characterize an OTU. In another embodiment, the V3, V4, and V5 regions are used to characterize an OTU. In another embodiment, the V4 region is used to characterize an OTU.
[0206] Bacterial Compositions Excluding Certain Bacterial Species or Strains In one embodiment, the bacterial composition does not include at least one of Enterococcus faecalis (formerly known as Streptococcus faecalis), Clostridium innocuum, Clostridium ramosum, Bacteroides ovatus, Bacteroides vulgatus, Bacteroides thetaoiotaomicron, Escherichia coli (1109 and 1108-1), Clostridium bifermentans, and Blautia producta (formerly known as Peptostreptococcus productus).
[0207] In another embodiment, the bacterial composition does not include at least one of Acidaminococcus intestinalis, Bacteroides ovatus, two species of Bifidobacterium adolescentis, two species of Bifidobacterium longum, Collinsella aerofaciens, two species of Dorea longicatena, Escherichia coli, Eubacterium eligens, Eubacterium limosum, four species of Eubacterium rectale, Eubacterium ventriosumi, Faecalibacterium prausnitzii, Lactobacillus casei, Lactobacillus paracasei, Paracateroides distasonis, Raoultella sp., one species of Roseburia (selected from Roseburia faecalis or Roseburia faecis), Roseburia intestinalis, two species of Ruminococcus torques, and Streptococcus mitis.
[0208] In yet another embodiment, the bacterial composition does not include at least one of: Barnesiellaintestinihominis; Lactobacillus reuteri; a species characterized as one of Enterococcus hirae, Enterococcus faecium, or Enterococcus durans; a species characterized as one of Anaerostipescaccae or Clostridium indolis; a species characterized as one of Staphylococcus warneri or Staphylococcus pasteuri; and Adlercreutzia equolifaciens.
[0209] In other embodiments, the bacterial composition is Clostridium absonum, Clostridium argentinense, Clostridium baratii, Clostridium bifermentans, Clostridium botulinum, Clostridium butyricum, Clostridium cadaveris, Clostridium camis, Clostridium celatum, Clostridium chauvoei, Clostridium clostridioforme, Clostridium cochlearium, Clostridium difficile, Clostridium fallax, Clostridium felsineum, Clostridium ghonii, Clostridium glycolicum, Clostridium haemolyticum, Clostridium hastiforme, Clostridium histolyticum, Clostridium indolis, Clostridium innocuum, Clostridium irregulare, Clostridium limosum, Clostridium malenominatum, Clostridium novyi, Clostridium oroticum, Clostridium paraputrificum, Clostridium perfringens, Clostridium piliforme, Clostridium putrefaciens, Clostridium putrificum, Clostridium ramosum, Clostridium sardiniense, Clostridium sartagoforme, Clostridium scindens, Clostridium septicum, Clostridium sordellii, Clostridium sphenoides, Clostridium spiroforme, Clostridium sporogenes, Clostridium subterminale, Clostridium symbiosum, ClostridiumThe strain does not contain at least one of Clostridium tertium, Clostridium tetani, Clostridium welchii, and Clostridium villosum.
[0210] In another embodiment, the bacterial composition does not include at least one of Clostridium innocuum, Clostridium bifermentans, Clostridium butyricum, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, three strains of Escherichia coli, and Lactobacillus sp.
[0211] In another embodiment, the bacterial composition does not include at least one of Clostridium bifermentans, Clostridium innocuum, Clostridium butyricum, three strains of Escherichia coli, three strains of Bacteroides, and Blautia producta (formerly known as Peptostreptococcus productus).
[0212] In another embodiment, the bacterial composition does not include at least one of Bacteroides sp., Escherichia coli, and non-pathogenic Clostridium, including Clostridium innocuum, Clostridium bifermentans, and Clostridium ramosum.
[0213] In another embodiment, the bacterial composition is free of two or more Bacteroides species, Escherichia coli, and at least one of non-pathogenic Clostridium, such as Clostridium butyricum, Clostridium bifermentans, and Clostridium innocuum.
[0214] In another embodiment, the bacterial composition does not include at least one of Bacteroides caccae, Bacteroides capillosus, Bacteroides coagulans, Bacteroides distasonis, Bacteroides eggerthii, Bacteroides forsythus, Bacteroides fragilis, Bacteroides fragilis-ryhm, Bacteroides gracilis, Bacteroides levii, Bacteroidesmacacae, Bacteroides merdae, Bacteroidesovatus, Bacteroides pneumosintes, Bacteroides putredinis, Bacteroides pyogenes, Bacteroides splanchnicus, Bacteroides stercoris, Bacteroides tectum, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides ureolyticus, and Bacteroides vulgatus.
[0215] In another embodiment, the bacterial composition does not include at least one of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, Escherichia coli, Gemmiger, Desulfomonas, and Peptostreptococcus.
[0216] In another embodiment, the bacterial composition is Bacteroides fragilis ss. Vulgatus, Eubacterium aerofaciens, Bacteroides fragilis ss. Thetaiotaomicron, Blautiaproducta (formerly known as Peptostreptococcus productus II), Bacteroides fragilis ss. Distasonis, Fusobacteriumprausnitzii, Coprococcus eutactus, Eubacterium aerofaciens III, Blautia producta (formerly known as Peptostreptococcus productus I), Ruminococcus bromii, Bifidobacterium adolescentis, Gemmiger formicilis, Bifidobacterium longum, Eubacterium siraeum, Ruminococcus torques, Eubacterium rectale III-H, Eubacterium rectale IV, Eubacterium eligens, Bacteroides eggerthii, Clostridium leptum, Bacteroides fragilis ss.A, Eubacterium biforme, Bifidobacterium infantis, Eubacterium rectale III-F, Coprococcus comes, Bacteroidescapillosus, Ruminococcus albus, Eubacterium formicigenerans, Eubacterium hallii, Eubacterium ventriosum I, Fusobacteriumrussii, Ruminococcus obeum, Eubacterium rectale II, Clostridium ramosum I, Lactobacillus leichmanii, Ruminococcus cailidus, Butyrivibrio crossotus, Acidaminococcus fermentans, Eubacterium ventriosum, Bacteroides fragilis ss. fragilis, Bacteroides AR, Coprococcus catus, Eubacterium hadrum, Eubacterium cylindroides, Eubacterium ruminantium, Eubacterium CH-1, Staphylococcus epidermidis, PeptostreptococcusBL, Eubacterium limosum, Bacteroides praeacutus, Bacteroides L, Fusobacterium mortiferum I, Fusobacterium naviforme, Clostridium innocuum, Clostridium ramosum, Propionibacterium acnes, Ruminococcus flavefaciens, Ruminococcus AT, Peptococcus AU-1, Eubacterium AG, -AK, -AL, -AL-1, -AN; Bacteroides fragilis ss. ovatus, -ss. d, -ss.f;Bacteroides L-1, L-5;Fusobacterium nucleatum, Fusobacterium mortiferum, Escherichia coli, Streptococcus morbiliorum, Peptococcus magnus, Peptococcus G, AU-2;Streptococcus intermedius, Ruminococcus lactaris, Ruminococcus CO Gemmiger X, Coprococcus BH, -CC; Eubacterium tenue, Eubacterium ramulus, Eubacterium AE, -AG-H, -AG-M, -AJ, -BN-1; Bacteroides clostridiiformis ss.clostridliformis, Bacteroides coagulans, Bacteroides orails, Bacteroides ruminicolass. brevis, -ss. ruminicola, Bacteroides splanchnicus, Desuifomonas pigra, Bacteroides L-4, -Ni; Fusobacterium H, Lactobacillus G, and Succinivibrio A.
[0217] Inhibition of Bacterial Pathogens In some embodiments, the bacterial compositions provide a protective or therapeutic effect against infection by one or more GI pathogens of interest. Table 1 provides a list of OTUs that are either pathogens, pesticides, or opportunistic pathogens.
[0218] In some embodiments, the pathogenic bacteria are Yersinia, Vibrio, Treponema, Streptococcus, Staphylococcus, Shigella, Salmonella, Rickettsia, Orientia, Pseudomonas, Neisseria, Mycoplasma, Mycobacterium, Listeria, Leptospira, Legionella, Klebsiella, Helicobacter, Haemophilus, Francisella, Escherichia, Ehrlichia, Enterococcus, Coxiella, Corynebacterium, Clostridium, Chlamydia, Chlamydophila, Campylobacter, Burkholderia, Brucella, Borrelia, Bordetella, Bifidobacterium , Bacillus, multidrug-resistant bacteria, extended-spectrum beta-lactam-resistant Enterococci (ESBL), carbapenem-resistant Enterobacteriaceae (CRE), and vancomycin-resistant Enterococci (VRE).
[0219] In some embodiments, these pathogens include Aeromonas hydrophila, Campylobacter fetus, Plesiomonas shigelloides, Bacillus cereus, Campylobacter jejuni, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, enteroaggregative Escherichia coli, enterohemorrhagic Escherichia coli, enteroinvasive Escherichia coli, enterotoxigenic Escherichia coli (such as, but not limited to, LT and / or ST), Escherichia coli 0157:H7, Helicobacter pylori, Klebsiellia pneumonia, Lysteria monocytogenes, Plesiomonas shigelloides, Salmonella spp., Salmonella typhi, Salmonella paratyphi, Shigellas pp., Staphylococcus spp., Staphylococcus aureus, vancomycin-resistant enterococcus spp., Vibrio spp., Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, and Yersinia enterocolitica.
[0220] In one embodiment, the pathogen of interest is at least one pathogen selected from Clostridium difficile, Salmonella spp., pathogenic Escherichia coli, vancomycin-resistant Enterococcus spp., and extended-spectrum beta-lactam-resistant Enterococci (ESBL).
[0221] Purified Spores. In some embodiments, bacterial compositions comprise purified spores or a combination of purified and non-spore spores. Purified spores comprise a combination of commensal bacteria of the human gut microbiota that, when administered to a mammalian subject, are capable of providing significant normal microbiota functions. Without being limited to a particular mechanism, such compositions are believed to inhibit the growth of pathogens such as C. difficile, Salmonella spp., enteropathogenic E. coli, and vancomycin-resistant Enterococcus spp., such that a normal, diverse, and protective microbiota is maintained and, in the case of pathogenic bacterial infections such as C. difficile infection, repopulates the intestinal lumen and reestablishes biological control against potential pathogens. In some embodiments, yeast spores and other fungal spores are also purified and selected for therapeutic use.
[0222] Provided herein are therapeutic and prophylactic compositions comprising non-pathogenic germinable bacterial spores, spore-forming organisms, and non-spore-forming organisms for the prevention, regulation, and treatment of gastrointestinal diseases, disorders, and conditions, as well as general nutritional health. These compositions have the advantage of being suitable for safe administration to humans and other mammalian subjects, and are effective in a number of gastrointestinal diseases, disorders, and conditions, as well as general nutritional health. While spore-based compositions are known, they are generally prepared according to various techniques, such as freeze-drying or spray-drying liquid bacterial cultures, which lead to insufficient efficacy, instability, substantial variability, and a lack of sufficient safety.
[0223] It has now been discovered that populations of bacterial spores can be obtained from biological material obtained from mammalian subjects, including humans, and these populations can be formulated into compositions and administered to mammalian subjects using the methods provided herein.
[0224] Provided herein are therapeutic bacterial compositions comprising purified populations of bacterial spores, spore-forming organisms and non-spore-forming organisms.
[0225] As used herein, the terms "purify," "purified," and "purifying" refer to the state of a population of desired bacterial spores or bacteria (e.g., a large number, known or unknown amount and / or concentration) that has undergone one or more processes of purification, e.g., selection or enrichment of desired bacterial spores, or removal or reduction of residual habitat products as described herein. In some embodiments, the purified population has no detectable undesired activity, or alternatively, the level or amount of undesired activity is below an acceptable level or amount. In other embodiments, the purified population has an amount and / or concentration of desired bacterial spores or bacteria that is above an acceptable amount and / or concentration. In other embodiments, the purified population of bacterial spores or bacteria is enriched compared to the starting material (e.g., fecal material liquid culture) from which the population was obtained. The enrichment can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% enrichment compared to the starting material.
[0226] In certain embodiments, the purified population of bacterial spores have reduced or undetectable levels of one or more pathogenic activities, such as toxicity, infection of a mammalian recipient subject, immunomodulatory activity, autoimmune response, metabolic response, or inflammatory or neurological response. Such a reduction in pathogenic activity can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999% reduction compared to the starting material. In other embodiments, the purified population of bacterial spores have reduced odor, taste, appearance, and sensory components, such as umami, compared to fecal material.
[0227] Purified populations of bacterial spores or bacteria are provided that are substantially free of residual habitat products. In certain embodiments, this means that the bacterial spores or bacterial compositions are free of substantial amounts of biological material associated with microbial communities while living on or in a human or animal subject, and the purified population of spores is 100% free, 99% free, 98% free, 97% free, 96% free, or 95% free of any contaminating biological material associated with microbial communities. Freedom from any residual habitat products can also mean that the bacterial spore composition does not contain any detectable cells of human or animal origin, and only microbial cells, particularly desired microbial cells, are detectable. In another embodiment, 1×10 of cells in the bacterial composition are free of any contaminants of biological material associated with microbial communities. -2 %, 1×10 -3 %, 1×10 -4 %, 1×10 -5 %, 1×10 -6 %, 1×10 -7 %, 1×10 -8 % are human or animal cells compared to microbial cells. In another embodiment, the residual habitat products present in the purified population are reduced by at least a certain level from fecal material obtained from a mammalian donor subject, for example, reduced by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99%, 99.999%, 99.9999%, or greater than 99.9999%.
[0228] In one embodiment, substantially free of residual habitat products or substantially free of detectable levels of pathogenic material means that the bacterial composition is free of any detectable viruses (including bacterial viruses (i.e., phages)), fungal, or mycoplasma or toxoplasma contaminants, or eukaryotic parasites such as helminths, or the purified spore population is substantially free of acellular material, such as DNA, viral coat material, or non-viable bacterial material.
[0229] As described herein, purified spore populations can be demonstrated by genetic analysis (e.g., PCR, DNA sequencing), serological and antigenic analysis, and methods that use reagents and instrumentation such as flow cytometry to distinguish desired bacterial spores from undesired contaminants.
[0230] Exemplary biological materials include fecal material, such as feces or material isolated from various portions of the small intestine and large intestine. The fecal material can be obtained from a mammalian donor subject, or from two or more donor subjects, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 200, 300, 400, 500, 750, 1000, or more than 1000 donors, where such material is then pooled prior to purification of the desired bacterial spores.
[0231] In an alternative embodiment, the desired bacterial spores or bacteria are purified from a single sample of fecal material obtained from a single donor and, following such purification, are combined with purified spores or bacteria from other purifications either from the same donor at a different time, or from one or more different donors, or both.
[0232] Preferred bacterial genera include Acetonema, Alkaliphilus, Alicyclobacillus, Amphibacillus, Ammonifex, Anaerobacter, Anaerofustis, Anaerostipes, Anaerotruncus, Anoxybacillus, Bacillus, Blautia, Brevibacillus, Bryantella, Caldicellulosiruptor, Caloramator, Candidatus, Carboxydibrachium, Carboxydothermus, Clostridium, Cohnella, Coprococcus, Dendrosporobacter, Desulfitobacterium, Desulfosporosinus, Desulfotomaculum, Dorea, Eubacterium, Faecalibacterium, Filifactor, Geobacillus, Halobacteroides, Heliobacillus, Heliobacterium, Heliophilum, Heliorestis, Lachnoanaerobaculum, Lysinibacillus, Moorella, Oceanobacillus, Orenia (S.), Oxalophagus, Oxobacter, Paenibacillus, Pelospora, Pelotomaculum, Propionispora, Roseburia, Ruminococcus, Sarcina, Sporobacterium, Sporohalobacter, Sporolactobacillus, Sporomusa, Sporosarcina, Sporotomaculum, Subdoligranulum, Symbiobacterium, Syntrophobotulus, Syntrophospora, Terribacillus, Thermoanaerobacter, and Thermosinus.
[0233] In some embodiments, spore-forming bacteria are identified by the presence of nucleic acid sequences that regulate sporulation. In particular, signature sporulation genes are highly conserved across members of distantly related genera, including Clostridium and Bacillus. Traditional forward genetic approaches have identified many, if not all, genes essential for sporulation (spo). The developmental program of sporulation is governed, in part, by the sequential action of four compartment-specific sigma factors (σF, σE, σG, and σK, in that order) whose activity is restricted to the forespore (σF and σG) or the mother cell (σE and σK).
[0234] A spore population is provided that includes two or more types of bacteria. As used herein, a "type" or two or more "types" of bacteria may be distinguished at the genus level, species level, subspecies level, strain level, or any other taxonomic method described herein and otherwise known in the art.
[0235] In some embodiments, all or substantially all of the bacterial spores or bacterial species present in the purified population are originally isolated from fecal material processed as described herein or otherwise known in the art. In alternative embodiments, one or more bacterial spores, bacteria, or types of bacterial spores are cultured and combined to form a purified bacterial composition comprising a purified spore population. In other alternative embodiments, one or more of these cultured populations are combined with a fecal material-derived population to create a hybrid population. The bacterial composition may include at least two of these preferred bacteria, including strains of the same species. For example, the bacterial composition may include at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 or more species of bacteria defined by species or operational taxonomic units (OTUs) encompassing such species.
[0236] Thus, provided herein are methods for the production of bacterial compositions comprising a population of bacterial spores and / or non-spore-forming bacteria suitable for therapeutic administration to a mammalian subject in need thereof. The compositions are typically produced by (a) providing fecal material obtained from a mammalian donor subject; and (b) subjecting the fecal material to at least one purification treatment or step, under conditions such that a population of bacterial spores is produced from the fecal material. The compositions are intended to provide a single oral dose of at least about 1 x 10 4 A single oral dose is typically formulated to contain approximately 1 x 10 colony-forming units of bacterial spores. 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 or 1 x 10 15 The presence and / or concentration of a given type of bacteria or bacterial spores in a given population of purified spores may be known or unknown. If known, for example, the concentration of bacteria or spores in an aggregate of a given strain or all strains may be greater than, for example, 1 x 10 per gram of composition or per administered dose. 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 or 1 x 10 15 These are viable bacteria or bacterial spores.
[0237] In some formulations, the composition comprises at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90% spores by mass. In some formulations, the administered dose does not exceed 200, 300, 400, 500, 600, 700, 800, 900 milligrams or 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, or 1.9 grams by mass.
[0238] Bacterial compositions are generally formulated for oral or gastric administration, usually to mammalian subjects. In specific embodiments, the compositions are formulated for oral administration as a solid, semi-solid, gel, or liquid form, such as a pill, tablet, capsule, or lozenge. In some embodiments, such formulations include or are coated with an enteric coating that protects the bacteria throughout the stomach and small intestine, even though spores normally resist the stomach and small intestine.
[0239] The bacterial composition can be formulated to be effective in a given mammalian subject in a single administration or over multiple administrations. For example, a single administration is substantially effective to reduce Cl. difficile and / or Cl. difficile toxin content in the mammalian subject to which the composition is administered. By substantially effective, it is meant that Cl. difficile and / or Cl. difficile toxin content in the subject is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or greater than 99% following administration of the composition.
[0240] Kits for Diagnosing a Dysbiosis Condition in a Subject In some embodiments, the present invention encompasses kits for carrying out the methods of the present invention described and claimed herein. In some embodiments, the present invention encompasses kits for diagnosing a dysbiosis condition in a mammalian subject in need thereof. In one embodiment, the kit comprises a plurality of detection means suitable for detecting (1) a first bacterial entity, including a keystone bacterial entity, and (2) a second bacterial entity, wherein the first and second bacterial entities comprise a network ecology described herein. The kit may include instructions for use with the kit.
[0241] In other embodiments, the kit provides detection means, reagents, and instructions for detecting a first bacterial entity and a second bacterial entity comprising a network ecology by obtaining a fecal sample from a mammalian subject comprising a plurality of bacterial entities, contacting the fecal sample with a first detection moiety (in some examples, a second detection moiety) capable of detecting the first bacterial entity and the second bacterial entity present in the network, detecting the absence of the first and / or second bacterial entity in the fecal sample, and thereby detecting microbial incompatibility in the mammalian subject. In some embodiments, the kit provides reagents and steps for administering to the mammalian subject a composition comprising an effective amount of the first and / or second bacterial entity.
[0242] In some embodiments, the kit comprises the detection means and instructions for obtaining a fecal sample from the mammalian subject comprising a plurality of bacterial entities; contacting the fecal sample with a first detection means capable of detecting a first bacterial entity present in the network; detecting the absence of the first bacterial entity in the fecal sample, thereby detecting dysbiosis in the mammalian subject; and administering to the mammalian subject a composition comprising an effective amount of the first bacterial entity.
[0243] In another embodiment, the kit comprises reagents and instructions for a method of treating, preventing, or lessening the severity of a disorder selected from the group consisting of Clostridium difficile associated diarrhea (CDAD), type 2 diabetes, obesity, irritable bowel disease (IBD), colonization by a pathogen or pasobiont, and infection by a drug-resistant pathogen or pasobiont, the method comprising administering to a mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, the therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, the plurality of isolated bacteria or purified bacterial preparations capable of forming a network ecology selected from the group consisting of the network ecologies described in claims 1-61 below and throughout this specification.
[0244] In another embodiment, a kit comprises reagents and instructions for a method of producing short chain fatty acids (SCFAs) in a mammalian subject, the method comprising administering an effective amount of a therapeutic bacterial composition to the mammalian subject in need thereof, the therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, the plurality of isolated bacteria or purified bacterial preparations capable of forming one or more bacterial functional pathways, the one or more bacterial functional pathways capable of forming a functional network ecology selected from the group consisting of the functional network ecologies described in claims 69-71 and throughout this specification.
[0245] In another embodiment, a kit comprises reagents and instructions for a method of catalyzing the secondary metabolism of bile acids in a mammalian subject, the method comprising administering an effective amount of a therapeutic bacterial composition to the mammalian subject in need thereof, the therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, the plurality of isolated bacteria or purified bacterial preparations capable of forming one or more bacterial functional pathways, the one or more bacterial functional pathways capable of forming a functional network ecology selected from the group consisting of claims 72-74 and the entire specification.
[0246] System for predicting microbial incompatibility in a subject The present invention provides a system for predicting microbial incompatibility in a subject, the system comprising: a storage memory that stores a dataset associated with a sample obtained from the subject and including content data for at least one of the bacterial entity networks described herein; and a processor communicatively coupled to the storage memory for determining, with an interpretation function, a score that is predictive of microbial incompatibility in the subject.
[0247] In some embodiments, the present invention provides a system for detecting microbial incompatibility in a subject, the system comprising: a storage memory that stores a dataset associated with a sample obtained from the subject and that includes content data for at least one of the bacterial entity networks described herein; and a processor communicatively coupled to the storage memory for determining, with an interpretation function, a score that is predictive of microbial incompatibility in the subject.
[0248] An example of a computer system and its elements that can be used to implement the methods of the present invention is illustrated below in FIG.
[0249] Computer Overview Figure 21 is a high-level block diagram illustrating an example computer 2100 for use as a server or user device, according to one embodiment. Illustrated is at least one processor 2102 coupled to a chipset 2104. The chipset 2104 includes a memory controller hub 2120 and an input / output (I / O) controller hub 2122. A memory 2106 and a graphics adapter 2112 are coupled to the memory controller hub 2120, and a display device 2118 is coupled to the graphics adapter 2112. A storage device 2108, a keyboard 2110, a pointing device 2114, and a network adapter 2116 are coupled to the I / O controller hub 2122. Other embodiments of the computer 2100 have different configurations. For example, the memory 2106 is coupled directly to the processor 2102 in some embodiments.
[0250] The storage device 2108 is a non-transitory computer-readable storage medium such as a hard drive, compact disc read-only memory (CD-ROM), DVD, or solid-state memory device. The memory 2106 holds instructions and data used by the processor 2102. A pointing device 2114 is used in combination with the keyboard 2110 to input data into the computer system 200. The graphics adapter 2112 displays images and other information on the display device 2118. In some embodiments, the display device 2118 includes touchscreen capabilities for receiving user input and selections. The network adapter 2116 couples the computer system 2100 to a network. Some embodiments of the computer 2100 have different and / or other elements than those shown in FIG. 21 . For example, a server may be formed from multiple blade servers and may lack a display device, keyboard, and other elements.
[0251] The computer 2100 is designed to execute computer program modules to provide the functionality described herein. As used herein, the term "module" refers to computer program instructions and other logic used to provide a particular functionality. As such, a module may be implemented in hardware, firmware, and / or software. In one embodiment, program modules formed of executable computer program instructions are stored on the storage device 2108, loaded into memory 2106, and executed by the processor 2102.
[0252] Methods of the Invention Methods for Determining Network Ecology Methods are provided for computational approaches based in part on network theory that build the ecology of a group of microorganisms based on the presence or absence of a particular OTU (i.e., microbial genus, species, or strain) in a given set of sampled objects. See Figure 16. See, e.g., Cormen TH, Leiserson CE, Rivest RL, and Stein C. 2009. Introduction to Algorithms. Third edition. The MIT Press. Garey MR, and Johnson DS. 1979. Computers and Intractability: A Guide to the Theory of NP-Completeness. First Edition. WH Freeman. The approach involves: (i) identifying microbial network ecologies present in both healthy and diseased subjects, (ii) identifying keystone OTUs and / or functions (Figure 17) and phylogenetic clades that characterize a given ecology, and (iii) providing specific metrics that prioritize different network ecologies for their ability to help restore the microbiome from a state of dysbiosis to a healthy state. In general, the method first defines low- and high-order networks within a given set of subjects and then uses a comparative approach to define biologically significant networks.
[0253] This method involves calculating a co-occurrence matrix (i.e., presence or absence) of OTUs for each subject across defined subject groups (groups defined by specific phenotypes, such as, but not limited to, "healthy subjects" or "disease subjects"). The method involves calculating all nodes (OTUs or species or strains) and ends (co-occurrences between OTUs or species or strains) that define the network ecology within a given subject's sample. Each co-occurrence is scored using a separate binary variable indicating presence or absence. While the algorithm allows for co-occurrences to be weighted based on the relative abundance of OTUs in the sample, this is generally undesirable because low-abundance OTUs can also be ecologically important. Furthermore, a discretized measure of node presence or absence eliminates bias and error in computational network ecology that arises from bias in the method used to generate relative abundance measures. A discreet method of measuring presence or absence allows for the detection of low-frequency OTUs and the elucidation of networks often missed by relative abundance. The entire network ecology of a given phenotype (i.e., the set of subject datasets with integrative characteristics, e.g., the entire dataset of healthy subjects) can be defined by defining the combination of nodes and terminals that are maximally observed in all subjects according to the induction of all low- and high-order networks for the given subject. Without being limited by theory, such network ecologies have been found to exist in mammalian subjects. The algorithm iteratively constructs network ecologies and ranks all ecologies (i.e., nodes and terminals) within each sample based on co-occurrence [maximum co-occurrence; maximum co-occurrence minus 1; maximum co-occurrence minus 2; etc.] until a network with minimal co-occurrence is defined (i.e., the minimum terminal score is achieved). This method can be computationally intensive for datasets containing a large number of subjects. For datasets containing a large number of subjects, the algorithm employs a strategy whereby a first seed network ecology is constructed in a subset of subjects using the method described above, and then a combination of these seed networks is used to explore higher-order networks across the entire dataset.
[0254] Biological significance can be assigned to observed network ecologies and members of a given network ecology based on multiple computational metrics, including, but not limited to: (i) the frequency with which a given OTU or network ecology is observed; (ii) the number of OTUs in the network; the frequency of occurrence of the network across subjects (i.e., pervasiveness); (iii) the phylogenetic extent of the network; (iv) specific functional properties; and (v) whether the network occurs preferentially in healthy individuals versus disease-carrying individuals (i.e., different phenotypes). All network ecologies or OTUs occurring in one phenotype (e.g., healthy) are compared with those occurring in other phenotypes (e.g., one or more specific disease states), and network ecologies or OTUs found in one, two, or any number of phenotypes are considered related. Network ecologies are considered related if at least 70%, 80%, or 90% of their OTUs are common. Every network ecology or OTU is assigned a score for its biological importance, which is based on, but not limited to: (i) whether a phenotype occurs or does not occur, the intersection of the phenotype (e.g., present in healthy states but absent in disease states), and (ii) the various metrics listed above. The final output of all these steps defines a set of network ecologies with high biological importance, as well as a set of keystone OTUs and / or metabolic functions that are important components of these derived ecologies.
[0255] From these network ecologies, the method includes defining network classes that represent network groups or clusters with specific related compositional characteristics in terms of OTU content, phylogenetic diversity, and metabolic functional capacity (Figure 18). Network classes can be defined by first establishing an inclusion threshold for networks to be included in the analysis based on biological characteristics of the network, such as, but not limited to, size (number of OTUs) and pervasiveness (i.e., how frequently a given network is observed in a group of individuals). The selected network ecologies are then clustered using two vectors: one vector representing the phylogenetic relatedness of each OTU defined in the computational phylogenetic tree, and the second vector representing network relatedness based on the OTU content of each network. In another embodiment, the clustering vectors are related based on the metabolic functional pathways possessed by each OTU, and the network relatedness is based on the functional pathways present in each network, respectively. Network classes are defined by specific nodes in the dendrogram representing computational network relatedness, and each class is characterized by a specific combination of OTUs. In one embodiment, these nodes are defined as branches of a hierarchical clustering tree based on a measure of morphological overlap; this measure is a very powerful measure of network interconnectedness. See Langfelder P, Zhang B, Horvath S. 2008. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics24: 719-720.
[0256] From these network classes, target microbial compositions useful, for example as therapeutics, are selected with desired phylogenetic and functional properties for subsequent testing in in vitro and in vivo models. Exemplary network classes are shown in Table 12, and taxonomic families characteristic of the network classes are defined in Table 13.
[0257] As described herein, compositions are provided that include keystone OTUs for health conditions (Table 8), such as one or more OTUs provided in Table 9 below.
[0258] As described herein, compositions are provided that include keystone OTUs, keystone metabolic functions, and optionally non-keystone OTUs, including one or more OTUs provided in Table 10 below.
[0259] In some therapeutic compositions, the keystone OTU is provided from a member of a genus or family selected from Table 9.
[0260] Exemplary network ecologies are provided in Tables 8, 11, 12, 14a, 14b and 14c, and 17.
[0261] Exemplary functional network ecologies are provided in Tables 18 and 21.
[0262] Thus, provided herein are methods for producing compositions suitable for therapeutic administration to a mammalian subject in need thereof, comprising a population of bacteria as either vegetative cells or spores, or both. The compositions are typically produced according to the following steps: (a) defining a target composition by selecting a network ecology, functional network ecology, network class, or set of keystone OTUs or keystone metabolic functions that constitute the network ecology or functional network ecology of interest; (a) providing bacterial OTUs obtained from one or more bacterial cultures, biological or environmental sources, or mammalian donor subjects; and (b) combining the bacterial OTUs in proportions and amounts sufficient to form a network ecology or functional network ecology. The compositions are suitable for therapeutic administration to a mammalian subject in need thereof, wherein a single oral dose is at least about 1 x 10 4 A single oral dose is typically formulated to contain approximately 1 x 10 colony-forming units of bacteria. 4 , 1×10 5 , 1×10 6 , 1×10 7, 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 or 1 x 10 15 The concentration of bacteria of a given species or strain, or aggregates of all species or strains, can be greater than, for example, 1 x 10 per gram of composition or per single administered dose. 4 , 1×10 5 , 1×10 6 , 1×10 7 , 1×10 8 , 1×10 9 , 1×10 10 , 1×10 11 , 1×10 12 , 1×10 13 , 1×10 14 , 1×10 15 or 1 x 10 15 It is the most viable bacterium.
[0263] Bacterial compositions are generally formulated for oral or gastric administration, usually to mammalian subjects. In specific embodiments, the compositions are formulated for oral administration in solid, semi-solid, gel, or liquid form, such as in pill, tablet, capsule, or lozenge form. In some embodiments, such formulations include or are coated with an enteric coating that protects the bacteria throughout the stomach and small intestine, although spore-containing compositions typically tolerate the stomach and small intestine environment. Alternatively, bacterial compositions may be formulated for nasogastric and rectal administration.
[0264] The bacterial composition can be formulated to be effective in a given mammalian subject in a single administration or over multiple administrations. For example, a single administration is substantially effective to reduce Clostridium difficile (i.e., C. difficile) and / or Cl. difficile toxin content and / or toxin activity in the mammalian subject to which the composition is administered. By substantially effective, it is meant that Cl. difficile and / or Cl. difficile toxin content in the subject is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or greater than 99% after administration of the composition.
[0265] Methods for Determining 16S Sequences OTUs can be defined by either the entire 16S sequence of the rRNA gene, by sequencing specific hypervariable regions of this gene (i.e., V1, V2, V3, V4, V5, V6, V7, V8, or V9), or by sequencing any combination of hypervariable regions of this gene (e.g., V1-3 or V3-5). Bacterial 16S rDNA is approximately 1500 nucleotides long and is used to reconstruct the evolutionary relationships and sequence homology of one bacterial isolate to another using a phylogenetic approach. 16S sequences are used for phylogenetic reconstruction because, while generally highly conserved, they contain specific hypervariable regions that possess sufficient nucleotide diversity to distinguish most microbial genera and species.
[0266] To determine the sequence of either the entire 16S sequence or a hypervariable region of the 16S sequence using known techniques, genomic DNA is extracted from the bacterial sample, the 16S rDNA (either the entire region or a specific hypervariable region) is amplified using polymerase chain reaction (PCR), the PCR product is cleaned, and the nucleotide sequence is delineated to determine the genetic composition of the 16S gene or a subdomain of that gene. When performing entire 16S sequencing, the sequencing method used is, but is not limited to, Sanger sequencing. When more than one hypervariable region, such as the V4 region, is used, sequencing can be performed using the Sanger method or next-generation sequencing methods, such as, but not limited to, Illumina (sequencing by synthesis) methods, which use barcoded primers to allow for multiplex reactions.
[0267] OTUs can be defined by a combination of nucleotide markers or genes, particularly highly conserved genes (e.g., "housekeeping" genes), or a combination thereof, whole genome or partial genome sequences generated using amplified gene products, or whole genome sequencing (WGS). Using well-defined methods, DNA extracted from bacterial samples contains specific genomic regions, which are amplified using PCR and sequenced to determine the nucleotide sequence of the amplified products. In the whole genome shotgun (WGS) method, extracted DNA is sequenced directly without amplification. Sequence data can be generated using any sequencing technology, including, but not limited to, Sanger, Illumina, 454Life Sciences, Ion Torrent, ABI, Pacific Biosciences, and / or Oxford Nanopore.
[0268] Methods of Preparing Bacterial Compositions for Administration to a Subject Methods of producing bacterial compositions can include three main processing steps, combined with one or more mixing steps: organism banking, organism production, and storage.
[0269] With respect to banking, the strains included in the bacterial composition may be (1) isolated directly from a specimen or obtained from a banked stock, (2) cultured on nutrient agar or broth that supports growth to create a viable biomass, and (3) biomass that may be stored in multiple aliquots in long-term storage.
[0270] In embodiments using a culture process, the agar or broth may contain nutrients that provide essential components and specific factors that enable growth. One example is a medium composed of 20 g / L glucose, 10 g / L yeast extract, 10 g / L soy peptone, 2 g / L citric acid, 1.5 g / L monobasic sodium phosphate, 100 mg / L ammonium ferric citrate, 80 mg / L magnesium sulfate, 10 mg / L hemin chloride, 2 mg / L calcium chloride, and 1 mg / L menadione. Various microbiological media and variations are well known in the art (e.g., RM Atlas, Handbook of Microbiological Media (2010) CRC Press). Media may be added to the culture at the start, during the culture, or intermittently / continuously flowed throughout the culture. Strains of the bacterial composition may be cultured singly, as a subset of the bacterial composition, or as a whole consortium comprising the bacterial composition. As an example, a first strain may be grown in mixed continuous culture with a second strain at a dilution rate lower than the maximum growth rate of either cell to prevent the culture from running off.
[0271] The inoculated culture is incubated under favorable conditions for a time sufficient to establish biomass. For bacterial compositions for human use, this is often a temperature of 37°C, pH, and other parameters with values similar to the normal human niche. The environment can be actively controlled (e.g., via buffers) or left as is. For example, for anaerobic bacterial compositions (e.g., gut microbiota), anoxic / reducing conditions can be used. This can be achieved by adding a reducing agent, such as cysteine, to the broth and / or by removing oxygen. As an example, a culture of the bacterial composition can be grown at 37°C and pH 7 in the above medium pre-reduced with 1 g / L cysteine·HCl.
[0272] Once a culture has produced sufficient biomass, it can be preserved for banking. The organisms are distributed among multiple (possibly identical) containers to create a uniform bank. The cultures can then be processed for storage by placing them in a chemical environment that protects them from freezing (by adding a "cryoprotectant"), drying (a "lyoprotectant"), and / or osmotic shock (an "osmoprotectant"). The containers are typically impermeable and have closures that ensure isolation from the environment. Cryopreservation is achieved by freezing the liquid at very low temperatures (e.g., below -80°C). Dry storage removes water from the culture by evaporation (in the case of spray drying or "chill drying") or sublimation (e.g., for lyophilization, spray-freeze drying). Water removal improves the long-term storage stability of bacterial compositions at temperatures higher than cryogenic temperatures. If the bacterial composition contains spore-forming species and results in the production of spores, the final composition can be purified by additional means, such as density gradient centrifugation, before being preserved using the techniques described above. Banking of bacterial compositions can be performed by culturing and storing strains individually or by mixing strains together to create a combined bank. As an example of cryopreservation, a culture of a bacterial composition can be harvested by centrifugation to pellet the cells from the culture medium, the supernatant can be decanted, and replaced with fresh culture broth containing 15% glycerol. The culture can then be aliquoted into 1 mL cryotubes, sealed, and placed at -80°C for long-term viability. This procedure achieves acceptable viability upon recovery from cryopreservation.
[0273] Organism production can be performed using a culture process similar to banking, including media composition and culture conditions. Larger scale operations can be performed, particularly for clinical development or commercial production. At larger scales, there can be multiple subcultures of the bacterial composition before the final culture. At the end of the culture, the culture is harvested to ensure further formulation into an administration dosage form. This can involve concentration, removal of unwanted media components, and / or introduction into a chemical environment that preserves the bacterial composition and makes it acceptable for administration by the chosen route. For example, the bacterial composition can be cultured at 10 10The culture can be grown to a concentration of 100 CFU / mL and concentrated 20-fold by tangential flow microfiltration; the spent medium can be replaced by diafiltration with a storage medium consisting of 2% gelatin, 100 mM trehalose, and 10 mM sodium phosphate buffer. The suspension can then be lyophilized to a powder and titrated.
[0274] After drying, the powder can be mixed to an appropriate working strength and mixed with other cultures and / or fillers such as microcrystalline cellulose for hardness and ease of handling, and the bacterial composition can be formulated as provided herein.
[0275] Methods of Treating a Subject In some embodiments, the compositions disclosed herein are administered to a patient or user (sometimes collectively referred to as a "subject"). As used herein, "administer" and "administration" encompass embodiments in which one person instructs another person to take a bacterial composition in a particular manner and / or for a particular purpose, and also encompass situations in which a user uses a bacterial composition in a particular manner and / or for a particular purpose, independent of or different from any instructions received from a second person. Non-limiting examples of embodiments in which one person instructs another person to take a bacterial composition in a particular manner and / or for a particular purpose include when a physician prescribes a course of action and / or treatment to a patient, when a parent instructs a minor user (such as a toddler) to take a bacterial composition, when a trainer encourages a user (such as an athlete) to follow a particular course of action and / or treatment, and when a manufacturer, distributor, or sales company recommends conditions of use to an end user, for example, through advertising or labeling on packaging or other materials provided in connection with the sale or shipping of the product.
[0276] The bacterial compositions provide protective and / or therapeutic benefits against diseases, disorders, or conditions associated with intestinal microbiota dysbiosis, including, but not limited to, metabolic disorders such as pre-diabetes, type 1 diabetes, type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD), gastrointestinal disorders such as inflammatory bowel disease (IBD, ulcerative colitis, and Crohn's disease), pouchitis, and irritable bowel syndrome (IBS), and infectious diseases described herein.
[0277] In some embodiments, the bacterial compositions provide a protective and / or therapeutic effect against diseases, disorders, or conditions associated with intestinal microbiota dysbiosis, and are useful in treating metabolic diseases (e.g., type 1 diabetes, type 2 diabetes, gestational diabetes, diabetic complications, prediabetes, NAFLD / NASH, obesity, weight loss), GI diseases (inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), ulcerative colitis, Crohn's disease), infectious diseases (Clostridium difficile-associated diarrhea (CDAD), carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant Acinetobacter, drug-resistant Campylobacter, extended-spectrum β-lactam-producing Enterobacteriaceae (ESBL), vancomycin-resistant Enterococcus (VRE), multidrug-resistant Pseudomonas aeruginosa, drug-resistant non-typhoidal Salmonella, drug-resistant Salmonella Typhi, drug-resistant Shigella, methicillin-resistant Staphylococcus aureus (MRSA), drug-resistant Streptococcus pneumonia, vancomycin-resistant Staphylococcus aureus (VRSA), erythromycin-resistant Group A Streptococcus, clindamycin-resistant Group B Streptococcus, pathogenic fungi or Candida infections).
[0278] The bacterial compositions can be administered to animals, including humans, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cattle, sheep, goats, pigs, turkeys, and chickens), and household pets (e.g., dogs, cats, and rodents).
[0279] In the present methods, the bacterial composition may be administered enterally, i.e., by a route that provides access to the gastrointestinal tract, including oral administration, rectal administration (enema, suppository, colonoscopy), or oral or nasogastric (nasojejunal, orogastric, or orojejunal) administration, as described more fully herein.
[0280] Pre-treatment Protocols Prior to administration of the bacterial composition, the patient may have a pre-treatment protocol to prepare the gastrointestinal tract to receive the bacterial composition.
[0281] One method of preparing a patient for administration of a microbial ecosystem can be to administer at least one antibiotic to alter the bacteria in the patient. Another method of preparing a patient for administration of a microbial ecosystem can be to administer a standard colon cleansing preparation, such as that used to prepare a patient for colonoscopy, to the patient, and to substantially empty the contents of the colon. As used herein, "substantially empty the contents of the colon" means to remove at least 75%, at least 80%, at least 90%, at least 95%, or about 100% of the normal volume of the colon contents. Antibiotic treatment can be administered before the colon cleansing protocol.
[0282] If the patient is receiving antibiotics for the treatment of an infection, or if the patient is receiving antibiotics as part of a specific pretreatment protocol, in one embodiment, the antibiotics may be stopped for a sufficient time to allow the concentration of the antibiotic in the intestine to substantially decrease before administering the bacterial composition. In one embodiment, the antibiotics may be stopped 1, 2, or 3 days before administering the bacterial composition. In another embodiment, the antibiotics may be stopped 3, 4, 5, 6, or 7 days before administering the bacterial composition. In another embodiment, the antibiotics may be selected so that the components of the bacterial composition have a higher MIC50 than the concentration of the antibiotic in the intestine.
[0283] The MIC50 of a bacterial composition or a component in the composition can be determined by methods known in the art. Reller et al., Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices, Clinical Infectious Diseases 49(11):1749-1755 (2009). In such embodiments, no additional time is required between administration of the antibiotic and administration of the bacterial composition. If the pretreatment protocol is part of the treatment of an acute infection, the antibiotic can be selected so that the infection is susceptible to the antibiotic, but the components of the bacterial composition are not susceptible to the antibiotic.
[0284] Administration of Bacterial Compositions The bacterial compositions of the present invention are suitable for administration to mammals and non-mammals in need thereof. In certain embodiments, the mammalian subject is a human subject with one or more symptoms of microbial incompatibility.
[0285] The bacterial compositions described herein are suitable for treating mammalian subjects suffering from diseases, disorders, or conditions characterized by an abnormal microbiota. In some embodiments, the mammalian subject has not received antibiotics prior to treatment with the bacterial composition. For example, the mammalian subject has not received at least two doses of vancomycin, metronidazole, and / or similar antibiotic compounds within one week prior to administration of the therapeutic composition. In other embodiments, the mammalian subject has not received any prior antibiotic compounds within one month prior to administration of the therapeutic composition. In other embodiments, the mammalian subject has received one or more treatments with one or more different antibiotic compounds, and such treatment(s) did not result in any improvement or worsening of symptoms.
[0286] In some embodiments, the gastrointestinal disease, disorder, or condition includes diarrhea caused by C. difficile, including recurrent C. difficile infection, ulcerative colitis, colitis, Crohn's disease, or sensitive or irritable bowel disease. Advantageously, the therapeutic composition is administered only once before improvement of the disease, disorder, or condition occurs. In some embodiments, the therapeutic composition is administered every three or more days, such as every three, four, five, or six days, or weekly or less frequently. Alternatively, the preparation may be administered intermittently, for example, according to a set schedule, such as once daily, once weekly, or once monthly, or when the subject experiences a recurrence of the primary disease. In another embodiment, the preparations may be administered on a chronic basis to subjects at risk of infection with these pathogens or who may be carriers of these pathogens, including subjects undergoing invasive medical procedures (such as surgery), subjects who are hospitalized, subjects residing in long-term care or rehabilitation facilities, subjects who are occupationally exposed to pathogens (livestock and animal processing workers), or subjects who may be carriers of pathogens (including hospital workers such as doctors, nurses, and other healthcare workers).
[0287] In embodiments, the bacterial composition is administered enterally. Enteral administration preferably includes oral administration or administration via oral or nasogastric (nasojejunal, orogastric, or orojejunal) tubes. In other embodiments, administration includes rectal administration (enema, suppository, or colonoscopy). The bacterial composition may be administered to at least one region of the gastrointestinal tract, including the mouth, esophagus, stomach, small intestine, large intestine, and rectum. In some embodiments, the bacterial composition is administered to all regions of the gastrointestinal tract. The bacterial composition may be administered orally in pharmaceutical form such as powder, capsule, tablet, gel, or liquid. The bacterial composition may also be administered orally or via nasogastric tube in gel or liquid form, rectally in gel or liquid form, via colonoscopy by enema or instillation, or by suppository.
[0288] If the composition is administered colonoscopically, and optionally if the bacterial composition is administered by other rectal routes (such as an enema or suppository) or if the subject is receiving oral administration, the subject may receive a colon cleansing preparation. The colon cleansing preparation may facilitate proper use of the colonoscopy or other administration device, but may also maximize the proportion of the bacterial composition relative to other organisms pre-existing in the subject's gastrointestinal tract, even if it does not serve a medical purpose. Any conventional, acceptable colon cleansing preparation may be used, such as one normally provided when a subject undergoes a colonoscopy.
[0289] Dosage and schedule of administration
[0290] In some embodiments, the bacteria and bacterial compositions are provided in a dosage form. In certain embodiments, the dosage form is designed for administration of at least one OTU disclosed herein or combinations thereof, wherein the total amount of bacterial composition administered is selected from 0.1 ng to 10 g, 10 ng to 1 g, 100 ng to 0.1 g, 0.1 mg to 500 mg, 1 mg to 100 mg, or 10 to 15 mg. In other embodiments, the bacterial composition is taken at a rate of 0.1 ng to 10 g per day, 10 ng to 1 g per day, 100 ng to 0.1 g per day, 0.1 mg to 500 mg per day, 1 mg to 100 mg per day, or 10 to 15 mg per day or more.
[0291] In certain embodiments, the treatment period is at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, or at least 1 year. In some embodiments, the treatment period is 1 day to 1 week, 1 week to 4 weeks, 1 month, to 3 months, 3 months to 6 months, 6 months to 1 year, or more than 1 year.
[0292] In one embodiment, a total of 10 5 and 10 12In another embodiment, the effective amount is 10 per ml or gram. 7 ~10 11 1 to 500 ml or 1 to 500 grams of a bacterial composition having 10 bacteria, or 7 ~10 11 It may be provided in capsules, tablets, or suppositories containing 1 mg to 1000 mg of lyophilized powder containing the bacteria. Patients receiving acute treatment may receive higher doses than patients receiving chronic treatment.
[0293] Any of the preparations described herein can be administered once or multiple times, such as once daily for several days, or more than once daily on the day of administration, including twice daily, three times daily, or up to five times daily. In another embodiment, the preparations can be administered according to a set schedule, for example, once weekly or once monthly, or intermittently if the patient experiences a recurrence of the primary disease. In one embodiment, the preparations can be administered on a long-term basis to individuals at risk of infection with these pathogens or who may be carriers of these pathogens.
[0294] Patient Selection Specific bacterial compositions can be selected for each patient or for patients with a particular profile. For example, 16S sequencing can be performed for a given patient to identify the bacteria present in their microbiome. Sequencing can either profile the patient's entire microbiome (down to the family, genus, or species level) using 16S sequencing, a portion of the patient's microbiome using 16S sequencing, or be used to detect the presence or absence of specific candidate bacteria that are biomarkers for health or specific disease states. Based on biomarker data, specific compositions can be selected for administration to the patient to replenish or supplement the patient's microbiome to restore health or treat or prevent disease. In another embodiment, patients can be screened to determine the composition of their microbiome and determine the likelihood of successful treatment.
[0295] Combination Therapy The bacterial composition can be administered in a combination therapy with other agents, including antimicrobial agents and prebiotics. Administration can be sequential over a period of hours or days, or can be simultaneous.
[0296] In one embodiment, the bacterial composition is included in a combination therapy together with one or more antimicrobial agents, including antibacterial, antifungal, antiviral and antiparasitic agents.
[0297] Antibacterial agents may include cephalosporin antibiotics (ceflexine, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole); fluoroquinolone antibiotics (cipro, levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); and carbapenem antibiotics (ertapenem, doripenem, imipenem / cilastatin, and meropenem).
[0298] Antiviral agents may include abacavir, acyclovir, adefovir, amprenavir, atazanavir, cidofovir, darunavir, delavirdine, didanosine, docosanol, efavirenz, elvitegravir, emtricitabine, enfuvirtide, etravirine, famciclovir, foscarnet, fomivirsen, ganciclovir, indinavir, idoxuridine, lamivudine, lopinavir maraviroc, MK-2048, nelfinavir, nevirapine, penciclovir, raltegravir, rilpivirine, ritonavir, saquinavir, stavudine, tenofovir, trifluridine valacyclovir, valganciclovir, vidarabine, ibacitabine, amantadine, oseltamivir, rimantidine, tipranavir, zalcitabine, zanamivir, and zivudodine.
[0299] Examples of antifungal compounds include, but are not limited to, polyene antifungals such as natamycin, rimocidin, filipin, nystatin, amphotericin B, candicin, and hamycin; imidazole antifungals such as miconazole, ketoconazole, clotrimazole, econazole, omoconazole, bifonazole, butoconazole, fenticonazole, isoconazole, oxiconazole, sertaconazole, sulconazole, and tioconazole; triazole antifungals such as fluconazole, itraconazole, isavuconazole, ravuconazole, posaconazole, voriconazole, terconazole, and albaconazole; thiazole antifungals such as abafungin; arylamine antifungals such as terbinafine, naftifine, and butenafine; and echinocandin antifungals such as anidulafungin, caspofungin, and micafungin. Other compounds with antifungal properties include, but are not limited to, polygodial, benzoic acid, ciclopirox, tolnaftate, undecylenic acid, flucytosine or 5-fluorocytosine, griseofulvin, and haloprogin.
[0300] In one embodiment, the bacterial composition is included in a combination therapy with one or more corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressants, cyclosporin A, mercaptopurine, azathioprine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, sodium cromoglycate, anti-leukotrienes, anticholinergics for rhinitis, anticholinergic decongestants, mast cell stabilizers, monoclonal anti-IgE antibodies, vaccines, and combinations thereof.
[0301] Prebiotics are selectively fermented ingredients that allow specific changes in both the composition and / or activity of the gastrointestinal microflora, which confer benefits to the well-being and health of the host. Prebiotics may include complex polysaccharides, amino acids, peptides, or other essential nutrients for the survival of bacterial compositions. Prebiotics include, but are not limited to, amino acids, biotin, fructooligosaccharides, galactooligosaccharides, inulin, lactulose, mannanoligosaccharides, oligofructose-enriched inulin, oligofructose, oligodextrose, tagatose, transgalactooligosaccharides, and xylooligosaccharides.
[0302] Methods for Testing Bacterial Compositions for Colonization Efficacy In Vivo Assays for Determining Whether a Bacterial Composition Colonizes the Gastrointestinal Tract of a Subject To determine whether a bacterial composition colonizes the gastrointestinal tract of a subject, an animal model, such as a mouse model, can be used. The model can begin by assessing the mouse's microbiota. Qualitative assessment can be achieved using 16S profiling of the microbial community in the feces of normal mice. Quantitative assessment can also be achieved by whole genome sequencing, whole genome shotgun sequencing (WGS), or traditional microbiological techniques. Quantitative assessment can be performed using quantitative PCR (qPCR) or by enumerating colonies using traditional microbiological techniques, as follows:
[0303] Mice may be given antibiotic treatment to mimic a state of dysbiosis. Antibiotic treatment can reduce the taxonomic richness, diversity, and evenness of the community, including a reduction in the abundance of a significant number of bacterial taxa. Dethlefsen et al., The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing, PLoS Biology 6(11):3280 (2008). At least one antibiotic may be used, and the antibiotic may be known. Antibiotics may include aminoglycoside antibiotics (amikacin, arbekacin, gentamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodostreptomycin, streptomycin, tobramycin, and apramycin), amoxicillin, ampicillin, Augmentin (amoxicillin / potassium clavulanate combination), cephalosporins (cefachlor, defadroxil, cefazolin, cefixime, defoxitin, cefprozil, ceftazimdime, cefuroxime, ceflexine), potassium clavulanate, clindamycin, colistin, gentamicin, kanamycin, metronidazole, or vancomycin. As specific, non-limiting examples, mice may be given drinking water containing a mixture of the antibiotics kanamycin, colistin, gentamicin, metronidazole, and vancomycin at 40 mg / kg, 4.2 mg / kg, 3.5 mg / kg, 21.5 mg / kg, and 4.5 mg / kg (mg per average mouse body weight), respectively, for 7 days. Alternatively, mice may be given ciprofloxacin at a dose of 15-20 mg / kg (mg per average mouse body weight) for 7 days. If mice are given antibiotics, a 1-3 day washout period may be provided without antibiotic and bacterial composition treatment.
[0304] The bacterial composition is then administered to the mice by oral gavage. 4The bacterial composition containing CFU of each type of bacteria can be administered in a volume of 0.2 ml. Dose response can be assessed using various doses, including 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 and / or 10 10 These include, but are not limited to:
[0305] Mice can be evaluated using 16S sequencing, whole genome sequencing, whole genome shotgun sequencing (WGS), or traditional microbiological techniques to determine whether the bacterial composition is inhabiting the gastrointestinal tract of the mice. By way of example only, 16S profiling can be performed 1 day, 3 days, 1 week, 2 weeks, and 1 month after administration of the bacterial composition to the mice to determine whether the test bacterial composition is inhabiting the gastrointestinal tract of the mice. Quantitative evaluations, including traditional microbiological techniques such as qPCR and colony counting, can additionally or alternatively be performed at the same time intervals.
[0306] Additionally, the number of sequence counts that match those of the bacterial composition can be evaluated over time to specifically determine which components of the bacterial composition are inhabiting the gastrointestinal tract after a particular time. In one embodiment, the strains of the bacterial composition persist for a desired period of time. In another embodiment, while the components of the bacterial composition persist for a desired period of time, the ability of other microorganisms (those present in the environment, food, etc.) to populate the gastrointestinal tract is also increased, further increasing overall diversity, as discussed below.
[0307] Ability of Bacterial Compositions to Populate Different Regions of the Gastrointestinal Tract The bacterial compositions may also be evaluated for their ability to populate different regions of the gastrointestinal tract. In one embodiment, the bacterial compositions may be selected for their ability to populate one or more regions of the gastrointestinal tract, including but not limited to the stomach, small intestine (duodenum, jejunum, and ileum), large intestine (cecum, colon (ascending colon, transverse colon, descending colon, and sigmoid colon) and rectum).
[0308] In vivo experiments can be performed to determine which regions of the gastrointestinal tract a given bacterial composition inhabits. A mouse model similar to the one described above can be performed, except that rather than evaluating the feces produced by the mice, specific regions of the gastrointestinal tract can be removed and studied individually. For example, at least one specific region of the gastrointestinal tract can be removed, and qualitative or quantitative determinations can be performed on the contents of that region of the gastrointestinal tract. In another embodiment, the contents can be removed, and qualitative or quantitative determinations can be performed on tissue removed from the mouse.
[0309] qPCR Quantitative PCR (qPCR) can be performed as a quantitative method for determining whether a bacterial composition inhabits the gastrointestinal tract. Standard curves of the bacterial composition of interest can be generated for all components of the bacterial composition, either collectively, individually, or in subsets (if appropriate), according to standard techniques. Genomic DNA can be extracted from samples using commercially available kits such as the Mo Bio Powersoil®-htp 96 Well Soil DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), Mo Bio Powersoil® DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), or QIAamp DNA Stool Mini Kit (QIAGEN, Valencia, CA), according to the manufacturer's instructions.
[0310] In some embodiments, qPCR can be performed using HotMasterMix (5PRIME, Gaithersburg, MD) and primers specific for the bacterial composition of interest, and can be performed on a MicroAmp® Fast Optical 96-well Reaction Plate with Barcode (0.1 mL) (LifeTechnologies, Grand Island, NY) on a BioRad C1000™ Thermal Cycler equipped with a CFX96™ Real-Time System (BioRad, Hercules, CA) with fluorescence readings in the FAM and ROX channels. The Cq value for each well in the FAM channel is determined using CFX Manager™ software version 2.1. The log of each experimental sample is then calculated. 10 (cfu / ml) is the Cq value of a given sample and the Cq values of the standard curve wells are multiplied by the known log 10 The values are calculated by inputting the values (cfu / ml) into a linear regression model generated from the standard curve. Alternative qPCR formats may be used by those skilled in the art.
[0311] Methods for Characterizing Bacterial Compositions In certain embodiments, methods are provided for testing specific characteristics of bacterial compositions. For example, the sensitivity of a bacterial composition to specific environmental variables is determined, e.g., to select for specific desired characteristics in a given composition, formulation, and / or use. For example, components of a bacterial composition may be tested for pH tolerance, bile acid tolerance, and / or antibiotic susceptibility, either individually on a component-by-component basis or collectively as a bacterial composition comprised of multiple bacterial components (referred to collectively in this section as the bacterial composition).
[0312] pH Sensitivity Testing If the bacterial composition is administered other than to the colon or rectum (i.e., for example, orally), optional pH tolerance testing enhances the selection of bacterial compositions that survive with the highest possible yield across the various pH environments of distinct regions of the GI tract. Understanding how a bacterial composition responds to the pH of the GI tract can aid in formulation, so that the number of bacteria in a dosage form can be increased if advantageous, and / or so that the composition can be administered in an enteric-coated capsule or tablet, or with a buffering or protective composition. Because the pH of the stomach can briefly drop to a pH of 1-2 after a high-protein meal before physiological mechanisms regulate it to a pH of 3-4 and often remain at a resting pH of 4-5, and the pH of the small intestine can range from 6-7.4, bacterial compositions can be prepared that survive these various pH ranges (e.g., at least 1%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or even 100% of the bacteria can survive intestinal transit times across various pH ranges), which can be tested by exposing the bacterial compositions to various pH ranges and predicting intestinal transit times across these pH ranges. Thus, by way of non-limiting example only, an 18-hour culture of the bacterial composition may be grown in a standard medium such as gut microbiota medium ("GMM," Goodman et al., Extensive personal human gut microbiota culture collections characterized and manipulated in gnotobiotic mice, PNAS 108(15):6252-6257 (2011)) or other animal-product-free medium, with the addition of pH adjusters to achieve pH 1-2 for 30 minutes, pH 3-4 for 1 hour, pH 4-5 for 1-2 hours, and pH 6-7.4 for 2.5-3 hours. Alternative methods for testing acid stability are described in U.S. Pat. No. 4,839,281. Bacterial viability may be determined by culturing the bacteria on an appropriate selective or non-selective medium and counting colonies.
[0313] Bile Acid Susceptibility Testing: Furthermore, in some embodiments, testing for bile acid tolerance enhances the selection of bacterial compositions that survive exposure to bile acids during transit through the GI tract. Bile acids are secreted into the small intestine and, like pH, affect the survival of bacterial compositions. This can be tested by exposing the bacterial composition to bile acids for the expected intestinal exposure time. For example, a bile acid solution can be prepared at the desired concentration using 0.05 mM Tris at pH 9 as the solvent. After dissolving the bile acids, the pH of the solution can be adjusted to 7.2 with 10% HCl. The bacterial composition can be cultured with 2.2 ml of a bile acid composition mimicking the patient's bile acid concentration and type, 1.0 ml of 10% sterile filtered fecal broth, and 0.1 ml of an 18-hour culture of a given bacterial strain. Incubation can be performed for 2.5 to 3 hours or longer. An alternative method for testing bile acid stability is described in U.S. Patent No. 4,839,281. Bacterial survival can be determined by culturing the bacteria on an appropriate selective or non-selective medium and counting the colonies.
[0314] Antibiotic Susceptibility Testing As a further optional susceptibility test, the bacterial composition may be tested for susceptibility to antibiotics. In one embodiment, the bacterial composition may be selected such that the bacterial components are susceptible to antibiotics such that the bacterial components are optionally eliminated or substantially reduced from the patient's gastrointestinal tract by at least one antibiotic that targets the bacterial composition.
[0315] Adherence to Gastrointestinal Cells Bacterial compositions may be tested for their ability to adhere to gastrointestinal cells. Methods for testing adhesion to gastrointestinal cells are described in U.S. Patent No. 4,839,281.
[0316] Methods for Purifying Spores: Solvent Treatment To purify bacterial spores, fecal material is subjected to one or more solvent treatments. The solvent treatments may be miscible (either partially miscible or completely miscible) or immiscible. Miscibility is the ability of two liquids to mix with each other to form a homogeneous solution. For example, water and ethanol are completely miscible, such that a mixture containing water and ethanol in any proportion will exhibit only one phase. Miscibility is provided as wt / wt%, i.e., the weight of one medium in 100 g of final solution. If two solvents are completely miscible in all proportions, the miscibility is 100%. Examples of solutions that are completely miscible with water include alcohols, such as methanol, ethanol, isopropanol, and butanol. Alcohols can be provided already combined with water; for example, solutions containing 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 89%, 85%, 90%, 95%, or more than 95% water. Other solvents are only partially miscible, meaning that only a portion dissolves in water. For example, diethyl ether is partially miscible with water. Up to 7 grams of diethyl ether can be dissolved in 93 g of water to obtain a 7% (wt / wt%) solution. Adding more diethyl ether leads to a two-phase solution with a separate diethyl ether layer on top of the water. Other miscible substances include ethers, dimethoxyethane, or tetrahydrofuran. In contrast, oils such as alkanes and water are immiscible and form two phases. Furthermore, the immiscibility treatment can be combined with a surfactant, either an ionic surfactant or a nonionic surfactant. Exemplary surfactants include Triton X-100, Tween 20, Tween 80, Nonidet P40, pluronics or polyols.
[0317] Chromatography To purify the spore population, the fecal material is subjected to one or more chromatography steps, either sequentially or in parallel. In a chromatography step, a solution containing the fecal material is contacted with a solid medium comprising a hydrophobic interaction chromatography (HIC) medium or an affinity chromatography medium. In an alternative embodiment, a solid medium capable of absorbing residual habitat products present in the fecal material is contacted with a solid medium that absorbs the residual habitat products. In certain embodiments, the HIC medium comprises Sepharose or a derivatized Sepharose, such as butyl Sepharose, octyl Sepharose, phenyl Sepharose, or butyl-s Sepharose. In other embodiments, the affinity chromatography medium comprises a material derivatized with type I, II, III, IV, V, or VI mucin, or an oligosaccharide derived from or similar to the oligosaccharide of type I, II, III, IV, V, or VI mucin. Alternatively, the affinity chromatography medium comprises a material derivatized with an antibody that recognizes spore-forming bacteria.
[0318] Mechanical Treatment Provided herein is physical disruption of fecal material by one or more mechanical treatments, particularly blending, mixing, shaking, stirring, impact trituration, and sonication. As provided herein, mechanical disruption treatment substantially disrupts non-spore material present in the fecal material, but does not substantially disrupt spores present in the fecal material. Mechanical treatment may include filtration, in which undesired (non-spore) fecal components pass through while the desired spore population remains on the filter, and the spore fraction is then recovered from the filter medium. Alternatively, bacterial cells, including spores, may pass through while undesired particles and eukaryotic cells remain on the filter. In some embodiments, to further reduce or remove undesired fecal components, the spore fraction remaining on the filter medium is subjected to a diafiltration step in which the remaining spores are contacted with a wash liquid, typically a sterile saline-containing solution or other diluent.
[0319] Thermal destruction of fecal material is provided herein. Typically, the fecal material is mixed with a saline-containing solution, such as phosphate buffered saline (PBS), and subjected to a heated environment, such as a greenhouse, incubator, water bath, etc., to allow sufficient heat transfer between the heated environment and the fecal material. Preferably, the fecal material solution is mixed during incubation to increase heat transfer and break down particle aggregates. The heat treatment can be controlled by the temperature of the environment and / or the duration of the heat treatment. For example, the fecal material or a liquid containing fecal material is subjected to a heated environment, e.g., a hot water bath of at least about 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, or 100°C or higher, for at least about 1, 5, 10, 15, 20, 30, 45 seconds, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, or 50 minutes, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 10 hours or more. In certain embodiments, the heat treatment occurs at two different temperatures, such as 30 seconds in a 100°C environment followed by 10 minutes in a 50°C environment. In a preferred embodiment, the heat treatment is at a temperature and for a duration sufficient to kill or eliminate pathogenic agents while not substantially impairing or reducing the germination ability of the spores.
[0320] Irradiation Treatment Provided herein are methods for treating fecal material or separated contents of fecal material with ionizing radiation, typically gamma, ultraviolet, or electron beam radiation, provided at an energy level sufficient to kill pathogenic agents while leaving the desired spore population substantially unharmed. 2 254 nm ultraviolet radiation provided at energy levels of less than about 22,000 microwatt seconds per spore is generally not destructive to the desired spores.
[0321] Centrifugation and Density Separation Processes Provided herein are methods for separating desired spores from other components of fecal material by centrifugation. A solution containing fecal material is subjected to one or more centrifugation processes, for example, at about 1000×g, 2000×g, 3000×g, 4000×g, 5000×g, 6000×g, 7000×g, 8000×g, or greater than 8000×g. Differential centrifugation separates desired spores from undesired non-spore material; at low forces, spores remain in solution, while at higher forces, the spores are pelleted while smaller impurities (e.g., virus particles, phages) remain in solution. For example, a first, low-force centrifugation pellets fibrous material; a second, higher-force centrifugation pellets undesired eukaryotic cells, and a third, even higher-force centrifugation pellets desired spores while smaller contaminants remain in suspension. In some embodiments, a density or mobility gradient or cushion (eg, a step cushion) such as a Percoll, Ficoll, Nycodenz, Histodenz, or sucrose gradient is used to separate the desired spore population from other materials in the fecal material.
[0322] Also provided herein are methods for producing spore populations that combine two or more of the treatments described herein to synergistically purify desired spores while killing or removing undesirable substances and / or activities from the spore population. It is typically desirable to maintain the spore population under non-germination- and non-growth-promoting conditions and media to minimize the growth of pathogenic bacteria present in the spore population and to minimize germination of the spores into vegetative bacterial cells.
[0323] Pharmaceutical compositions and formulations of the present invention Formulations are provided for administration to humans and other subjects in need thereof. Typically, the bacterial composition is combined with additional active and / or inactive substances to create a final product, which may be in single-dose or multi-dose form.
[0324] In some embodiments, the composition comprises at least one carbohydrate. "Carbohydrate" refers to a sugar or a polymer of sugar. The terms "sugar," "polysaccharide," "carbohydrate," and "oligosaccharide" may be used interchangeably. Most carbohydrates are aldehydes or ketones with many hydroxyl groups, usually one on each carbon atom of the molecule. Carbohydrates typically have the molecular formula C n H 2n O n Carbohydrates can be monosaccharides, disaccharides, trisaccharides, oligosaccharides, or polysaccharides. The most basic carbohydrates are monosaccharides, such as glucose, sucrose, galactose, mannose, ribose, arabinose, xylose, and fructose. Disaccharides are two linked monosaccharides. Exemplary disaccharides include sucrose, maltose, cellobiose, and lactose. Oligosaccharides typically contain between three and six monosaccharide units (e.g., raffinose, stachyose), and polysaccharides contain six or more monosaccharide units. Exemplary polysaccharides include starch, glycogen, and cellulose. Carbohydrates can also contain modified sugar units, such as 2'-deoxyribose, where the hydroxyl group has been removed, 2'-fluororibose, where the hydroxyl group has been replaced with fluorine, or N-acetylglucosamine, nitrogen-containing forms of glucose (e.g., 2'-fluororibose, deoxyribose, and hexose). Carbohydrates can exist in many different forms, for example, conformers, cyclic, acyclic, stereoisomers, tautomers, anomers and isomers.
[0325] In some embodiments, the composition comprises at least one lipid. As used herein, "lipid" includes fats, oils, triglycerides, cholesterol, phospholipids, and fatty acids in any form, including free fatty acids. Fats, oils, and fatty acids can be saturated, unsaturated (cis or trans), or partially unsaturated (cis or trans). In some embodiments, the lipid is selected from the group consisting of lauric acid (12:0), myristic acid (14:0), palmitic acid (16:0), palmitoleic acid (16:1), margaric acid (17:0), heptadecenoic acid (17:1), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), octadecatetraenoic acid (18:4), and arachidic acid. In another embodiment, the composition comprises at least one fatty acid selected from 20:0, eicosenoic acid (20:1), 20:2, eicosatetraenoic acid (20:4), 20:5, eicosapentaenoic acid (20:5) (EPA), docosanoic acid (22:0), docosenoic acid (22:1), docosapentaenoic acid (22:5), docosahexaenoic acid (22:6) (DHA), and tetracosanoic acid (24:0). In another embodiment, the composition comprises at least one modified lipid, e.g., a lipid modified by cooking.
[0326] In some embodiments, the composition includes at least one supplemental mineral or mineral source. Examples of minerals include, but are not limited to, chloride, sodium, calcium, iron, chromium, copper, iodine, zinc, magnesium, manganese, molybdenum, phosphorus, potassium, and selenium. Suitable forms of any of the foregoing minerals include soluble mineral salts, slightly soluble mineral salts, insoluble mineral salts, chelated minerals, mineral complexes, non-reactive minerals such as carbonyl minerals, and reduced minerals, and combinations thereof.
[0327] In certain embodiments, the composition includes at least one supplemental vitamin. The at least one vitamin can be a fat-soluble or water-soluble vitamin. Suitable vitamins include, but are not limited to, vitamin C, vitamin A, vitamin E, vitamin B12, vitamin K, riboflavin, niacin, vitamin D, vitamin B6, folic acid, pyridoxine, thiamine, pantothenic acid, and biotin. Suitable forms of any of the foregoing include salts of the vitamin, derivatives of the vitamin, compounds having the same or similar activity as the vitamin, and metabolites of the vitamin.
[0328] In other embodiments, the composition comprises an excipient. Non-limiting examples of suitable excipients include buffering agents, preservatives, stabilizers, binders, compression agents, lubricants, dispersion enhancers, disintegrants, flavors, sweeteners, and colorants.
[0329] In another embodiment, the excipient is a buffering agent. Non-limiting examples of suitable buffering agents include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate, and calcium bicarbonate.
[0330] In some embodiments, the excipient comprises a preservative. Non-limiting examples of suitable preservatives include antioxidants such as alpha-tocopherol and ascorbate, and antimicrobial agents such as parabens, chlorobutanol, and phenol.
[0331] In other embodiments, the composition comprises a binder as an excipient. Non-limiting examples of suitable binders include starch, pregelatinized starch, gelatin, polyvinylpyrrolidone, cellulose, methylcellulose, sodium carboxymethylcellulose, ethylcellulose, polyacrylamide, polyvinyloxoazolidone, polyvinyl alcohol, C 12 -C 18 Included are fatty acid alcohols, polyethylene glycols, polyols, sugars, oligosaccharides, and combinations thereof.
[0332] In another embodiment, the composition comprises a lubricant as an excipient. Non-limiting examples of suitable lubricants include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, Sterotex, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil.
[0333] In other embodiments, the composition comprises a dispersion enhancing agent as an excipient. Non-limiting examples of suitable dispersing agents include starch, alginic acid, polyvinylpyrrolidone, guar gum, kaolin, bentonite, purified wood cellulose, sodium starch glycolate, isoamorphous silicate, and microcrystalline cellulose as a high HLB emulsifier surfactant.
[0334] In some embodiments, the composition includes a disintegrant as an excipient. In other embodiments, the disintegrant is a non-foaming disintegrant. Non-limiting examples of suitable non-foaming disintegrants include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays such as bentonite, microcrystalline cellulose, alginate, sodium starch glycolate, gums such as agar, gaur, carob, karaya, pecitin, and tragacanth. In other embodiments, the disintegrant is a foaming disintegrant. Non-limiting examples of suitable foaming disintegrants include sodium bicarbonate in combination with citric acid and sodium bicarbonate in combination with tartaric acid.
[0335] In another embodiment, the excipient comprises a flavoring agent. The flavoring agent may be selected from synthetic flavor oils and flavorings; natural oils, plant, leaf, flower, and fruit extracts; and combinations thereof. In some embodiments, the flavoring agent is selected from cinnamon oil; wintergreen oil; peppermint oil; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oils such as lemon oil, orange oil, grape oil, and grapefruit oil; and fruit extracts including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple, and apricot.
[0336] In another embodiment, the excipient comprises a sweetener. Non-limiting examples of suitable sweeteners include glucose (corn syrup), dextrose, invert sugar, fructose, and combinations thereof (when not used as a carrier); saccharin and its various salts, such as the sodium salt; dipeptide sweeteners, such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (stevioside); chloro derivatives of sucrose, such as sucralose; and sugar alcohols, such as sorbitol, mannitol, and sylitol. Hydrogenated starch hydrolysates and synthetic sweeteners, such as 3,6-dihydro-6-methyl-1,2,3-oxathiazin-4-one-2,2-dioxide, particularly the potassium salt (acesulfame-K), and their sodium and calcium salts, are also contemplated.
[0337] In another embodiment, the composition includes a colorant. Non-limiting examples of suitable colorants include Food, Drug, and Cosmetic Colors (FD&C), Drug and Cosmetic Colors (D&C), and External Drug and Cosmetic Colors (Ext. D&C). The colorant may be used as a dye or its corresponding lake.
[0338] The weight fraction of the excipient or combination of excipients within the formulation is typically about 99% or less, such as about 95% or less, about 90% or less, about 85% or less, about 80% or less, about 75% or less, about 70% or less, about 65% or less, about 60% or less, about 55% or less, 50% or less, about 45% or less, about 40% or less, about 35% or less, about 30% or less, about 25% or less, about 20% or less, about 15% or less, about 10% or less, about 5% or less, about 2% or less, or about 1% or less of the total weight of the composition.
[0339] The bacterial compositions disclosed herein can be formulated into a variety of forms and administered by several different means. The compositions can be administered orally, rectally, or parenterally, in formulations containing conventionally acceptable carriers, adjuvants, and vehicles. As used herein, "parenteral" includes subcutaneous, intravenous, intramuscular, or intrasternal injection and infusion techniques. In an exemplary embodiment, the bacterial composition is administered orally.
[0340] Solid dosage forms for oral administration include capsules, tablets, caplets, pills, lozenges, lozenges, powders, and granules. Capsules typically comprise a core material containing the bacterial composition and a shell wall encapsulating the core material. In some embodiments, the core material comprises at least one of a solid, a liquid, and an emulsion. In other embodiments, the shell wall material comprises at least one of soft gelatin, hard gelatin, and a polymer. Suitable polymers include, but are not limited to, cellulose polymers such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose (HPMC), methylcellulose, ethylcellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose succinate, and sodium carboxymethylcellulose; acrylic acid polymers and copolymers such as those formed from acrylic acid, methacrylic acid, methyl acrylate, methylammonio acrylate, ethyl acrylate, methyl methacrylate, and / or ethyl methacrylate (e.g., copolymers sold under the trademark "Eudragit"); vinyl polymers and copolymers such as polyvinylpyrrolidone, polyvinyl acetate, polyvinyl acetate phthalate, vinyl acetate crotonic acid copolymer, and ethylene-vinyl acetate copolymer; and shellac (purified lac). In yet another embodiment, at least one polymer functions as a taste masking agent.
[0341] Tablets, pills, etc. may be compressed, multi-compressed, multi-layered, and / or coated. The coating may be single or multi-layered. In one embodiment, the coating material may comprise at least one of sugars, polysaccharides, and glycoproteins extracted from at least one of plants, fungi, and microorganisms. Non-limiting examples include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, dextran, maltodextrin, cyclodextrin, inulin, pectin, mannan, gum arabic, locust bean gum, mesquite gum, guaia gum, karaya gum, gadi gum, tragacanth gum, funori, carrageenan, agar, alginate, chitosan, or gellan gum. In some embodiments, the coating material comprises a protein. In another embodiment, the coating material comprises at least one of a fat and an oil. In other embodiments, the at least one of the fat and oil melts at high temperatures. In yet another embodiment, at least one of the fats and oils is hydrogenated or partially hydrogenated. In one embodiment, at least one of the fats and oils is derived from a plant. In another embodiment, at least one of the fats and oils comprises at least one of a glyceride, a free fatty acid, and a fatty acid ester. In some embodiments, the coating material comprises at least one edible wax. The edible wax may be derived from an animal, insect, or plant. Non-limiting examples include beeswax, lanolin, white bayberry wax, carnauba wax, and rice bran wax. Tablets and pills may further be prepared with an enteric coating.
[0342] Alternatively, powders or granules containing the bacterial compositions disclosed herein can be incorporated into food products. In some embodiments, the food product is a beverage for oral administration. Non-limiting examples of suitable beverages include fruit juices, fruit drinks, artificially flavored beverages, artificially sweetened beverages, carbonated beverages, sports drinks, liquid diary products, shakes, alcoholic beverages, caffeinated beverages, infant formula, etc. Other suitable means for oral administration include aqueous and non-aqueous solutions, emulsions, suspensions, and solutions and / or suspensions reconstituted from non-foaming granules, containing at least one of suitable solvents, preservatives, emulsifiers, suspending agents, diluents, sweeteners, colorants, and flavorants.
[0343] In some embodiments, the food product may be a solid food. Suitable examples of solid food include, but are not limited to, food bars, snack bars, cookies, brownies, muffins, crackers, ice cream bars, frozen yogurt bars, etc.
[0344] In other embodiments, the compositions disclosed herein are incorporated into therapeutic foods. In some embodiments, the therapeutic foods can be ready-to-eat foods that may contain some or all of the essential macronutrients and micronutrients. In another embodiment, the compositions disclosed herein are incorporated into supplemental foods designed to be mixed into existing meals. In one embodiment, the supplemental foods contain some or all of the essential macronutrients and micronutrients. In another embodiment, the bacterial compositions disclosed herein are mixed or added to existing foods to fortify the protein nutrients of the foods. Examples include staple foods (grains, salt, sugar, cooking oils, margarine), beverages (coffee, tea, soda, beer, liquor, sports drinks), snacks, sweets, and other foods.
[0345] In one embodiment, the formulation is packed into a gelatin capsule for oral administration. An example of a suitable capsule contains 10 mg (up to 100 mg) of lyophilized powder (10 8 ~10 11In an alternative embodiment, the capsule contains 10 mg of PEG-1000 (100 mg of PEG-1000) or ... 5 ~10 12 of bacteria can be used, with concomitant adjustment of excipients if necessary, to 5 ~10 7 , 10 6 ~10 7 or 10 8 ~10 10 In alternative embodiments, bacteria may be used in conjunction with enteric coated capsules or tablets or buffering or protective compositions. [Example]
[0346] Below are examples of specific embodiments for carrying out the present invention. The examples are provided for illustrative purposes only and are not intended to limit the scope of the invention in any way. While efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), some experimental error and deviation should, of course, be accounted for.
[0347] The practice of the present invention will employ, unless otherwise indicated, conventional methods of protein chemistry, biochemistry, recombinant DNA technology, and pharmacology within the skill of the art. Such techniques are fully explained in the literature. See, for example, T.E. Creighton, Proteins: Structures and Molecular Properties (W.H. Freeman and Company, 1993); A.L. Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pennsylvania: Mack Publishing Company, 1990); Carey and Sundberg Advanced Organic Chemistry 3 rd See Ed. (Plenum Press) Vols A and B (1992).
[0348] Example 1: Sequence-based gene characterization of operational taxonomic units (OTUs) and functional genes Method for determining 16S rDNA gene sequences As described above, OTUs are determined by complete 16S sequencing of the rRNA gene, by sequencing specific hypervariable regions of this gene (i.e., V1, V2, V3, V4, V5, V6, V7, V8, or V9), or by sequencing any combination of hypervariable regions from this gene (e.g., V1-3 or V3-5). The 16S rRNA bacterial gene is approximately 1500 nucleotides long and is used to reconstruct the evolutionary relationships and sequence similarity between one bacterial isolate and another using a phylogenetic approach. 16S sequences are used for phylogenetic reconstruction if they contain specific hypervariable regions that, while typically highly conserved, possess sufficient nucleotide diversity to distinguish most microbial genera and species. The rRNA gene sequencing method is applicable to the analysis of both unenriched samples and for identification after enrichment steps, which enrich for microorganisms of interest from either microbial compositions and / or nucleic acids with the appropriate rDNA gene sequences described below. For example, 16S rDNA gene characterization after enrichment treatment increases the sensitivity of 16S, as well as characterizing nucleic acids based on other molecules purified from microorganisms.
[0349] To determine the sequence of the complete 16S sequence or any hypervariable region of the 16S rRNA sequence, well-known techniques are used to extract genomic DNA from the bacterial sample, amplify the 16S rDNA (complete region or specific hypervariable region) using polymerase chain reaction (PCR), purify the PCR product, and delineate the nucleotide sequence to determine the genetic organization of the 16S gene or subdomain of the gene. When complete 16S sequencing is performed, the sequencing method used may be, but is not limited to, Sanger sequencing. When using one or more hypervariable regions, such as the V4 region, sequencing can be performed using the Sanger method or next-generation sequencing methods, such as, but not limited to, Illumina (sequencing by synthesis) using barcoded primers to generate multiplex reactions.
[0350] Methods for determining 18S rDNA and ITS gene sequences Genetic methods for designating and identifying fungal OTUs can be achieved by analyzing the 18S sequence and internal transcribed spacer (ITS). Fungal rRNA, which forms the core of the ribosome, is transcribed as a signal gene and consists of the 8S, 5.8S, and 28S regions, with ITS4 and 5 between the 8S and 5.8S regions, and between the 5.8S and 28S regions, respectively. These two intercistronic regions, between the 18S and 5.8S regions and between the 5.8S and 28S regions, are removed by splicing and contain significant variations between species for barcoding purposes, as previously described (Schoch et al., Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. PNAS 109:6241-6246. 2012). Traditionally, 18S rDNA has been used for phylogenetic reconstruction, but the ITS can fulfill this function if it contains hypervariable regions that, although usually highly conserved, have sufficient nucleotide diversity to distinguish most fungal genera and species.
[0351] To determine the complete 18S and ITS sequences or small hypervariable regions of these sequences, well-known techniques are used to extract genomic DNA from the microbial sample, amplify rDNA using polymerase chain reaction (PCR), purify the PCR product, and delineate the nucleotide sequence to determine the genetic organization of the rDNA gene or subdomain of the gene. The sequencing method used may be, but is not limited to, Sanger sequencing or next-generation sequencing, such as Illumina (sequencing by synthesis), which uses barcoded primers in a multiplex reaction.
[0352] Other methods for determining marker gene sequences In addition to the 16S and 18S rRNA genes, OTUs may be defined by sequencing a set of selected genes known as marker genes for a given species or taxon of the OTU. These genes may alternatively be assayed using PCR-based screening tests. As an example, various strains of pathogenic E. coli can be distinguished using DNA from genes encoding thermolabile (LTI, LTIIa, and LTIIb) and thermostable (STI and STII) toxins, verotoxins types 1, 2, and 2e (VT1, VT2, and VT2e, respectively), cytotoxic necrotizing factors (CNF1 and CNF2), binding and excision machinery (eaeA), enteroaggregation machinery (Eagg), and enteroinvasive machinery (Einv). The optimal genes for use in taxonomic assignment of OTUs through the use of marker genes will be familiar to those skilled in the art of sequence-based taxonomic identification.
[0353] Genomic DNA extraction Genomic DNA is extracted from pure microbial cultures using the hot alkaline lysis method. 1 μl of microbial culture is added to 9 μl of lysis buffer (25 mM NaOH, 0.2 mM EDTA), and the mixture is incubated at 95°C for 30 minutes. Subsequently, the sample is cooled to 4°C, neutralized by adding 10 μl of neutralization buffer (40 mM Tris-HCl), and then diluted 10-fold in elution buffer (10 mM Tris-HCl). Alternatively, genomic DNA is extracted from pure microbial cultures using a commercially available kit, such as the Mo Bio Ultraclean® Microbial DNA Isolation Kit (Mo Bio Laboratories, Carlsbad, CA), or by conventional methods known to those skilled in the art. For fungal samples, DNA extraction can be performed using a previously described method (US20120135127) for preparing a lysate from fruiting bodies by mechanical grinding.
[0354] Amplification of 16S sequences for downstream Sanger sequencing To amplify bacterial 16S rDNA (e.g., in Figure 1), 2 μl of extracted gDNA is added to a PCR reaction with a final volume of 20 μl. For full-length 16S sequencing, the PCR reaction also contains 1x HotMasterMix (5PRIME, Gaithersburg, MD), 250 nM 27f (AGRGTTTGATCMTGGCTCAG, IDT, Coralville, IA), and 250 nM 1492r (TACGGYTACCTTGTTAYGACTT, IDT, Coralville, IA), with PCR water (Mo Bio Laboratories, Carlsbad, CA) to balance the volume.
[0355] Figure 1 shows hypervariable regions mapped to 16S sequences and the corresponding sequence regions on a sequence map. A schematic diagram of the 16S rRNA gene is shown, showing the coordinates of hypervariable regions 1 through 9 (V1 through V9) according to an embodiment of the present invention. The coordinates of V1 through V9 are 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294, and 1435-1465, respectively, based on numbering using the Escherichia coli system of nomenclature defined in Brosius et al., *Complete nucleotide sequence of a 16S ribosomal RNA gene (16S rRNA) from Escherichia coli*, PNAS 75(10):4801-4805 (1978).
[0356] Alternatively, other common bacterial primers or thermostable polymerases known to those skilled in the art can be used. For example, one skilled in the art can utilize primers for sequencing the "V1-V9 regions" of 16S rRNA (e.g., FIG. 1). These regions correspond to the first through ninth hypervariable regions of the 16S rRNA gene, which are used to genotype bacterial samples. These regions in bacteria are defined by nucleotides 69-99, 137-242, 433-497, 576-682, 822-879, 986-1043, 1117-1173, 1243-1294, and 1435-1465, respectively, using numbering based on the E. coli system of nomenclature. See Brosius et al., Complete nucleotide sequence of a 16S ribosomal RNA gene from Escherichia coli, PNAS 75(10):4801-4805 (1978). In some embodiments, at least one of the V1, V2, V3, V4, V5, V6, V7, V8, and V9 regions is used to characterize the OTU. In some embodiments, the V1, V2, and V3 regions are used to characterize the OTU. In another embodiment, the V3, V4, and V5 regions are used to characterize the OTU. In another embodiment, the V4 region is used to characterize the OTU. One skilled in the art can identify specific hypervariable regions of a candidate 16S rRNA (e.g., FIG. 1) by comparing the candidate sequence in question to a reference sequence (such as that in FIG. 2) and identifying hypervariable regions based on similarity to the reference hypervariable regions. In Figure 2, the nucleotide sequence for each hypervariable region in the exemplary reference E. coli 16S sequence from Brosius et al. is highlighted in bold.
[0357] PCR is performed in a commercially available thermocycler, such as the BioRad MyCycler™ Thermal Cycler (BioRad, Hercules, CA). The reaction is performed at 94°C for 2 minutes, followed by 30 cycles of 94°C for 30 seconds, 51°C for 30 seconds, and 68°C for 1 minute 30 seconds, followed by an extension at 72°C for 7 minutes and an indefinite hold at 4°C. Following PCR, gel electrophoresis of an aliquot of the reaction is used to confirm subsequent amplification of a product of approximately 1.5 kb.
[0358] To remove nucleotides and oligonucleotides from the PCR product, 2 μl of HT ExoSap-IT (Affymetrix, Santa Clara, CA) was added to 5 μl of PCR product, followed by incubation at 37°C for 15 min and then inactivation at 80°C for 15 min.
[0359] Amplification of 16S sequences for downstream characterization by massively parallel sequencing techniques Amplification for downstream sequencing by short-read technologies such as Illumina requires amplification using primers known to those skilled in the art that further comprise sequence-based barcode labels. As an example, to amplify the 16s hypervariable region V4 of bacterial 16S rDNA, 2 μl of extracted gDNA is added to a PCR reaction with a final volume of 20 μl. The PCR reaction also contained 1x HotMasterMix (5PRIME, Gaithersburg, MD), 200 nM V4_515f_adapt (AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTGTGCCAGCMGCCGCGGTAA, IDT, Coralville, IA), and 200 nM barcoded 806rbc (CAAGCAGAAGACGGCATACGAGAT_12bpGolayBarcode_AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT, IDT, Coralville, IA), with PCR Water (Mo Bio Laboratories, Carlsbad, CA) to balance the volumes. These primers incorporate barcoded adapters for synthetic Illumina sequencing. Optionally, identical, triplicate, or quadruplicate reactions may be run. Alternatively, other common bacterial primers or thermostable polymerases known to those skilled in the art may be used, resulting in different amplification and sequencing error rates, as well as alternative sequencing techniques.
[0360] PCR amplification is performed in a commercially available thermocycler, such as the BioRad MyCycler™ Thermal Cycler (BioRad, Hercules, CA). The reaction is performed at 94°C for 3 minutes, followed by 25 cycles of 94°C for 45 seconds, 50°C for 1 minute, and 72°C for 1 minute 30 seconds, followed by a 10 minute extension at 72°C and an indefinite hold at 4°C. Following PCR, gel electrophoresis of a portion of the reaction product is used to confirm subsequent amplification of an approximately 1.5 kb product. PCR purification is performed as described above.
[0361] Sanger sequencing of target amplicons from pure homogeneous samples To detect nucleic acids for each sample, two sequencing reactions are performed to generate forward and reverse sequencing reads. Primers 27f and 1492r are used for full-length 16s sequencing. 40 ng of ExoSap-IT-purified PCR product is mixed with 25 pmol of parallel determinant primer and Mo Bio Molecular Biology Grade Water (Mo BioLaboratories, Carlsbad, CA) to a total volume of 15 μl. This reaction is then subjected to a commercially available sequencing system, such as Genewiz (South Plainfield, NJ), for Sanger sequencing.
[0362] Amplification of the 18S and ITS regions for downstream sequencing To amplify the 18S or ITS region, 2 μl of fungal DNA was added to 15 μl of AmpliTaqGold 360 Mastermix, PCR primers, and water for a final volume of 30 μl. The forward and reverse primers for PCR of the ITS region were 5′-TCCTCCGCTTATTGATATGC-3′ and 5′-GGAAGTAAAAGTCGTAACAAGG-3′, each added at a concentration of 0.2 μM. The forward and reverse primers for the 18s region were 5′-GTAGTCATATGCTTGTCTC-3′ and 5′-CTTCCGTCAATTCCTTTAAG-3′, each added at a concentration of 0.4 μM. PCR was performed using the following protocol: 95°C for 10 minutes, 35 cycles of 95°C for 15 seconds, 52°C for 30 seconds, and 72°C for 1.5 seconds; and finally, 72°C for 7 minutes followed by storage at 4°C. All forward primers contained the M13F-20 sequencing primer, and all reverse primers contained the M13R-27 sequencing primer. PCR products (3 μL) were enzymatically purified and then cycle sequenced with 1 μL of ExoSap-IT and 1 μL of Tris-EDTA, incubated at 37°C for 20 minutes, followed by 80°C for 15 minutes. The cycle sequencing reaction contained 5 μL of purified PCR product, 2 μL of BigDye Terminator v3.1 Ready Reaction Mix, 1 μL of 5x sequencing buffer, 1.6 pmol of the appropriate sequencing primer designed by our experts, and water in a final volume of 10 μL. The standard cycle sequencing protocol consisted of 27 cycles of 96°C for 10 seconds, 50°C for 5 seconds, 60°C for 4 minutes, and a 4°C hold. Sequencing purification is performed using the BigDye XTerminator Purification Kit in a volume of 10 μL according to the manufacturer's recommendations. The resulting 18S and ITS sequences are sequenced using methods well known to those skilled in the art using either Sanger sequencing or next-generation sequencing technologies such as, but not limited to, Illumina.
[0363] Preparation of extracted nucleic acids for metagenomic characterization by massively parallel sequencing technology. Extracted nucleic acids (DNA or RNA) are purified and prepared for downstream sequencing using standard methods well known to those skilled in the art and as described in the sequencing technology's instructions for library preparation. Briefly, RNA or DNA is purified using a standard purification kit, such as, but not limited to, Qiagen's RNeasy Kit or Promega's Genomic DNA purification kit. For RNA, the RNA is converted to cDNA, followed by sequence library construction. After nucleic acid purification, the RNA is converted to cDNA using reverse transcription techniques, such as, but not limited to, the Nugen Ovation RNA-Seq System or Illumina Truseq, according to the instructions. The extracted DNA or transcribed cDNA is sheared using physical techniques (e.g., Hydroshear), acoustic techniques (e.g., Covaris), or molecular techniques (e.g., Nextera), and then size-selected according to the sequencing technology's instructions. After size selection, the nucleic acids are prepared for sequencing according to instructions for sample indexing and sequencing adaptor ligation using methods well known to those skilled in the art of genome sequencing.
[0364] Massively parallel sequencing of target amplicons from heterogeneous samples DNA quantification and library construction The purified PCR amplification products are quantified using the Quant-iT™ PicoGreen® dsDNA Assay Kit (Life Technologies, Grand Island, NY) according to the manufacturer's instructions. After quantification, the barcoded purified PCR products are combined to generate Illumina libraries, each containing an equimolar ratio of the different PCR products.
[0365] Nucleic Acid Detection The prepared library is sequenced on an Illumina HiSeq or MiSeq sequencer (Illumina, San Diego, CA) using cluster generation, template hybridization, isothermal amplification, linearization, blocking, denaturation, and sequencing primer hybridization according to the manufacturer's instructions. 16SV4SeqFw (TATGGTAATTGTGTGCCAGCMGCCGCGGTAA), 16SV4SeqRev (AGTCAGTCAGCCGGACTACHVGGGTWTCTAAT), and 16SV4Index (ATTAGAWACCCBDGTAGTCCGGCTGACTGACT) (IDT, Coralville, IA) are used for sequencing. Other sequencing technologies can be used, including but not limited to 454, Pacific Biosciences, Helicos, Ion Torrent, and Nanopore, using protocols commonly known to those skilled in the art of genome sequencing.
[0366] Example 2. Sequence read annotation Primary read annotation: Nucleic acid sequences are analyzed and annotated to determine taxonomic assignments using sequence similarity and phylogenetic alignment, or a combination of the two methods. A variety of approaches can be used to annotate protein names, protein functions, transcription factor names, and any other classification method for nucleic acid sequences. Sequence similarity-based methods include, but are not limited to, methods well known to those skilled in the art, such as BLAST, BLASTx, tBLASTn, tBLASTx, RDP classifier, DNAclust, and various implementations of these algorithms, such as Qiime or Mothur. These methods rely on mapping sequence reads to a reference database and selecting matches with the highest scores and e-values. Common databases for taxonomic assignment include, but are not limited to, the Human Microbiome Project, the NCBI non-redundant database, Greengenes, RDP, and Silva. For functional assignment, reads are mapped to various functional databases, such as, but not limited to, COG, KEGG, BioCyc, and MetaCyc. Further functional predictions may be derived from 16S taxonomic annotation using programs such as PICRUST (M. Langille, et al. 2013. Nature Biotechnology 31, 814-821). Systematic methods can be used in combination with sequence similarity methods to improve the accuracy of annotation or taxonomic assignment calls. Herein, tree and node structures are used to refine the resolution of the analysis.In this approach, nucleic acid sequences are analyzed using one of a number of sequence similarity approaches and leverage systematic methods well known to those skilled in the art, including, but not limited to, maximum likelihood phylogenetic reconstruction (see, e.g., Liu K, Linder CR, and Warnow T. 2011. RAxML and FastTree: Comparing Two Methods for Large-Scale Maximum Likelihood Phylogeny Estimation. PLoS ONE6: e27731; McGuire G, Denham MC, and Balding DJ. 2001. Models of sequence evolution for DNA sequences containing gaps. Mol. Biol. Evol 18: 481-490. WrobeiB. 2008. Statistical measures of uncertainty for branches in phylogenetic trees inferred from molecular sequences by using model-based methods. J. Appl. Genet.49: 49-67). Sequence reads (e.g., 16S, 18S, or ITS) are placed in a reference phylogenetic tree of an appropriate reference sequence. Annotations are generated based on the placement of the reads in the phylogenetic tree. The certainty or significance of the OTU annotation is determined based on the sequence similarity of the OTU to the reference nucleic acid sequence and the proximity of the OTU to one or more reference sequences in the phylogenetic tree. For example, the specificity of taxonomic assignment is determined at the family, genus, species, or lineage level with confidence determined based on the placement of bootstrap support branches in the reference phylogenetic tree relative to the placement of the identified OTU sequence. Nucleic acid sequences can be assigned functional predictions using the methods described above.
[0367] Clade assignment The ability of 16S-V4 OTU identification to assign an OTU to a specific species depends in part on the resolution of the 16S-V4 region of the 16S gene for a particular species or group of species. The density of available reference 16S sequences in different regions of the phylogenetic tree and the inherent variability in the 16S gene among different species both determine the taxonomic annotation. Given the morphological nature of phylogenetic trees and the fact that they show the hierarchical relationships of OTUs to each other based on their sequence similarity and the underlying evolutionary model, the taxonomic annotation of reads can be increased to a higher level using a clade-based assignment procedure. Using this approach, clades are determined based on the morphology of phylogenetic trees constructed from full-length 16S sequences using a maximum likelihood model or other phylogenetic models familiar to those in the field of phylogenetics. Clades are constructed to ensure that all OTUs in a given clade: (i) are within a predetermined number of bootstrap support nodes (typically bootstraps 1-5) from each other, and (ii) share a defined percentage similarity (based on 16S molecular data, typically set at 95%-97% sequence similarity). OTUs within the same clade can be identified as genetically and phylogenetically distinct from OTUs in different clades based on 16S-V4 sequence data. OTUs within the same clade are closely evolutionarily related and may or may not be distinguishable from each other using 16S-V4 sequence data. The power of clade-based analysis is that, due to their evolutionary relatedness, members of the same clade may play similar functional roles in microbial ecologies such as those found in the human gut. Compositions that substitute one species for another from the same clade are useful in the present invention because they may preserve ecological function. In addition to 16S-V4 sequences specifically, clade-based analysis can be used to analyze 18S, ITS, and other gene sequences.
[0368] In particular, the 16S sequences of isolates of a given OTU are systematically placed within their respective clades. These can sometimes conflict with microbial-based assignments of species and genus that may precede 16S-based assignments. Discrepancies between taxonomic assignments based on microbial characteristics versus genetic sequencing are known to exist in the literature.
[0369] For a given network ecology or functional network ecology, a set of OTUs can be defined from representative clades of the network. For example, if the network consists of clade_100 and clade_102, it can be said that at least one OTU consists of the group consisting of Corynebacterium coyleae, Corynebacterium mucifaciens, and Corynebacterium ureicelerivorans, and at least one OTU consists of the group consisting of Corynebacterium appendicis, Corynebacterium genitalium, Corynebacterium glaucum, Corynebacterium imitans, Corynebacterium riegelii, Corynebacterium sp. L_2012475, Corynebacterium sp. NML 93_0481, Corynebacterium sundsvallense, and Corynebacterium tuscaniae (see Table 1). Conversely, by way of example, if a network could be said to consist of Corynebacterium coyleae, and / or Corynebacterium mucifaciens, and / or Corynebacterium ureicelerivorans, and also Corynebacterium appendicis, and / or Corynebacterium genitalium, and / or Corynebacterium glaucum, and / or Corynebacterium imitans, and / or Corynebacterium riegelii, and / or Corynebacterium sp. L_2012475, and / or Corynebacterium sp. NML 93_0481, and / or Corynebacterium sundsvallense, and / or Corynebacterium tuscaniae, then it could be said to consist of clade_100 and clade_102.
[0370] Applicants have made clade assignments for all OTUs reported in the application using the methods described above. These assignments are shown in Table 1. In some embodiments, the network analysis allows for the replacement of clade_172 with clade_172i. In other embodiments, the network analysis allows for the replacement of clade_198 with clade_198i. In other embodiments, the network analysis allows for the replacement of clade_260 with clade_260c, clade_260g, or clade_260h. In other embodiments, the network analysis allows for the replacement of clade_262 with clade_262i. In other embodiments, the network analysis allows for the replacement of clade_309 with clade_309c, clade_309e, clade_309g, clade_309h, or clade_309i. In other embodiments, the network analysis allows for the replacement of clade_313 with clade_313f. In another embodiment, the network analysis allows for the replacement of clade_325 with clade_325f. In another embodiment, the network analysis allows for the replacement of clade_335 with clade_335i. In another embodiment, the network analysis allows for the replacement of clade_351 with clade_351e. In another embodiment, the network analysis allows for the replacement of clade_354 with clade_354e. In another embodiment, the network analysis allows for the replacement of c...
Claims
1. 1. A method for treating, preventing or lessening the severity of a disorder selected from the group consisting of Clostridium difficile associated diarrhea (CDAD), type 2 diabetes, obesity, irritable bowel disease (IBD), colonization by a pathogen or pathobiont, and infection by a drug-resistant pathogen or pathobiont, comprising: The method includes administering an effective amount of a therapeutic bacterial composition to a mammalian subject in need thereof, said therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations, said plurality of isolated bacteria or purified bacterial preparations being selected from the group consisting of N262.S, N290.S, N284.S, N271.S, N282.S, N288.S, N302.S, N279.S, N310.S, N323.S, N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, N341.S, N346.S, N338.S, N336.S, N345.S, N355.S, N356.S, N343.S, N344.S, N345.S, N356.S, N346.S, N347.S, N348.S, N349.S, N357.S, N359.S, N360.S, N361.S, N362.S, N363.S, N364.S, N365.S, N366.S, N367.S, N368.S, N369.S, N370.S, N371.S, N372.S, N373.S, N374.S, N375.S, N376.S, N377.S, N378.S, N379.S, N380.S, N382.S, N384.S, N386.S, N388.S, N388.S, N389.S, N390.S, N384.S, N382.S, N388.S, N S, N329. S, N361. S, N353. S, N381. S, N344. S, N352. S, N357. S, N358. S, N369. S, N372. S, N375. S, N380. S, N374. S, N377. S, N368. S, N370. S, N373. S, N376. S, N389. S, N394. S, N431. S, N434. S, N390. S, N397. S, N387. S, N440. S, N396. S, N399. S, N403. S, N414. S, N430. S, N432. S, N436. S, N437. S, N457. S, N545, N386. S, N402. S, N405. S, N415. S, N421. S, N422. S, N423. S, N458. S, N459. S, N493. S, N416. S, N439. S, N447. S, N490. S, N526, N429. S, N433. S, N448. S, N488. S, N508. S, N509. S, N510. S, N511. S, N408. S, N446. S, N451. S, N474. S, N520. S, N521. S, N535. S, N516. S, N463. S, N518. S, N586, N450. S, N465. S, N519. S, N537. S, N419. S, N468. S, N477. S, N514. S, N382. S, N460. S, N462. S, N512. S, N517. S, N523. S, N547. S, N548. S, N577. S, N581. S, N585. S, N616. S, N466. S, N469. S, N480. S, N482. S, N484. S, N515. S, N533. S, N709, N730, N478. S, N572. S, N400. S, N543. S, N582. S, N621. S, N689,N769、N481.S、N525.S、N528.S、N534.S、N574.S、N580.S、N590.S、N591.S、N597.S、N664、N693、N530.S、N687、N470.S、N529.S、N539.S、N546.S、N570.S、N579.S、N602.S、N614.S、N648.S、N652.S、N655.S、N672.S、N681.S、N690.S、N692.S、N698.S、N737.S、N738.S、N785、N841、N878、N880、N881、N987、N988、N996、N1061、N479.S、N538.S、N542.S、N578.S、N609.S、N611.S、N617.S、N666.S、N675.S、N682.S、N844、N845、N846、N852、N876、N982、N1008、N649.S、N657.S、N678.S、N686.S、N710.S、N522.S、N651.S、N653.S、N654.S、N680.S、N712.S、N792、N802、N804、N807、N849、N858、N859、N875、N885、N942、N961、N972、N1051、N587.S、N589.S、N612.S、N625.S、N656.S、N714.S、N779、N781、N828、N829、N860、N894、N925、N927、N935、N947、N983、N1023、N441.S、N584.S、N794、N788、N524.S、N604.S、N610.S、N623.S、N663.S、N669.S、N676.S、N703.S、N775.S、N777.S、N780.S、N817.S、N827.S、N836.S、N871.S、N874.S、N898.S、N907.S、N998.S、N1088、N1089、N660.S、N665.S、N667.S、N733.S、N734.S、N739.S、N741.S、N782.S、N789.S、N796.S、N798.S、N800.S、N809.S、N816.S、N842.S、N843.S、N869.S、N986.S、N995.S、N1002.S、N1004.S、N1019.S、N1093、N668.S、N685.S、N835.S、N851.S、N464.S、N695.S、N776.S、The method is capable of forming a network ecology selected from the group consisting of N793.S, N815.S, N833.S, N891.S, N1070.S, N1092, N795.S, N797.S, N808.S, N811.S, N826.S, N830.S, N832.S, N840.S, N945.S, N960.S, N968.S, N1091, N805.S, N822.S, N928.S, N936.S, N1078.S and N913.S.
2. The therapeutic bacterial composition comprises at least one bacterial entity, The bacterial entity is capable of forming a network ecology with another bacterial entity present in the gastrointestinal tract of the mammalian subject at the time of administration or after administration.
3. The network ecology includes N1008, N1023, N1051, N1061, N1070.S, N1G88, N1089, N1092, N381.S, N3S2.S, N387.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N471.S, N472.S, N463.S, N464.S, N472.S, N473.S, N474.S, N475.S, N476.S, N477.S, N478.S, N479.S, N480.S, N481.S, N482.S, N483.S, N484.S, N485.S, N486.S, N487.S, N488.S, N489.S, N490.S, N491.S, N492.S, N493.S, N494.S, N495.S, N496.S, N497.S, N498.S, N499.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, S, N474. S, N488. S, N490. S, N493. S, N508. S, N509. S, N510. S, N511. S, N512. S, N514. S, N515. S, N517. S, N518. S, N519. S, N520. S, N523. S, N524. S, N529. S, N539. S, N543. S, N546. S, N547. S, N548. S, N570. S, N574. S, N577. S, N579. S, N580. S, N582. S, N584. S, N585. S, N589. S, N591. S, N597. S, N602. S, N604. S, N609. S, N610. S, N611. S, N612. S, N614. S, N616. S, N621. S, N623. S, N625. S, N648. S, N651. S, N652. S, N653. S, N654. S, N655. S, N660. S, N663. S, N664, N665. S, N666. S, N669. S, N672. S, N676. S, N681. S, N687, N689, N690. S, N692. S, N693, N695. S, N698. S, N703. S, N709, N712. S, N714. S, N730, N734. S, N737. S, N738. S, N769, N775. S, N777. S, N779, N780. S, N781, N785, N788, N792, N793. S, N794, N797. S, N798. S, N802, N804, N807, N817. S, N827. S, N828, N830. S, N832. S, N833. S, N836. S, N840. S, N841, N844, N845, N849, N852, N858, N859, N860, N869. S, N871. S, N874. S, N875, N878, N880, N881, N885, N894, N898. S, N907. S,2. The method of claim 1, wherein the avian influenza virus is selected from the group consisting of N913.S, N925, N927, N942, N947, N961, N968.S, N972, N982, N983, N986.S, N987, N988, N996 and N998.S.
4. The network ecology includes N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N387.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N471.S, N472.S, N463.S, N464.S, N472.S, N473.S, N474.S, N475.S, N476.S, N477.S, N478.S, N479.S, N480.S, N481.S, N482.S, N483.S, N484.S, N485.S, N486.S, N487.S, N488.S, N489.S, N490.S, N491.S, N492.S, N493.S, N494.S, N495.S, N496.S, N497.S, N498.S, N499.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, S, N474. S, N488. S, N490. S, N493. S, N508. S, N509. S, N510. S, N511. S, N512. S, N514. S, N515. S, N517. S, N518. S, N519. S, N520. S, N523. S, N524. S, N529. S, N539. S, N543. S, N546. S, N547. S, N548. S, N570. S, N574. S, N577. S, N579. S, N580. S, N582. S, N584. S, N585. S, N589. S, N591. S, N597. S, N602. S, N604. S, N609. S, N610. S, N611. S, N612. S, N614. S, N616. S, N621. S, N623. S, N625. S, N648. S, N651. S, N652. S, N653. S, N654. S, N655. S, N660. S, N663. S, N664, N665. S, N666. S, N669. S, N672. S, N676. S, N681. S, N687, N689, N690. S, N692. S, N693, N695. S, N698. S, N703. S, N709, N712. S, N714. S, N730, N734. S, N737. S, N738. S, N769, N775. S, N777. S, N779, N780. S, N781, N785, N788, N792, N793. S, N794, N797. S, N798. S, N802, N804, N807, N817. S, N827. S, N828, N830. S, N832. S, N833. S, N836. S, N840. S, N841, N844, N845, N849, N852, N858, N859, N860, N869. S, N871. S, N874. S, N875, N878, N880, N881, N885, N894, N898. S, N907. S,2. The method of claim 1, consisting essentially of N913.S, N925, N927, N942, N947, N961, N968.S, N972, N982, N983, N986.S, N987, N988, N996 or N998.S.
5. 4. The method of claim 3, wherein the network ecology is selected from the group consisting of N387.S, N399.S, N512.S, N462.S, N651.S, N982 and N845.
6. 6. The method of claim 5, wherein the network ecology comprises N387.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_396, Clade_444, Clade_478, Clade_500, and Clade_553.
7. 6. The method of claim 5, wherein the network ecology comprises N387.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_396, Clade_444, Clade_478, Clade_500, and Clade_553.
8. Clade_262 includes one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; Clade_396 includes one or more bacteria selected from the group consisting of Acetivibrio ethanolgignens, Anaerosporobacter mobilis, Bacteroides pectinophilus, Clostridium aminovalericum, Clostridium phytofermentans, Eubacterium hallii, and Eubacterium xylanophilum; Clade_444 includes one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacterium rectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburia faecalis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69; Clade_478 includes one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii, Gemmiger formicilis, and Subdoligranulum variabile; Clade_500 includes one or more bacteria selected from the group consisting of Alistipes finegoldii, Alistipes onderdonkii, Alistipes putredinis, Alistipes shahii, Alistipes sp. HGB5, Alistipes sp. JC50, and Alistipes sp. RMA 9912; The method of claim 6 or 7, wherein clade_553 comprises one or more bacteria selected from the group consisting of Collinsella aerofaciens, Collinsella intestinalis, Collinsella stercoris, and Collinsella tanakaei.
9. Clade_262 includes one or more bacteria of the genus Ruminococcus torques; Clade_396 contains one or more Eubacterium hallii bacteria; Clade_444 includes one or more bacteria selected from the group consisting of Eubacterium rectale and Roseburia inulinivorans; Clade_478 contains one or more Faecalibacterium prausnitzii bacteria; Clade_500 includes one or more bacteria of the genus Alistipes putredinis; The method of claim 6 or 7, wherein clade_553 includes one or more bacteria of Collinsella aerofaciens.
10. Clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_396 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; Clade_444 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; Clade_478 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932; Clade_500 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, and SEQ ID NO:136; 8. The method of claim 6 or 7, wherein clade_553 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:659, SEQ ID NO:660, SEQ ID NO:661, and SEQ ID NO:
662.
11. Clade_262 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_396 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; Clade_444 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; Clade_478 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932; Clade_500 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:129, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, and SEQ ID NO:136; 8. The method of claim 6 or 7, wherein clade_553 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:659, SEQ ID NO:660, SEQ ID NO:661 and SEQ ID NO:
662.
12. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1670; Clade_396 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:848; Clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1639 and SEQ ID NO: 856; Clade_478 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:880; Clade_500 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:132, and 8. The method of claim 6 or 7, wherein clade_553 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:
659.
13. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1670; Clade_396 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:848; Clade_444 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1639 and SEQ ID NO:856; Clade_478 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:880; Clade_500 includes one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:132, and The method of claim 6 or 7, wherein clade_553 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:
659.
14. 6. The method of claim 5, wherein the network ecology comprises N399.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_360, Clade_396, Clade_444, Clade_478, and Clade_494.
15. 6. The method of claim 5, wherein the network ecology comprises N399.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_360, Clade_396, Clade_444, Clade_478, and Clade_494.
16. Clade_262 includes one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; Clade_360 includes one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceaebacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8; Clade_396 includes one or more bacteria selected from the group consisting of Acetivibrio ethanolgignens, Anaerosporobacter mobilis, Bacteroidespectinophilus, Clostridium aminovalericum, Clostridium phytofermentans, Eubacterium hallii, and Eubacterium xylanophilum; Clade_444 includes one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacterium rectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburiacecicola, Roseburia faecalis, Roseburiafaecis, Roseburia hominis, Roseburiaintestinalis, Roseburia inulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69; Clade_478 includes one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii, Gemmiger formicilis, and Subdoligranulum variabile; and The method of claim 14 or 15, wherein clade_494 comprises one or more bacteria selected from the group consisting of Clostridium orbiscindens, Clostridium sp. NML 04A032, Flavonifractorplautii, Pseudoflavonifractor capillosus, and Ruminococcaceae bacterium D16.
17. Clade_262 includes one or more bacteria of the genus Ruminococcus torques; Clade_360 includes one or more bacteria of the genus Dorea longicatena; Clade_396 contains one or more Eubacterium hallii bacteria; Clade_444 includes one or more bacteria of the genus Eubacterium rectale; 16. The method of claim 14 or 15, wherein clade_478 includes one or more bacteria of Faecalibacterium prausnitzii and clade_494 includes one or more bacteria of Pseudoflavonifractor capillosus.
18. Clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; Clade_396 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; Clade_444 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; Clade_478 includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932, and 16. The method of claim 14 or 15, wherein clade_494 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1591, SEQ ID NO:1655, SEQ ID NO:609, SEQ ID NO:637, and SEQ ID NO:
886.
19. Clade_262 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; Clade_396 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:875; Clade_444 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; Clade_478 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:932, and 16. The method of claim 14 or 15, wherein clade_494 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1591, SEQ ID NO:1655, SEQ ID NO:609, SEQ ID NO:637, and SEQ ID NO:
886.
20. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1670; Clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:774; Clade_396 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:848; Clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:856; Clade_478 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:880; and The method of claim 14 or 15, wherein clade_494 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1591.
21. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1670; Clade_360 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:774; Clade_396 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:848; Clade_444 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:856; Clade_478 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:880; and The method of claim 14 or 15, wherein clade_494 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:1591.
22. 6. The method of claim 5, wherein the network ecology comprises N462.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of clade_262, clade_360, and clade_478.
23. 6. The method of claim 5, wherein the network ecology comprises N462.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of clade_262, clade_360, and clade_478.
24. Clade_262 includes one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; Clade_360 includes one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceaebacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8; 24. The method of claim 22 or 23, wherein clade_478 comprises one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii, Gemmiger formicilis, and Subdoligranulum variabile.
25. Clade_262 contains one or more bacteria of the genus Coprococcus comes, Clade_360 includes one or more bacteria of the genus Dorea longicatena, as well as 24. The method of claim 22 or 23, wherein clade_478 comprises one or more bacteria selected from the group consisting of Faecalibacterium prausnitzii and Subdoligranulum variabile.
26. Clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and 24. The method of claim 22 or 23, wherein clade_478 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:
932.
27. Clade_262 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and 24. The method of claim 22 or 23, wherein clade_478 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896, SEQ ID NO:880, and SEQ ID NO:
932.
28. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:674; Clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:774, and 24. The method of claim 22 or 23, wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1896 and SEQ ID NO:
880.
29. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:674; Clade_360 includes one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:774, and 24. The method of claim 22 or 23, wherein clade_478 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1896 and SEQ ID NO:
880.
30. 6. The method of claim 5, wherein the network ecology comprises N512.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of clade_262, clade_360, and clade_444.
31. 6. The method of claim 5, wherein the network ecology comprises N512.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of clade_262, clade_360, and clade_444.
32. Clade_262 includes one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; Clade_360 includes one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceaebacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8; and The method of claim 30 or 31, wherein clade_444 comprises one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacterium rectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburia faecalis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69.
33. Clade_262 includes one or more bacteria selected from the group consisting of Coprococcus comes and Ruminococcus torques; Clade_360 includes one or more bacteria of the genus Dorea longicatena, as well as 32. The method of claim 30 or 31, wherein clade_444 includes one or more bacteria of Eubacterium rectale.
34. Clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and 32. The method of claim 30 or 31, wherein clade_444 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:
865.
35. Clade_262 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and 32. The method of claim 30 or 31, wherein Clade_444 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:
865.
36. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1670 and SEQ ID NO: 674; Clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:774, and 32. The method of claim 30 or 31, wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:
856.
37. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1670 and SEQ ID NO:674; Clade_360 includes one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:774, and 32. The method of claim 30 or 31, wherein clade_444 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:
856.
38. 6. The method of claim 5, wherein the network ecology comprises N845 and the therapeutic bacterial composition comprises at least one bacterium selected from each of Clade_262, Clade_360, and Clade_378.
39. 6. The method of claim 5, wherein the network ecology comprises N845 and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_262, Clade_360, and Clade_378.
40. Clade_262 includes one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques; Clade_360 includes one or more bacteria selected from the group consisting of Dorea formicigenerans, Dorea longicatena, Lachnospiraceae bacterium2_1_46FAA, Lachnospiraceae bacterium 2_1_58FAA, Lachnospiraceae bacterium 4_1_37FAA, Lachnospiraceaebacterium 9_1_43BFAA, Ruminococcus gnavus, and Ruminococcus sp. ID8; 43. The method of claim 38 or 39, wherein clade_378 comprises one or more bacteria selected from the group consisting of Bacteroides barnesiae, Bacteroides coprocola, Bacteroidescoprophilus, Bacteroides dorei, Bacteroidesmassiliensis, Bacteroides plebeius, Bacteroides sp. 3_1_33FAA, Bacteroides sp.3_1_40A, Bacteroides sp. 4_3_47FAA, Bacteroides sp. 9_1_42FAA, Bacteroides sp.NB_8, and Bacteroides vulgatus.
41. Clade_262 contains one or more bacteria of the genus Coprococcus comes, Clade_360 includes one or more bacteria of the genus Dorea longicatena, and 40. The method of claim 38 or 39, wherein clade_378 comprises one or more bacteria of the genus Bacteroides dorei.
42. Clade_262 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and 40. The method of claim 38 or 39, wherein clade_378 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:267, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:284, SEQ ID NO:289, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:323, and SEQ ID NO:
331.
43. Clade_262 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; Clade_360 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1050, SEQ ID NO:1051, SEQ ID NO:1053, SEQ ID NO:1058, SEQ ID NO:1661, SEQ ID NO:1668, SEQ ID NO:773, and SEQ ID NO:774; and 40. The method of claim 38 or 39, wherein clade_378 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:267, SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:274, SEQ ID NO:284, SEQ ID NO:289, SEQ ID NO:309, SEQ ID NO:310, SEQ ID NO:313, SEQ ID NO:314, SEQ ID NO:323, and SEQ ID NO:
331.
44. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:674; Clade_360 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:774; and 40. The method of claim 38 or 39, wherein clade_378 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:
274.
45. Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:674; Clade_360 includes one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:774; and 40. The method of claim 38 or 39, wherein clade_378 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:
274.
46. 6. The method of claim 5, wherein the network ecology comprises N982 and the therapeutic bacterial composition comprises at least one bacterium selected from each of clade_172, clade_262, and clade_396.
47. 6. The method of claim 5, wherein the network ecology comprises N982 and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of Clade_172, Clade_262, and Clade_396.
48. Clade_172 includes Bifidobacteriaceae genomosp.C1, Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium HM2, Bifidobacterium sp. HMLN12, Bifidobacterium sp. M45, Bifidobacterium sp.MSX5B, Bifidobacterium sp. TM_7 and Bifidobacterium thermophilum, 48. The method of claim 46 or 47, wherein clade_262 comprises one or more bacteria selected from the group consisting of Clostridium glycyrrhizinilyticum, Clostridium nexile, Coprococcus comes, Lachnospiraceae bacterium 1_1_57FAA, Lachnospiraceae bacterium 1_4_56FAA, Lachnospiraceae bacterium 8_1_57FAA, Ruminococcus lactaris, and Ruminococcus torques, and wherein clade_396 comprises one or more bacteria selected from the group consisting of Acetivibrio ethanolgignens, Anaerosporobacter mobilis, Bacteroides pectinophilus, Clostridium aminovalericum, Clostridium phytofermentans, Eubacterium hallii, and Eubacterium xylanophilum.
49. Clade_172 includes one or more Bifidobacterium longum bacteria; Clade_262 includes one or more bacteria of the genus Coprococcus comes, and 48. The method of claim 46 or 47, wherein clade_396 includes one or more bacteria of the genus Eubacterium hallii.
50. Clade_172 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, and SEQ ID NO:365; 48. The method of claim 46 or 47, wherein Clade_262 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674, and wherein Clade_396 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:
875.
51. Clade_172 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:345, SEQ ID NO:346, SEQ ID NO:347, SEQ ID NO:348, SEQ ID NO:350, SEQ ID NO:351, SEQ ID NO:352, SEQ ID NO:353, SEQ ID NO:354, SEQ ID NO:355, SEQ ID NO:356, SEQ ID NO:357, SEQ ID NO:358, SEQ ID NO:359, SEQ ID NO:360, SEQ ID NO:361, SEQ ID NO:362, SEQ ID NO:363, SEQ ID NO:364, and SEQ ID NO:365; Clade_262 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1048, SEQ ID NO:1049, SEQ ID NO:1057, SEQ ID NO:1663, SEQ ID NO:1670, SEQ ID NO:588, SEQ ID NO:607, and SEQ ID NO:674; and 48. The method of claim 46 or 47, wherein clade_396 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:161, SEQ ID NO:288, SEQ ID NO:551, SEQ ID NO:6, SEQ ID NO:613, SEQ ID NO:848, and SEQ ID NO:
875.
52. Clade_172 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:356; Clade_262 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:674; and 48. The method of claim 46 or 47, wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:
848.
53. Clade_172 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:356; Clade_262 includes one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:674; and 48. The method of claim 46 or 47, wherein clade_396 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:
848.
54. 6. The method of claim 5, wherein the network ecology comprises N651.S and the therapeutic bacterial composition comprises at least one bacterium selected from each of clade_444, clade_516, and clade_522.
55. 6. The method of claim 5, wherein the network ecology comprises N651.S and the therapeutic bacterial composition consists essentially of at least one bacterium selected from each of clade_444, clade_516, and clade_522.
56. Clade_444 includes one or more bacteria selected from the group consisting of Butyrivibrio fibrisolvens, Eubacterium rectale, Eubacterium sp. oral clone GI038, Lachnobacterium bovis, Roseburia cecicola, Roseburia faecalis, Roseburia faecis, Roseburia hominis, Roseburia intestinalis, Roseburia inulinivorans, Roseburia sp. 11SE37, Roseburia sp. 11SE38, Shuttleworthia satelles, Shuttleworthia sp. MSX8B, and Shuttleworthia sp. oral taxon G69; Clade_516 includes one or more bacteria selected from the group consisting of Anaerotruncus colihominis, Clostridium methylpentosum, Clostridium sp. YIT 12070, Hydrogenoanaerobacterium saccharovorans, Ruminococcus albus, and Ruminococcus flavefaciens; and 56. The method of claim 54 or 55, wherein clade_522 comprises one or more bacteria selected from the group consisting of Bacteroides galacturonicus, Eubacterium eligens, Lachnospira multipara, Lachnospira pectinoschiza, and Lactobacillus rogosae.
57. Clade_444 includes one or more bacteria of the genus Roseburia inulinivorans; Clade_516 includes one or more Anaerotruncus colihominis bacteria, as well as 56. The method of claim 54 or 55, wherein clade_522 includes one or more bacteria of Eubacterium eligens.
58. Clade_444 comprises another bacterium selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; 56. The method of claim 54 or 55, wherein clade_516 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1005, SEQ ID NO:164, SEQ ID NO:1656, SEQ ID NO:1660, SEQ ID NO:606, and SEQ ID NO:642, and wherein clade_522 comprises one more bacterium selected from the group consisting of bacteria having a 16S sequence with 97% or greater identity to SEQ ID NO:1046, SEQ ID NO:1047, SEQ ID NO:1114, SEQ ID NO:280, and SEQ ID NO:
845.
59. Clade_444 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1045, SEQ ID NO:1634, SEQ ID NO:1635, SEQ ID NO:1636, SEQ ID NO:1637, SEQ ID NO:1638, SEQ ID NO:1639, SEQ ID NO:1640, SEQ ID NO:1641, SEQ ID NO:1728, SEQ ID NO:1729, SEQ ID NO:1730, SEQ ID NO:456, SEQ ID NO:856, and SEQ ID NO:865; Clade_516 includes another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1005, SEQ ID NO:164, SEQ ID NO:1656, SEQ ID NO:1660, SEQ ID NO:606, and SEQ ID NO:642, and 56. The method of claim 54 or 55, wherein clade_522 comprises another bacterium selected from the group consisting of bacteria having 16S sequences SEQ ID NO:1046, SEQ ID NO:1047, SEQ ID NO:1114, SEQ ID NO:280, and SEQ ID NO:
845.
60. Clade_444 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO: 1639; Clade_516 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:164; and 56. The method of claim 54 or 55, wherein clade_522 comprises one or more bacteria selected from the group consisting of bacteria having a 16S sequence having 97% or greater identity to SEQ ID NO:
845.
61. Clade_444 comprises one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO: 1639; Clade_516 includes one or more bacteria selected from the group consisting of bacteria having the 16S sequence SEQ ID NO:164; and 56. The method of claim 54 or 55, wherein clade_522 comprises one or more bacteria selected from the group consisting of bacteria having 16S sequence SEQ ID NO:
845.
62. The method of any one of claims 1 to 61, wherein the composition further comprises a pharma- ceutically acceptable excipient.
63. 63. The method of claim 62, wherein the therapeutic bacterial composition is substantially depleted of residual habitat products of fecal matter.
64. The method of any one of claims 1 to 61, wherein the composition is formulated for oral administration.
65. 64. The method of any one of claims 1 to 63, wherein the composition is capable of inducing the formation of IgA, RegIII-gamma, IL-10, regulatory T cells, TGF-beta, alpha-defensin, beta-defensin, or an antimicrobial peptide in a mammalian subject.
66. The method of any one of claims 1 to 61, wherein the composition is edible.
67. A composition comprising any composition administered by the method of any one of claims 1 to 61.
68. A dosage unit comprising a dosage unit containing a predetermined ratio of isolated bacteria present in the network ecology of any one of claims 1 to 61.
69. 20. A method for producing short chain fatty acids (SCFAs) in a mammalian subject comprising administering to a mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, wherein the therapeutic bacterial composition comprises a plurality of isolated bacteria or purified bacterial preparations, wherein the plurality of isolated bacteria or purified bacterial preparations are capable of forming one or more bacterial functional pathways, wherein the one or more bacterial functional pathways are selected from the group consisting of N262.S, N290.S, N284.S, N271.S, N282.S, N288.S, N302.S, N279.S, N310.S, N323.S, N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, N341.S, N346.S, N338.S, N349.S, N350.S, N351.S, N352.S, N353.S, N354.S, N355.S, N356.S, N357.S, N358.S, N359.S, N360.S, N361.S, N362.S, N363.S, N364.S, N365.S, N366.S, N367.S, N368.S, N370.S, N371.S, N372.S, N373.S, N374.S, N375.S, N376.S, N377.S, N378.S, N379.S, N310.S, N323.S, N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, S, N336. S, N345. S, N355. S, N356. S, N343. S, N329. S, N361. S, N353. S, N381. S, N344. S, N352. S, N357. S, N358. S, N369. S, N372. S, N375. S, N380. S, N374. S, N377. S, N368. S, N370. S, N373. S, N376. S, N389. S, N394. S, N431. S, N434. S, N390. S, N397. S, N387. S, N440. S, N396. S, N399. S, N403. S, N414. S, N430. S, N432. S, N436. S, N437. S, N457. S, N545, N386. S, N402. S, N405. S, N415. S, N421. S, N422. S, N423. S, N458. S, N459. S, N493. S, N416. S, N439. S, N447. S, N490. S, N526, N429. S, N433. S, N448. S, N488. S, N508. S, N509. S, N510. S, N511. S, N408. S, N446. S, N451. S, N474. S, N520. S, N521. S, N535. S, N516. S, N463. S, N518. S, N586, N450. S, N465. S, N519. S, N537. S, N419. S, N468. S, N477. S, N514. S, N382. S, N460. S, N462. S, N512. S, N517. S, N523. S, N547. S, N548. S, N577. S, N581. S, N585. S, N616. S, N466. S, N469. S, N480. S,N482.S、N484.S、N515.S、N533.S、N709、N730、N478.S、N572.S、N400.S、N543.S、N582.S、N621.S、N689、N769、N481.S、N525.S、N528.S、N534.S、N574.S、N580.S、N590.S、N591.S、N597.S、N664、N693、N530.S、N687、N470.S、N529.S、N539.S、N546.S、N570.S、N579.S、N602.S、N614.S、N648.S、N652.S、N655.S、N672.S、N681.S、N690.S、N692.S、N698.S、N737.S、N738.S、N785、N841、N878、N880、N881、N987、N988、N996、N1061、N479.S、N538.S、N542.S、N578.S、N609.S、N611.S、N617.S、N666.S、N675.S、N682.S、N844、N845、N846、N852、N876、N982、N1008、N649.S、N657.S、N678.S、N686.S、N710.S、N522.S、N651.S、N653.S、N654.S、N680.S、N712.S、N792、N802、N804、N807、N849、N858、N859、N875、N885、N942、N961、N972、N1051、N587.S、N589.S、N612.S、N625.S、N656.S、N714.S、N779、N781、N828、N829、N860、N894、N925、N927、N935、N947、N983、N1023、N441.S、N584.S、N794、N788、N524.S、N604.S、N610.S、N623.S、N663.S、N669.S、N676.S、N703.S、N775.S、N777.S、N780.S、N817.S、N827.S、N836.S、N871.S、N874.S、N898.S、N907.S、N998.S、N1088、N1089、N660.S、N665.S、N667.S、N733.S、N734.S、N739.S、N741.S、N782.S、N789.S、N796.S、N798.S、N800.S、N809.S、N816.S、N842.S、N843.S、N869.S、N986.S、N995.S、N1002. S, N1004. S, N1019. S, N1093, N668. S, N685. S, N835. S, N851. S, N464. S, N695. S, N776. S, N793. S, N815. S, N833. S, N891. S, N1070. S, N1092, N795. S, N797. S, N808. S, N811. S, N826. S, N830. S, N832. S, N840. S, N945. S, N960. S, N968. S, N1091, N805. S, N822. A method capable of forming a functional network ecology selected from the group consisting of N928.S, N936.S, N1078.S and N913.S.
70. The functional network ecology includes N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N471.S, N472.S, N473.S, N474.S, N475.S, N476.S, N477.S, N478.S, N479.S, N480.S, N481.S, N482.S, N483.S, N484.S, N485.S, N486.S, N487.S, N488.S, N489.S, N490.S, N491.S, N492.S, N493.S, N494.S, N495.S, N496.S, N497.S, N498.S, N499.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S S, N474. S, N488. S, N490. S, N493. S, N508. S, N509. S, N510. S, N511. S, N512. S, N514. S, N515. S, N517. S, N518. S, N519. S, N520. S, N523. S, N524. S, N528. S, N529. S, N539. S, N543. S, N546. S, N547. S, N548. S, N570. S, N574. S, N577. S, N579. S, N580. S, N582. S, N584. S, N585. S, N589. S, N591. S, N597. S, N602. S, N604. S, N609. S, N610. S, N611. S, N612. S, N614. S, N616. S, N621. S, N623. S, N625. S, N648. S, N651. S, N652. S, N653. S, N654. S, N655. S, N660. S, N663. S, N664, N665. S, N666. S, N669. S, N672. S, N676. S, N681. S, N687, N689, N690. S, N692. S, N693, N695. S, N698. S, N703. S, N709, N712. S, N714. S, N730, N734. S, N737. S, N738. S, N769, N775. S, N777. S, N779, N780. S, N781, N785, N788, N792, N793. S, N794, N797. S, N798. S, N802, N804, N807, N817. S, N827. S, N828, N830. S, N832. S, N833. S, N836. S, N840. S, N841, N844, N845, N849, N852, N858, N859, N860, N869. S, N871. S, N874. S, N875, N878, N880, N881, N885, N894, N898. S, N907. S,70. The method of claim 69, wherein the avian influenza virus is selected from the group consisting of N913.S, N925, N927, N942, N947, N961, N968.S, N972, N982, N983, N986.S, N987, N988, N996 and N998.S.
71. 71. The method of claim 70, wherein the functional network ecology is N528.S and the multiple bacterial functional pathways include the following functional pathways: KO:K00656, KO:K01069, KO:K01734, KO:K03417, KO:K03778, KO:K07246.
72. 1. A method for catalyzing the secondary metabolism of a bile acid in a mammalian subject, comprising: administering to said mammalian subject in need thereof an effective amount of a therapeutic bacterial composition, said therapeutic bacterial composition comprising a plurality of isolated bacteria or purified bacterial preparations; The plurality of isolated bacteria or purified bacterial preparations are capable of forming one or more functional bacterial pathways; The one or more bacterial functional pathways include N262.S, N290.S, N284.S, N271.S, N282.S, N288.S, N302.S, N279.S, N310.S, N323.S, N331.S, N332.S, N301.S, N312.S, N339.S, N325.S, N340.S, N341.S, N346.S, N338.S, N336.S, N345.S, N355.S, N356.S, N343.S, N329.S, N361.S, N353.S, N381. S, N344. S, N352. S, N357. S, N358. S, N369. S, N372. S, N375. S, N380. S, N374. S, N377. S, N368. S, N370. S, N373. S, N376. S, N389. S, N394. S, N431. S, N434. S, N390. S, N397. S, N387. S, N440. S, N396. S, N399. S, N403. S, N414. S, N430. S, N432. S, N436. S, N437. S, N457. S, N545, N386. S, N402. S, N405. S, N415. S, N421. S, N422. S, N423. S, N458. S, N459. S, N493. S, N416. S, N439. S, N447. S, N490. S, N526, N429. S, N433. S, N448. S, N488. S, N508. S, N509. S, N510. S, N511. S, N408. S, N446. S, N451. S, N474. S, N520. S, N521. S, N535. S, N516. S, N463. S, N518. S, N586, N450. S, N465. S, N519. S, N537. S, N419. S, N468. S, N477. S, N514. S, N382. S, N460. S, N462. S, N512. S, N517. S, N523. S, N547. S, N548. S, N577. S, N581. S, N585. S, N616. S, N466. S, N469. S, N480. S, N482. S, N484. S, N515. S, N533. S, N709, N730, N478. S, N572. S, N400. S, N543. S, N582. S, N621. S, N689, N769, N481. S, N525. S, N528. S, N534. S, N574. S, N580. S, N590. S, N591. S, N597. S, N664,N693、N530.S、N687、N470.S、N529.S、N539.S、N546.S、N570.S、N579.S、N602.S、N614.S、N648.S、N652.S、N655.S、N672.S、N681.S、N690.S、N692.S、N698.S、N737.S、N738.S、N785、N841、N878、N880、N881、N987、N988、N996、N1061、N479.S、N538.S、N542.S、N578.S、N609.S、N611.S、N617.S、N666.S、N675.S、N682.S、N844、N845、N846、N852、N876、N982、N1008、N649.S、N657.S、N678.S、N686.S、N710.S、N522.S、N651.S、N653.S、N654.S、N680.S、N712.S、N792、N802、N804、N807、N849、N858、N859、N875、N885、N942、N961、N972、N1051、N587.S、N589.S、N612.S、N625.S、N656.S、N714.S、N779、N781、N828、N829、N860、N894、N925、N927、N935、N947、N983、N1023、N441.S、N584.S、N794、N788、N524.S、N604.S、N610.S、N623.S、N663.S、N669.S、N676.S、N703.S、N775.S、N777.S、N780.S、N817.S、N827.S、N836.S、N871.S、N874.S、N898.S、N907.S、N998.S、N1088、N1089、N660.S、N665.S、N667.S、N733.S、N734.S、N739.S、N741.S、N782.S、N789.S、N796.S、N798.S、N800.S、N809.S、N816.S、N842.S、N843.S、N869.S、N986.S、N995.S、N1002.S、N1004.S、N1019.S、N1093、N668.S、N685.S、N835.S、N851.S、N464.S、N695.S、N776.S、N793.S、N815.S、N833.S、N891.S、N1070.S、N1092、N795.S、N797.S、N808.S、N811.S、N826.S、The method can form a functional network ecology selected from the group consisting of N830.S, N832.S, N840.S, N945.S, N960.S, N968.S, N1091, N805.S, N822.S, N928.S, N936.S, N1078.S and N913.S.
73. The functional network ecology includes N1008, N1023, N1051, N1061, N1070.S, N1088, N1089, N1092, N381.S, N382.S, N399.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S, N448.S, N457.S, N460.S, N462.S, N463.S, N464.S, N470.S, N471.S, N472.S, N473.S, N474.S, N475.S, N476.S, N477.S, N478.S, N479.S, N480.S, N481.S, N482.S, N483.S, N484.S, N485.S, N486.S, N487.S, N488.S, N489.S, N490.S, N491.S, N492.S, N493.S, N494.S, N495.S, N496.S, N497.S, N498.S, N499.S, N400.S, N402.S, N403.S, N414.S, N429.S, N430.S, N432.S, N433.S, N436.S, N437.S, N439.S, N441.S, N447.S S, N474. S, N488. S, N490. S, N493. S, N508. S, N509. S, N510. S, N511. S, N512. S, N514. S, N515. S, N517. S, N518. S, N519. S, N520. S, N523. S, N524. S, N529. S, N539. S, N543. S, N546. S, N547. S, N548. S, N570. S, N574. S, N577. S, N579. S, N580. S, N582. S, N584. S, N585. S, N589. S, N591. S, N597. S, N602. S, N604. S, N609. S, N610. S, N611. S, N612. S, N614. S, N616. S, N621. S, N623. S, N625. S, N648. S, N651. S, N652. S, N653. S, N654. S, N655. S, N660. S, N663. S, N664, N665. S, N666. S, N669. S, N672. S, N676. S, N681. S, N687, N689, N690. S, N692. S, N693, N695. S, N698. S, N703. S, N709, N712. S, N714. S, N730, N734. S, N737. S, N738. S, N769, N775. S, N777. S, N779, N780. S, N781, N785, N788, N792, N793. S, N794, N797. S, N798. S, N802, N804, N807, N817. S, N827. S, N828, N830. S, N832. S, N833. S, N836. S, N840. S, N841, N844, N845, N849, N852, N858, N859, N860, N869. S, N871. S, N874. S, N875, N878, N880, N881, N885, N894, N898. S, N907. S, N913. S,73. The method of claim 72, wherein the avian influenza virus is selected from the group consisting of N925, N927, N942, N947, N961, N968.S, N972, N982, N983, N986.S, N987, N988, N996 and N998.S.
74. 74. The method of claim 73, wherein the functional network ecology is N660.S and the plurality of bacterial functional pathways comprises the functional pathways of KO:K00656 and KO:K01442.
75. 75. The method of any one of claims 69 to 74, wherein the composition further comprises a pharma- ceutically acceptable excipient.
76. 75. The method of any one of claims 69 to 74, wherein the composition is formulated for oral administration.
77. 75. The method of any one of claims 69-74, wherein the composition is capable of inducing the formation of butyrate, propionate, acetate, 7-deoxybile acid, deoxycholic acid (DCA) and lithocholic acid (LCA) in a mammalian subject.
78. 75. The method of any one of claims 69 to 74, wherein the composition is capable of inducing depletion of glucose, pyruvate, lactate, cellulose, fructan, starch, xylan, pectin, taurocholate, glycolate, ursocholate, cholate, glycochenodeoxycholate, taurochenodeoxycholate, ursodeoxycholate or chenodeoxycholate in a mammalian subject; or inducing the formation and depletion of the intermediate metabolites acetyl-CoA, butyryl-CoA, propanoyl-CoA, chenodeoxycholoyl-CoA or ursodeoxycholoyl-CoA.
79. 75. The method of any one of claims 69 to 74, wherein the composition is formulated with one or more prebiotic compounds.
80. 75. The method of any one of claims 69 to 74, wherein the composition is edible.
81. A composition comprising any composition administered by the method of any one of claims 69 to 74.
82. A dosage unit comprising a predetermined ratio of isolated bacteria present in the network ecology of any one of claims 69 to 74.
83. A formulation comprising a purified bacterial population consisting essentially of a bacterial network capable of forming germinating bacterial spores, the bacterial network being present in an amount effective to populate the gastrointestinal tract of a mammalian subject to which the formulation is administered, under conditions in which at least one type of bacteria that was not detectably present in the bacterial network or gastrointestinal tract prior to administration of the formulation is increased.
84. 1. A pharmaceutical preparation comprising a purified bacterial population comprising a plurality of bacterial entities, The bacterial entities require a formulation and are present in an amount effective to induce the formation of a functional bacterial network in the gastrointestinal tract of a mammalian subject to which the formulation is administered.
85. 85. The formulation of claim 84, wherein the functional bacterial network comprises bacterial entities present in the formulation.
86. 85. The formulation of claim 84, wherein the functional bacterial network comprises bacterial entities present in the gastrointestinal tract upon administration.
87. 85. The formulation of claim 84, wherein the functional bacterial network comprises bacterial entities that are not present in the formulation or in the gastrointestinal tract upon administration.
88. 85. The formulation of claim 83 or 84, provided as an oral finished pharmaceutical dosage form comprising at least one pharma- ceutically acceptable carrier.
89. 85. The formulation of claim 83 or 84, wherein the mammalian subject suffers from a gastrointestinal disease, disorder or condition selected from the group consisting of Clostridium difficile associated diarrhea (CDAD), type 2 diabetes, type 1 diabetes, obesity, irritable bowel syndrome (IBS), irritable bowel disease (IBD), ulcerative colitis, Crohn's disease, colitis, colonization by pathogens or pests, and infection by drug-resistant pathogens or pests.
90. 84. The preparation of claim 83, wherein the bacterial network is purified from fecal material that has been subjected to a processing step that includes depletion or inactivation of pathogenic substances.
91. 91. The formulation of claim 90, wherein the bacterial network is substantially depleted of detectable levels of the first pathogenic agent.
92. 91. The formulation of claim 90, wherein the bacterial network is substantially depleted of residual habitat products of fecal matter.
93. 85. A method of treating or preventing microbial incompatibility in a human subject, comprising administering to the human subject a formulation of claim 83 or claim 84 in an amount effective to treat or prevent microbial incompatibility or reduce the severity of at least one symptom of microbial incompatibility in the human subject to which the formulation is administered.
94. The formulation is provided as an oral finished pharmaceutical dosage form comprising at least one pharma- ceutical acceptable carrier, the dosage form comprising at least about 1 x 10 colony forming units of bacterial spores per dose of the composition; 94. The method of claim 93, wherein the bacterial spore comprises at least two bacterial entities comprising a 16S rRNA sequence having at least 97% identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:674, SEQ ID NO:1670, SEQ ID NO:774, SEQ ID NO:848, SEQ ID NO:856, SEQ ID NO:1639, SEQ ID NO:880, SEQ ID NO:1896, SEQ ID NO:1591, SEQ ID NO:164, SEQ ID NO:845, and SEQ ID NO:
659.
95. 94. The method of claim 93, wherein administration of the formulation leads to a reduction or elimination of at least one pathogen and / or pestbiont present in the gastrointestinal tract at the time the therapeutic composition is administered.
96. 94. The method of claim 93, wherein administration of the formulation leads to engraftment of at least one spore-forming bacterium present in the therapeutic composition.
97. 94. The method of claim 93, wherein administration of the formulation leads to an increase in at least one type of bacteria not present in the formulation in the gastrointestinal tract of a subject to which the formulation is administered.
98. 97. The method of claim 96, wherein the at least one type of spore-forming bacteria is not detectably present in the gastrointestinal tract of a subject to which the formulation is administered at the time the formulation is administered.
99. 94. The method of claim 93, wherein administration of the formulation results in at least two of: i) a reduction or elimination of at least one pathogen and / or pestbiont present in the gastrointestinal tract at the time the formulation is administered; ii) engraftment of at least one spore-forming bacterium present in the therapeutic composition; and iii) an increase in at least one spore-forming or non-spore-forming bacterium not present in the therapeutic composition.
100. 91. The method of claim 90, wherein administration of the therapeutic composition results in a reduction or elimination of at least one pathogen and / or pestbiont present in the gastrointestinal tract at the time the therapeutic composition is administered, and results in at least one of: i) engraftment of at least one spore-forming bacterium present in the therapeutic composition; and ii) an increase in at least one bacterium not present in the therapeutic composition.
101. A method for inducing colonization of a bacterial population in the gastrointestinal tract of a human subject, comprising administering to the human subject an orally acceptable pharmaceutical formulation comprising a purified bacterial network under conditions such that at least i) a subset of spore-forming bacteria persists in the gastrointestinal tract, or ii) at least one species of bacteria not present in the therapeutic composition grows in the gastrointestinal tract.
102. A pharmaceutical preparation comprising a purified first bacterial entity and a purified second bacterial entity, wherein the first bacterial entity comprises a first nucleic acid sequence encoding a first polypeptide capable of catalyzing a first chemical reaction, and the second bacterial entity comprises a second nucleic acid sequence encoding a second polypeptide capable of catalyzing a second chemical reaction, the pharmaceutical preparation formulated for oral administration to a mammalian subject in need thereof; The formulation, wherein a first chemical reaction and a second chemical reaction are capable of occurring in the gastrointestinal tract of a mammalian subject, under conditions where a first product of the first chemical reaction, a substance present in the mammalian subject, or a combination of the first product and a substance, is used as a substrate in a second chemical reaction to form a second product, and the second product induces a host cell reaction.
103. 103. The formulation of claim 102, wherein the substance is a protein of a mammalian subject or a food-derived protein.
104. The formulation of claim 102, wherein the host cell reaction comprises production of a biological substance by a host cell.
105. 103. The formulation of claim 102, wherein the biological material comprises a cytokine, a growth factor, or a signaling polypeptide.
106. The formulation of claim 102, wherein the host cell response comprises an immune response.
107. The formulation of claim 102, wherein the host cell response comprises a decrease in gastric motility.
108. The formulation of claim 102, wherein the host cell response comprises altered host gene expression, increased host metabolism, decreased intestinal permeability, increased epithelial cell junctional integrity, decreased lipolysis by the action of lipoprotein lipase in adipose tissue, decreased hepatic gluconeogenesis, increased insulin sensitivity, increased production of FGF-19 or altered energy harvest and / or storage.
109. 1. A pharmaceutical formulation comprising a purified first bacterial entity and a purified second bacterial entity, wherein the first bacterial entity and the second bacterial entity form a functional bacterial network in the gastrointestinal tract of a mammalian subject to which the pharmaceutical formulation is administered, the functional network controlling the amount and / or activity of a biological substance capable of inducing a host cell response.
110. 1. A pharmaceutical formulation comprising a purified first bacterial entity and a purified second bacterial entity, wherein the first bacterial entity and the second bacterial entity form a functional bacterial network in the gastrointestinal tract of a mammalian subject to which the pharmaceutical formulation is administered, the functional network inducing the production of a biological substance capable of inducing a host cell response.
111. A therapeutic composition comprising a network of at least two bacterial entities, the network comprising at least one keystone bacterial entity and at least one non-keystone bacterial entity; A composition, wherein each of the at least two bacterial entities is provided in an amount effective to treat or prevent a gastrointestinal disease, disorder or condition in a mammalian subject.
112. 112. The composition of claim 111, wherein the network comprises at least three bacterial entities.
113. 112. The composition of claim 111, wherein the network comprises at least three bacterial entities including at least two keystone bacterial entities.
114. A therapeutic composition comprising: a first network of at least two bacterial entities, the first network comprising a keystone bacterial entity and a non-keystone bacterial entity; and a second network of at least two bacterial entities, the second network comprising at least one keystone bacterial entity and at least one non-keystone bacterial entity, each of the networks being provided in an amount effective for treating or preventing a gastrointestinal disease, disorder or condition in a mammalian subject.
115. 115. The therapeutic composition of claim 114, comprising a network of at least two keystone bacterial entities capable of forming germination competent spores.
116. A therapeutic composition comprising: a first network of at least two bacterial entities, the first network comprising a keystone bacterial entity and a non-keystone bacterial entity; and a second network of at least two bacterial entities, the second network comprising at least one keystone bacterial entity and at least one non-keystone bacterial entity, each of the networks being provided in an amount effective for treating or preventing a gastrointestinal disease, disorder or condition in a mammalian subject.
117. A therapeutic composition comprising a network of at least two bacterial entities, the network comprising a first keystone bacterial entity and a second keystone bacterial entity, each of the two bacterial entities being provided in an amount effective for treating or preventing a gastrointestinal disease, disorder or condition in a mammalian subject.
118. The composition of claim 117, wherein the first and second keystone bacterial entities are present within the same network.
119. 118. The composition of claim 117, wherein the first and second keystone bacterial entities are present in different networks.
120. A diagnostic composition for detecting dysbiosis, comprising a first detection moiety capable of detecting a first keystone bacterial entity and a second detection moiety capable of detecting a first non-keystone bacterial entity, wherein the keystone bacterial entity and the non-keystone bacterial entity form a network, and wherein absence of at least one of the keystone bacterial entity and the non-keystone bacterial entity in a mammalian subject indicates dysbiosis.
121. 1. A method for altering the microbiome population present in a mammalian subject, the method comprising the steps of determining the presence of an incomplete network of bacterial entities in the gastrointestinal tract of the mammalian subject, and introducing into the gastrointestinal tract of the mammalian subject an effective amount of one or more auxiliary bacterial entities that were not detectable in the gastrointestinal tract of the mammalian subject prior to administration, such that the incomplete network is completed, thereby altering the microbiome population.
122. 122. The method of claim 121, wherein the one or more auxiliary bacterial entities become part of an incomplete network, thereby forming a complete network.
123. The method of claim 121, wherein the one or more supplemental bacterial entities alter the microbiota of the mammalian subject such that the one or more additional bacterial entities complete an incomplete network.
124. 122. The method of claim 121, wherein the one or more auxiliary bacterial entities comprise a network.
125. A method for detecting and correcting microbial incompatibility in a mammalian subject in need thereof, comprising the steps of: providing a fecal sample from the mammalian subject comprising a plurality of bacterial entities; contacting the fecal sample with a first detection moiety capable of detecting a first bacterial entity present in a network; detecting the absence of the first bacterial entity in the fecal sample, thereby detecting microbial incompatibility in the mammalian subject; and administering to the mammalian subject a composition comprising an effective amount of the first bacterial entity.
126. 126. The method of claim 125, comprising confirming that the microbial incompatibility of the mammalian subject has been corrected.
127. A system for predicting microbial incompatibility in a subject, comprising: a storage memory for storing a dataset including content data of at least one network of bacterial entities and associated with a sample obtained from the subject; and a processor communicatively coupled to the storage memory for determining, with an interpretation function, a score predictive of microbial incompatibility in the subject.
128. 1. A kit for diagnosing a microbial incompatibility condition in a mammalian subject in need thereof, comprising: (1) a first bacterial entity, including a keystone bacterial entity; and (2) a plurality of detection means adapted for use in detecting a second bacterial entity; The first and second bacterial entities constitute a functional network ecology, kit.
